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Summary
Glutamate can be considered a ‘Jekyll and Hyde’ molecule that serves an essential 
role as neurotransmitter whilst having potentially damaging, neurotoxic effects. The 
neurotransmitter and neurotoxic properties of glutamate are partly mediated by 
AMPA receptors. Due to their ubiquitous distribution in the central nervous system 
(CNS), events occurring at the AMPA receptor can have profound consequences for 
CNS functioning. In this thesis, two AMPA receptor-mediated events were 
examined. Firstly, the neurotoxic potential of AMPA receptor-mediated 
excitotoxicity was examined in white matter. Secondly, AMPA receptor potentiators, 
which enhance glutamatergic neurotransmission, were investigated.
The role of AMPA receptors in mediating axonal damage in vivo
White matter is vulnerable to injury in a variety of neurological disorders, however, 
comparatively less is known about the mechanisms of white matter injury compared 
to grey matter injury. In addition to their presence on neuronal perikarya, AMPA 
receptors are present on the cellular components of white matter. To determine if 
axons were vulnerable to AMPA receptor-mediated excitotoxicity in vivo, AMPA 
(2.5 or 25 nmol) or vehicle was injected into the subcortical white matter of rats. 
AMPA induced a dose dependent increase in axonal damage assessed with MAP 5 
immunohistochemistry. In addition, AMPA induced myelin, oligodendroglial and 
neuronal damage. The AMP A-induced damage was attenuated by pre-treatment with 
the AMPA receptor antagonist SPD 502 (16mg/kg), but not with co-administration of 
the NMDA receptor antagonist (MK 801, 5nmol); suggesting that it occurs through 
AMPA-receptor mediated mechanisms. The role of AMPA receptor-mediated 
excitotoxicity in mediating axonal damage following focal cerebral ischaemia was 
also examined. In addition to protecting grey matter damage, pre-treatment with the 
AMPA receptor antagonist SPD 502 (16mg/kg) significantly reduced axonal damage 
following middle cerebral artery occlusion. Collectively, these data suggest a role for 
AMPA receptors in mediating both grey and white matter damage, and suggest that 
AMPA receptor antagonists are capable of salvaging multiple cellular elements 
required for the functioning of the CNS.
XXI
Establishing a mouse model of AMPA-induced axonal damage
As transgenic mice were subsequently utilised in this thesis, an in vivo mouse model 
of AMPA-induced axonal damage was established by injecting AMPA in the caudate 
nucleus of mice. The effects of energy inhibition in mediating axonal damage were 
also examined by injecting the mitochondrial inhibitor, malonate, into the caudate 
nucleus of mice. AMPA-induced axonal swellings were evident in white matter tracts 
of the caudate nucleus in NF 200 immunostained sections, however axonal damage 
was not detected with APP immunohistochemistry. In contrast, malonate induced 
axonal swellings that were evident in both NF 200 and APP immunostained sections. 
To further examine the contrasting mechanisms by which AMPA and malonate act, 
the effects of either toxin of glucose metabolism were examined 1 hour following 
intrastriatal injection. AMPA induced a marked increase in glucose utilisation in the 
caudate nucleus, whereas malonate induced a marked decrease in glucose utilisation. 
Collectively, these studies highlight the divergent mechanisms by which these two 
pathogenic mediators of white matter pathology act.
AMPA-induced axonal damage is attenuated in PLP, but not MBP 
deficient mice
At present, there is no evidence to suggest that AMPA receptors are located on axons. 
Therefore, AMPA-induced axonal damage must be secondary to damage occurring at 
another cellular element. Transgenic mice deficient in PLP or MBP, the two major 
proteins expressed in oligodendroglia and myelin, contain axonal abnormalities and 
therefore provide a useful model for examining the role of glia-axonal relationships in 
mediating AMPA-induced axonal damage. In addition, it is possible that excitotoxic 
mechanisms may contribute to the pathology observed in these mice. To determine if 
PLP and MBP deficient mice exhibit altered sensitivity to excitotoxicity, AMPA was 
injected in the caudate nucleus of these mice. There was no difference in the amount 
of AMPA-induced axonal, or neuronal, damage in MBP deficient mice. However, 
AMPA-induced axonal damage was significantly attenuated (P<0.05), and neuronal 
damage was reduced (P=0.06) in PLP deficient mice. These data suggest that 
excitotoxic mechanisms do not contribute to the pathology exhibited by PLP or MBP 
deficient mice. However, PLP, but not MBP, mediated interactions with the axon 
may be important in mediating AMPA-induced axonal damage.
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Mapping the functional effects of the AMPA receptor potentiator, 
LY404187, with 14C-2-deoxyglucose autoradiography
AMPA receptor potentiators act as positive AMPA receptor modulators, which 
enhance AMPA receptor mediated glutamatergic neurotransmission. AMPA receptor 
potentiators have demonstrated efficacy in animal models of cognition and 
depression, however the anatomical basis of the action of AMPA receptor 
potentiators was not known. This was investigated using 14C-2-deoxyglucose 
autoradiography following administration of the biarylpropylsulfonamide AMPA 
receptor potentiator, LY404187 (0.05, 0.5, or 5mg/kg). The AMPA receptor 
potentiator LY404187 (0.5mg/kg) produced statistically significant increases in 
glucose utilisation in 28 of the 52 anatomical areas examined, which included the 
cerebral cortex (layer IV), the hippocampus, the dorsal raphe nucleus, locus coeruleus 
and lateral habenula. These increases were blocked by pre-treatment with the AMPA 
receptor antagonist, LY293558 (25mg/kg), suggesting that the AMPA receptor 
potentiator LY404187 acts through AMPA receptor mediated mechanisms. Despite 
the ubiquitous distribution of AMPA receptors, the anatomically discrete actions of 
the AMPA receptor potentiator LY404187 suggests that it may enhance specific 
AMPA receptor mediated processes in the cerebral cortex and limbic system. These 
data provide an anatomical basis for the cognitive enhancing and anti-depressant 
effects of LY404187.
The effects of the AMPA receptor potentiator LY404187 on regeneration 
in the dentate gyrus following entorhinal cortex lesion
AMPA receptor potentiators can enhance brain derived neurotrophic factor (BDNF) 
in the hippocampus in vitro and in vivo. BDNF may participate in the reorganisation 
of anatomical circuitry that occurs in the dentate gyrus, following lesioning of its 
afferent input from the entorhinal cortex. In addition, the generation of new neurons 
(neurogenesis) occurs in the dentate gyrus following entorhinal cortex lesioning, 
whose survival may depend upon neurotrophic factors. To determine if an AMPA 
receptor potentiator could enhance regeneration in the dentate gyrus, LY404187 
(0.5mg/kg), was administered twice daily, for 7 or 14 days, in animals that survived 
for 14 and 21 days respectively, following entorhinal cortex lesion (ECL). GAP 43 
and synaptophysin immunoreactivity were used to determine fibre sprouting and 
synaptogenesis, respectively. The effects of LY404187 on the number of BrdU cells
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labelled prior to drug treatment (day 6 post ECL) were also examined. Compared 
with vehicle treatment, there was no evidence that LY404187 altered the optical 
density of GAP 43 or synaptophysin immunostaining, at either time point. In 
addition, treatment with LY404187 did not significantly alter the number of BrdU 
cells in the dentate gyrus at either time point examined. These data suggest that, at 
the doses used in the current study, the AMPA receptor potentiator, LY404187 did 
not enhance regeneration in the dentate gyrus following entorhinal cortex lesioning.
Collectively, these data highlight the importance of AMPA-receptor mediated 
transmission for the normal functioning of the central nervous system. Based on their 
important role in neurotransmission, and their potentially damaging capacities,
AMPA receptors represent an important therapeutic target in a number of clinical 
conditions. The data presented in this thesis highlight the role of AMPA receptors in 
mediating white matter damage, and the clinical potential of AMPA receptor 
potentiators in treating cognitive deficits and depression.
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CHAPTER 1 
INTRODUCTION
1.1 AMPA receptors
1.1.1 Glutamate neurotransmission and receptor classification
The amino acid glutamate is a ubiquitous biological molecule, serving roles as an 
intermediate in metabolism and as a structural component of proteins. It is now 
almost 50 years since the pioneering experiments of Hayashi, Curtis and colleagues 
that suggested glutamate might have a role as a neurotransmitter within the central 
nervous system (CNS) (Hayashi, 1952,1954; Curtis et a l, 1959). During this era 
however, most scientists dismissed a putative role as a transmitter based on its other 
cellular functions. Numerous experiments have since established that glutamate 
meets the criteria for a CNS neurotransmitter.
Johnston and colleagues (1974) were first to suggest that analogues of glutamate 
might act at different glutamate receptor subtypes. Since then, the development and 
use of synthetic and natural agonists and antagonists of glutamate receptors; 
pharmacological, electrophysiological and ligand binding studies; and subsequent 
molecular cloning techniques have led to an evolution in the classification of 
glutamate receptor subtypes, which has culminated in the currently accepted 
classification, presented in figure 1.1 and figure 1.2.
Physiological and pharmacological studies in the 1970s inspired the early 
classification of glutamate receptor subtypes. A-methyl-D-aspartate (NMDA), 
quisqualic, kainic and ibotenic acids were among the first glutamate analogues to be 
developed and it was found that the potency of these compounds varied between 
cells (Curtis and Watkins, 1963; Shinozaki and Shibuya, 1970; Biscoe et al., 1976). 
Watkins and Evans (1981) reviewed the evidence and suggested three distinct 
glutamate receptor subtypes: kainate, quisqualate and NMDA. However, it was later 
discovered that quisqualate could activate a receptor coupled to the generation of 2nd 
messenger systems (Sladeczek et al., 1985; Nicoletti et al., 1986). In 1980, 
Krogsgaard-Larsen and co-workers synthesised the compound a-amino-3-hydroxy- 
5-methyl-4-isoxazole propionic acid (AMPA), which was a more selective, potent, 
quisqualate like agonist. This lead to a further revision of the nomenclature of 
glutamate receptor subtypes (Collingridge and Lester, 1989; Lodge and Collingridge, 
1990). It is currently accepted that glutamate receptors are subdivided into
1
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Figure 1.1 Diagrammatic representation of the major subtypes of 
glutamate receptors at the glutamate synapse
Glutamate is synthesised and stored in vesicles at the presynaptic terminal. 
Excitation o f  the presynaptic term inal causes the release o f  glutamate into the 
synapse, where it acts on glutamate receptors. There are three subtypes o f 
ionotrop ic glutamate receptor, NM DA, AM PA and kainate (KA). NMDA 
receptors are perm eable to Ca2 and N a+; whereas AM PA and kainate receptors 
primarily gate N a \  K efflux occurs through all ionotropic receptors. 
M etab otrop ie  glutamate receptors (mGluR) are coupled to G proteins that can 
activate second m essenger systems. Reuptake o f  glutamate occurs at high affinity 
glutamate transporters located on astrocytes and presynaptic terminals.
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ionotropic glutamate receptors (iGluRs) and metabotropic glutamate receptors
(mGluRs; see Fig. 1.1 and 1.2). Ionotropic receptors contain integral cationic ion
channels that are associated with a ligand binding site. iGluRs primarily gate Na+,
and in some cases Ca2+ influx, and K+ efflux. mGluRs receptors are coupled to G
proteins that modulate the production of intracellular second messenger systems. A
2+number of subtypes of mGluRs exist, which cause changes in intracellular Ca or 
cAMP levels.
iGluRs were subdivided into three major glutamate receptor subtypes, NMDA, 
AMPA and kainate on the basis of agonist specificities (Fig. 1.2 and 1.3). However, 
the iGluRs were commonly referred to as the NMDA and non-NMDA receptors 
because historically, no agonists or antagonists could clearly distinguish between 
AMPA or kainate receptors. Radioligand and electrophysiological studies revealed 
that there was an overlap between the actions of AMPA and kainate (reviewed in 
Fletcher and Lodge, 1996).
Using a variety of approaches, it was eventually proven that AMPA and kainate 
receptors are separate entities. Radioligand binding studies showed that separate 
high affinity [3H]AMPA and [3H]kainate binding sites are present in the rat brain 
(Young and Fagg, 1990). Secondly, the desensitising responses of the two receptors 
can differ upon application of agonists or modulators. At AMPA receptors, AMPA 
evokes rapidly desensitising responses, whereas kainate evokes comparatively 
nondesensitising responses. In contrast, at kainate receptors, kainate causes rapid 
desensitisation, whilst AMPA evokes weak, non-desensitising currents (Fletcher and 
Lodge, 1996, Wilding and Heuttner, 1997). The plant lectin concanavalin A (conA) 
selectively blocks desensitisation of only kainate receptors, whereas the 
benzothiazide cyclothiazide selectively blocks desensitisation of AMPA receptors, 
whilst remaining inactive at kainate receptors (Partin et al., 1993; Yamada and Tang, 
1993). These drugs have become extremely useful for distinguishing between 
AMPA and kainate receptors. Thirdly, crucial evidence for a distinction between 
AMPA and kainate receptors came from the synthesis of antagonists that are 
selective only for the AMPA or kainate receptor. For example the AMPA 
antagonists GYKI52466 and GKYI53655 (LY300168), which are a 2,3 
benzodiazepines, have a blocking effect on AMPA receptors, but have little effect on 
kainate receptors (Donevan and Rogawaski, 1993; Donevan et al., 1994; Wilding
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and Huettner, 1995). However, the ultimate, compelling evidence for distinct AMPA 
and kainate receptors came from revolutionary advances in molecular biology 
techniques. The molecular cloning of glutamate receptor subunits has identified the 
genetic basis for GluRs, and finally confirmed that there are distinct genes for 
AMPA and kainate receptors (Hollmann et al, 1989; Bettler et al, 1990; Keinanen 
et a l, 1990).
1.1.2 Molecular Biology of AMPA receptors
One of the most important advancements in the study of glutamate receptors was the 
discovery and cloning of the genes that encode the glutamate receptor subtypes. 
Several distinct but related genes have been identified; this diversity accounts for the 
pharmacological and functional heterogeneity of glutamate receptors throughout the 
brain (Hollmann and Heinemann, 1994). Hollmann and colleagues cloned the first 
glutamate receptor in 1989, which was later discovered to be an AMPA receptor 
subunit (GluRl). Using the sequence of GluRl enabled homology cloning of the 
other subunits of the AMPA receptor, which are named GluR2, GluR3 and GluR4 
(Bettler et al., 1990; Keinanen et al, 1990). Other ionotropic and metabotropic 
glutamate family member genes have been identified, as figure 1.3 shows. There are 
currently 6 families of iontropic glutamate receptors which have been identified by 
sequence homology: a single AMPA family, two for kainate and three for NMDA 
(see figure 1.3A, reviewed in Dingledine et al, 1999). Within a family, there is 
considerable homology, but between families a lesser degree of similarity exists, 
roughly 40-50%. This suggests a common evolutionary origin for all ionotropic 
glutamate receptor subtypes (Dingledine et al, 1999; Dingledine and McBain, 1999; 
see Fig. 1.3B).
AMPA Receptor Subunit Topology
The currently proposed topology for the glutamate receptor subunit is presented in 
figure 1.4. It is comprised of three transmembrane segments (M l, M3, M4), a loop 
segment in the membrane which does not transverse the membrane (M2), and an 
intracellular C terminus (figure 1.4; Bennett and Dingledine, 1995). The M3 to M4 
domain is extracellular, this loop is important for the desensitising properties of the 
receptor (Fletcher and Lodge, 1996). Regions in both the amino terminal (NH2) and 
in the loop between M3 and M4 (referred to as SI and S2) form glutamate binding 
domains, thought to exist as two lobes separated by a cleft (Armstrong et al, 1998).
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Figure 1.3 Molecular families of glutamate receptors
A . The receptor subtypes o f  iGluRs and mGluRs, which each have three 
defined groups o f receptors, which are com prised o f  individual subunits, 
each encoded by a different gene (from Dingledine and McBain, 1999).
B. Evolutionary relationship am ong cloned AM PA and kainate receptor 
subunits. The length o f  line separating the subunits is proportional to their 
evolutionary distance (adapted from Bettler and M ulle, 1995 and Fletcher 
and Lodge, 1996). KA=kainate; Dom= domoate; G lu^glutam ate; 
Quis=quisqualate.
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Figure 1.4 Structure of the AMPA receptor subunit
There are three transm embrane domains (M l, M3, M4). Two portions o f 
the extracellular domains (SI and S2) are thought to form  the ligand 
binding domain. The intracellular loop portion (M2) contains the Q/R 
site, editing here governs the Ca: perm eability o f  the receptor subunit. 
Adapted from Bennett and Dingledine (1995).
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The re-entrant membrane loop M2, is thought to be responsible for the ion pore 
lining region of the receptor; editing of this domain at a ‘Q/R’ site can affect the ion 
permeability of the receptor (see later).
AMPA receptor stoichiometry
In vivo, AMPA receptors are thought to be multimeric assemblies of individual 
subunits. Recent data favours a tetrameric complex (Dingledine et al, 1999; 
Egebjerg and Jensen, 2002). Considerable functional diversity arises from the 
conformation of the subunits, as AMPA receptor subunits can generate receptors in 
homomeric (i.e. composed of one receptor subtype) or heteromeric (i.e. composed of 
combinations of GluRl-4) combinations (Wenthold et al, 1996). In situ 
hybridisation and immunocytochemical studies have revealed a varied distribution of 
the subunits GluRl-4 in the CNS (Keinanen et al, 1990; Petralia and Wenthold, 
1992). However, little information is available regarding the exact subunit 
conformation of native AMPA receptors. Evidence suggests that AMPA receptor 
subunit stoichiometry is not fixed but can vary, and furthermore, different AMPA 
receptor combinations can co-exist within the same neuron (Dingledine et al, 1999).
Alternative Splicing and RNA editing o f AMPA receptor subunits 
The presence or absence of the GluR2 subunit in AMPA receptors has important 
implications for the ion permeability of the receptor. If GluR2 is present, the 
receptor has low permeability to Ca2+ and exhibits a linear relationship between 
voltage applied to the membrane and current passing through the ion channel. 
However, receptors that do not possess the GluR2 subunit have high Ca2+ 
permeability and current-voltage relationships that double rectify (Hollman et 
al, 1991; Bumashev et a l, 1992; Jonas and Bumashev, 1995). A single amino acid 
in the M2 channel pore is responsible for impermeability of GluR2 to Ca2+ (Hume et 
a l, 1991; Verdoom et a l, 1991). At position 586 in the protein, GluR2 has an 
arginine residue, whereas GluRl, -3 and -4  have a glutamine residue in the same 
location. Glutamine is a neutral amino acid that will confer Ca2+ permeability, 
whereas arginine is positively charged, and repels Ca2+‘ Based on the shorthand for 
arginine (R) and glutamine (Q), this site has been named the Q/R site, (see figure 
1.4). The conversion of glutamine (Q) to arginine (R) on GluR2 subunits is not
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encoded by the GluR2 gene, but instead arises as a result of post-transcriptional 
editing of the mRNA (Sommer et al., 1991; Higuchi et al, 1993). In health, the 
majority of GluR2 subunits have undergone this editing in the adult rat brain, and are 
therefore impermeable to Ca2+. However, in some neurodegenerative conditions, 
there is a down regulation of GluR2 gene expression, resulting in an increase of Ca2+ 
permeable AMPA receptors, which may enhance the toxicity of glutamate 
(Pellegrini-Giampietro et al., 1997; Weiss and Sensi, 2000).
Further heterogeneity in the physiological characteristics of AMPA receptors arises 
from the ‘flip’ and ‘flop’ exon splice variants of the AMPA receptor subunits. The 
mRNA encoding GluRl-4 can exist in two forms that differ by 9-11 amino acids 
contained within a 38 amino acid sequence in the M3-M4 extracellular loop (Figure 
1.4; Sommer et al., 1990). This flip/flop region comprises only -4% of the subunit 
protein, yet it can alter the electrophysiological and drug binding properties of the 
receptor. This is because ‘flip’ isoforms desensitise less rapidly than ‘flop’ isoforms, 
thus altering the sensitivity of the receptor to allosteric modulators (see section 1.1.4; 
Sommer et al., 1990). Greater levels of the flip isoform are expressed in the neonate, 
whereas the mature CNS contains predominately flop isoforms, although there are 
regional variances (Sommer et al, 1990; Monyer et al., 1991; Fletcher and Lodge, 
1996). Further diversity arises from editing at an exon preceding the flip/flop site.
At this site, editing of an arginine (R) to a glycine (G) results in currents that recover 
more rapidly from agonist-induced desensitisation. Editing at this R/G site occurs in 
GluR-2, -3 and -4  but not GluRl (Lomeli et al., 1994). Again, the extent of editing 
at the R/G site varies during development, but in adults, most R/G sites are edited to 
glycine. Taken together, these findings suggest that an array of functionally distinct 
AMPA receptors could exist in the brain depending on the subunit composition and 
degree of post-transcriptional editing. This heterogeneity could account for the 
diversity of excitatory neurotransmission within the CNS.
Post-translational modification o f AMPA receptors
Following synthesis of the AMPA receptor subunit, it can undergo enzymatic post- 
translational modifications that can affect the function of the receptor. For example, 
glutamate receptors are under tight control by various phosphokinases (Wenthold 
and Roche, 1998; Dingledine et al, 1999). Substantial evidence suggests that
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phosphorylation of AMPA receptors by cAMP-dependent protein kinase (PKA), 
protein kinase C (PKC) and calcium/calmodulin dependent protein kinase II (CAM- 
KH) potentiates current flow in AMPA receptors (reviewed in Wenthold and Roche, 
1998; Dingledine et al, 1999). Conversely, dephoshorylation of glutamate receptor 
subunit protein has the opposite effect, diminishing the response of the receptor to 
agonists, where as inhibiting phosphatases (enzymes that remove phosphate groups) 
enhances the currents stimulated by agonists (Raymond et al., 1993; Wang et al, 
1996). Phosphorylation and subsequent modulation of AMPA receptors is an 
important mechanism of synaptic plasticity. This will be discussed in more detail in 
section 1.1.6.
1.1.3 Neurotransmission at AMPA receptors
Within glutamatergic synapses, glutamate is stored in synaptic vesicles at relatively 
high concentrations (~20mM). Following depolarisation of the terminal, glutamate is 
released into the synaptic cleft in a Ca2+ dependent, quantal manner (roughly 
ImM/vesicle), where it can activate AMPA receptors located at the postsynaptic 
membrane (Nicholls, 1998). AMPA receptors are permeable to Na+, and depending 
on the receptor subunit composition, can be permeable to Ca2+ (see section 1.1.2). 
Glutamate evokes fast depolarising currents and rapid desensitisation at AMPA 
receptors. This contrasts with the slow, prolonged depolarisation that occurs 
following glutamate activation of NMDA receptors (Trussel, 1998). Glutamate must 
be removed from the synaptic cleft rapidly, so that postsynaptic stimulation reflects 
release, and to avoid the toxic effects of high concentrations of glutamate (see 
section 1.2). Glutamate is unable to diffuse across plasma membranes, and no 
extracellular enzymes are capable of metabolising it. Instead, high affinity, Na+ 
dependent glutamate transporters present on neurons and glial cells remove the 
extracellular glutamate. Five different Na+ dependent glutamate receptors have 
cloned so far: GLAST (EAAT1); GLT (EAAT2); EAAC (EAAT3); EAAT4 and 
EAAT5. These different subtypes of glutamate receptor are expressed differentially 
throughout the CNS. The transporters utilise the electrochemical gradients of Na+,
K+ and H+ to drive glutamate into cells (Levy, 2002).
In addition to their function as ion channels, AMPA receptors can act as signal 
transducers, which can transmit signals to the nucleus to influence gene expression.
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Figure 1.5 Glutamatergic neurotransmission at AMPA receptors
Glutamate is contained within synaptic vesicles, where it can reside at high 
concentrations (~20mM ). Glutamate is released from  synapses in a Ca 
dependent m anner following depolarisation o f the presynaptic neuron. 
Activation o f the AMPA receptor results in N a' influx; Ca2 influx can also 
occur if  GluR2 is absent from the receptor. High affinity glutamate 
transporters situated in the presynaptic neuron and adjacent glial cells 
rapidly take up glutamate from the synapse. Depolarisation o f  the 
postsynaptic membrane can cause Ca2 influx through voltage sensitive Ca2 
channels (VSCC). Ion channels in the postsynaptic m em brane actively 
pump ions to maintain the membrane potential (Na+/K7 ATPase; C a2'  
ATPase; Ca: /N a'anti-porter (not shown)). Activation o f  AM PA receptors 
can trigger mitogen-activated protein kinase pathways (M APK) via 
activation o f  Lyn, with which it interacts. AMPA receptors are anchored in 
the postsynaptic density through interactions with GRIP.
11
This occurs via mitogen-activated protein kinase (MAPK) signalling pathways 
(Wang and Durkin, 1995; Wang et al, 1997; Hayashi et al, 1999; Perkinton et 
al, 1999). For example, AMPA receptors have been shown to interact with the Src- 
family protein tyrosine Lyn, which can activate MAPK pathways that can induce 
synthesis of brain derived neurotrophic factor (Hayashi et al, 1999).
1.1.4 Pharmacology of AMPA receptors
Agonists
AMPA receptors were originally termed quisqualate receptors based on the potency 
of quisqualate at these receptors, however the synthesis of AMPA, and the discovery 
that it was more selective than quisqualate at AMPA receptors, led to the revised 
nomenclature that is accepted today (figure 1.2; Krogsgaard-Larsen et al, 1980; 
Collingridge and Lester, 1989; Lodge and Collingridge, 1990). Recombinant AMPA 
receptors (GluRl-4) have affinities for AMPA at least two fold higher than for 
kainate. However whilst AMPA, quisqualate, and glutamate evoke rapidly 
desensitising responses at AMPA receptors, kainate and domoate evoke non­
desensitising responses (Keinanen et al, 1990; Fletcher and Lodge, 1996). The rank 
order of agonist potency and order of binding affinity of these compounds is 
illustrated in figure 1.3B.
Competitive AMPA receptor antagonists
The development of a group of compounds called the quinoxalinediones, by Honore 
and colleagues (1988), revolutionised the study of selective AMPA antagonists, 
because until that point few non-NMDA antagonists were available. 6,7- 
dinitroquinoxaline-2,3-dione (DNQX) and 6-cyano-7-nitroquinoxaline-2,3-dione 
(CNQX) were the first reported compounds of this class. These are competitive 
antagonists at AMPA receptors; however, they also have antagonist effects at KA 
receptors, and can interact with the NMDA receptor glycine site (Birch et al, 1988). 
The quinoxalinediones 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline 
(NBQX) and 6-(lJ-imidazol-l-yl)-7-nitro-2,3(lH,4H)-quinoxalinedione 
hydrochloride (YM90K) were developed by further substitution and modification of 
this class of antagonist (Sheadown et al, 1990; Ohmori et a l, 1994). These AMPA 
receptor antagonists are considerably more potent and selective for AMPA compared 
to kainate receptors than CNQX or DNQX (Sheardown et a l, 1990). NBQX and 
other quinoxalinediones have been extremely useful compounds, used in a variety of
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studies for manipulating AMPA/kainate receptors, however the low solubility and 
toxic effects in the kidney precludes their development as clinical compounds.
In the last ten years, numerous other competitive AMPA receptor antagonists have 
been developed with improved solubility and brain penetration (reviewed in Lees,
2000). For example the modified quinoxalinedione fanapanel (ZK-200775) has 
increased solubility and similar affinities and selectivity to NBQX (Turski et al,
1998). An isatine oxime modification of the quinoxalinedione structure has resulted 
in the synthesis of SPD 502 (NS 1209) that exhibits similar potency to NBQX but is 
soluble, devoid of kidney toxicity and has longer lasting duration (Nielson et al,
1999). YM872 is a further competitive AMPA receptor antagonist that has been 
developed which is soluble and potent, with low affinity for other glutamate 
receptors (Takahashi et al, 2002).
A further class of potent, soluble competitive antagonists called the 
decahydroisoquinolines have been engineered, of which LY293558 is a 
representative compound (O’Neill et al, 1998). These compounds were initially 
reported to be potent, selective AMPA antagonists based on their action at cerebellar 
purkinje neurons thought to comprise the AMPA receptor subunits GluRl-4. 
However, it was later shown that they have antagonist activity at iGluR5 receptors 
(Bleakman et al, 1996).
Non-competitive AMPA receptor antagonists
The antagonists described in the previous section compete with agonists at the 
ligand-binding site. Non-competitive antagonists act at a different site on the 
receptor. One of the important and extensively studied groups of non-competitive 
AMPA antagonists are the 2,3 benzodiazepines, which are negative allosteric 
modulators (Vizi et al, 1996). They can act on either open or closed channels, and 
hence do not show voltage- or use- dependency (Donevan and Rogawski, 1993). 
Two examples of this group are GYKI 52466 and GYKI53655 (LY300164).
These compounds appear to show a high degree of selectivity for AMPA compared 
to kainate receptor mediated events, and have therefore become important tools for 
the pharmacological separation of these two receptor subtypes (Wilding and 
Heuttner, 1995; Fletcher and Lodge, 1996). The potencies of 2,3 benzodiazepines
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are affected by cyclothiazide, a desensitisation blocker that acts as a positive 
allosteric modulator (Palmer and Lodge, 1993). It was once thought that 
cyclothiazide and the 2,3 benzodiazepines may act at a common site. However, 
mutating the site on the AMPA receptor subunit at which cyclothiaziade acts does 
not alter the sensitivity of the receptor to 2,3 benzodiazepine (Partin and Mayer,
1996), confirming that these compounds act a different sites on the AMPA receptor. 
Further non-competitive AMPA receptor antagonists which have recently been 
developed are CP-465,022 and YM928 (Lazzaro et al., 2002; Menniti et al, 2003; 
Ohno et al., 2003).
AMPA receptor potentiators
AMPA receptor potentiators are positive allosteric modulators that increase current 
flux through the ion channel in the presence of agonist, by reducing desensitisation 
and/or deactivation of the receptor (Yamada and Tang, 1993; Partin et al, 1994, 
1995, 1996; Arai et al, 1996; Sekiguchi et al., 1997; Miu et a l, 2001). Fifteen years 
ago, relatively little was known about AMPA receptor potentiators, however since 
then a number of different classes of AMPA receptor potentiators have been 
synthesised, and a wealth of experiments has contributed to an increased 
understanding of their mechanism of action and effects. Experiments utilising these 
compounds have also contributed to the understanding of the kinetics of glutamate 
receptor desensitisation; furthermore, they represent a novel therapeutic strategy in a 
number of neurological conditions. Three major classes of AMPA receptor 
potentiators have been developed, the pyrrolidinones and related compounds, 
thiazide derivatives and the biarylpropylsulfonamides.
The plant lectin concanavalinA, was amongst the first non-NMDA receptor 
potentiator to be utilised (Mayer and Vycklicky, 1989; Huettner, 1990). Ito and 
colleagues (1990) then performed a crucial experiment that advanced the 
understanding and development of AMPA receptor potentiators. A group of 
‘nootropic’ drugs, called pyrrolidinones, of which aniracetam and piracetam are 
examples, had been known to possess positive effects in treating cognitive deficits 
(reviewed in Lee and Benfield, 1994). However, little was understood about the 
mechanism of action of pyrrolidinones. On the basis that non-NMDA receptors 
contributed to the cellular mechanisms of long term potentiation (LTP), a neural 
substrate that contributes to the formation of memory, Ito and colleagues (1990)
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hypothesised that aniracetam may act by potentiating activity at non-NMDA 
receptors. They reported that aniracetam could selectively enhance quisqualate or 
AMPA receptor-mediated responses in Xenopus oocytes injected with rat brain 
mRNA, or in hippocampal pyramidal cells. It was subsequently revealed that 
aniracetam enhanced AMPA receptor mediated responses by reducing receptor 
desensitisation and slowing the decay of fast excitatory synaptic currents upon 
removal of agonist (deactivation) (Icaason and Nicoll, 1991; Tang et al., 1991).
Pyrrolidones such as aniracetam are metabolised rapidly, have poor brain 
penetrability and low potencies. A group of structurally related benzoylpiperidines 
and benzoylpyrollidines that have AMPA receptor potentiating properties have been 
developed, which are commonly referred to as ‘Ampakines’ (Arai et al, 1994; 
Staubli et al, 1994a, b; Davies et al., 1997; Hamspson et al., 1998). These include 1- 
(l,3-benzodioxol-5-ylcarbonyl) piperidine (1-BCP, BDP, BA-14), BDP-12 (BA-74 
or CX-516) and its analogue BDP-20, and CX-546. These compounds have greater 
potency and blood brain barrier permeability than aniracetam and piracetam.
Another class of AMPA receptor potentiators are thiazide derivatives, of which 
diazoxide is the prototype. Yamada and Rothman (1992) initially used diazoxide to 
activate ATP-sensitive K+ channels, however unexpectedly discovered that it caused 
potentiation of glutamatergic synaptic responses. Structural similarities of diazoxide 
with a group of clinically utilised diuretics called benzothiazides prompted Yamada 
and Tang (1993) to evaluate the effects of these compounds on quisqualate evoked 
currents. This led to the discovery that cyclothiazide was a potent and efficacious 
AMPA receptor potentiator (Yamada and Tang, 1993). Since then, cyclothiazide has 
been one of the most extensively utilised AMPA receptor potentiators. Partin and 
colleagues (1993) used recombinant AMPA and kainate subunits to determine that 
cyclothiazide was a highly selective modulator of AMPA receptors; whereas ConA 
was a highly selective modulator of kainate receptors. In addition, cyclothiazide 
appears to have preferential activity at flip isoforms of AMPA receptors (Partin et 
al, 1995). Another thiazide derivative is IDRA 21, which acts selectively at AMPA 
receptors to reduce receptor desensitisation (Bertolino et a l, 1993; Impagnatiello et 
al, 1997).
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A third class of AMPA receptor potentiators has recently been developed, the 
biarylpropylsulfonamide compounds, of which LY404187 and LY392098 are 
representative compounds (Omstein et al, 2000). LY392098 and LY404187 
enhance AMPA- or glutamate-induced currents in vitro and in vivo, with greater 
potency than previously described AMPA receptor potentiators such as CX-516 
(Baumbarger et al., 2001a and b; Gates et al, 2001; Vandergriff et al, 2001). 
LY392098 can enhance the action potential discharge rate in response to stimulation 
of glutamatergic afferents in vivo (Baumarger et al, 2001a, b, Vandergriff et al,
2001). Furthermore, LY404187 or LY392098 have minimal effects on NMDA or 
GluR5 mediated-kainate induced currents in vitro, and AMPA receptor antagonism 
attenuates the effects of LY329098 in vitro, suggesting the these compounds are 
selective for AMPA receptors (Baumbarger et al, 2001a, b;Gates et al, 2001). 
Studies with recombinant homomeric AMPA receptor subunits have suggested that 
LY392098 and LY404187 have different potencies at receptors composed of GluRl- 
4, for example, LY404187 is most potent at GluR2 and least potent at GluR4 
receptor subunits (Miu et al, 2001). Furthermore, LY404187 is more potent at flip 
versus flop AMPA receptors (Miu et al, 2001).
Other compounds also possess modulatory influences on AMPA receptors. PEP A is 
a sulfonylamino compound that can potentiate glutamate-evoked currents in 
recombinant AMPA but not kainate or NMDA receptors. In contrast to cyclothiazide 
and LY404187, PEPA preferentially modulates AMPA receptor flop isoforms, with a 
selectivity profile for the AMPA receptor subunits of GluR3>GluR4>GluRl 
(Sekiguchi et al, 1997). Thiocyanate is a chaotropic modulator, previously shown to 
enhance high affinity AMPA binding, which decreases the desensitisation of 
recombinant GluRl flop, but increases the desensitisation of GluRl flip receptors 
(Partin et al, 1996).
Site directed mutagenesis studies have revealed that a single serine amino acid within 
the flip/flop domain (S750Q) of GluRl is responsible for determining the 
cyclothiazide sensitivity of the AMPA receptor subunit, (Partin et a l, 1994). 
Replacing the serine with a variety of different amino acids differentially modulates 
the effects of aniracetam or cyclothiazide on desensitisation and deactivation, 
suggesting that these two AMPA receptor potentiators may act at different sites or by 
different mechanisms (Partin et al, 1996). A mutation on the equivalent domain of
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GluR4 (S776Q) reduces, but does not eliminate the sensitivity of the subunit to 
potentiation by LY404187 (Quirk et al., 2002).
The different classes of AMPA receptor potentiator described above vary in potency 
and selectivity in a subunit and splice variant specific manner. In addition, AMPA 
receptor potentiators can have varying effects on AMPA receptors in situ. For 
example, cyclothiazide can potentiate synaptic responses to AMPA in brainstem 
slices, yet it has minimal effects in hippocampal slices (Yamada et al., 1998a), whilst 
LY404187 is more efficacious at purkinje cells compared to neurons from the 
prefrontal cortex (Quirk and Nisenbaum, 2002). This diversity is likely to reflect the 
heterogeneity of receptor subunit combinations and splice variants in the brain, 
which in turn suggests that there is physiological diversity of excitatory 
neurotransmission.
1.1.5 Distribution of AMPA receptors in the CNS
A variety of techniques have examined the distribution of AMPA receptors in the 
rodent CNS, which are abundant and widespread. The distribution of AMPA 
receptors within the CNS was initially investigated using [3H] AMPA ligand-binding 
studies. The brain regions that contain the highest levels of [3H] AMPA binding 
were the hippocampus, cerebral cortex, septum and striatum (Monaghan et al., 1984; 
Rainbow et al., 1984; Olsen et al; 1987; Insel et al., 1990). In particular, within the 
hippocampus, higher receptor densities were found in CA1 and dentate gyrus 
compared with CA2/3, and in the pyramidal cell layer compared to the stratum 
radiatum and stratum oriens (Olsen et al., 1987; Insel et al., 1990). In the cortex, 
similar levels of [3H] AMPA binding were reported in the frontal, parietal and 
temporal cortices; however, a laminar appearance was evident, with higher binding 
levels in the outer layers (I-HI) compared with the middle (V) and deep (VI) layers.
-a
The entorhinal and pyriform cortices contained a more uniform pattern of [ H]
AMPA binding, with particularly low and high levels of binding, respectively 
(Monaghan et al., 1984). In the striatum, the caudate nucleus contained intermediate 
levels of receptor binding, whereas the globus pallidus contains lower levels of 3H- 
AMPA binding. Lower levels of [3H] AMPA binding are reported in the midbrain 
and brainstem.
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The discovery of the genes encoding the four subunits of the AMPA receptor,
GluRl-4, initiated further investigation into the distribution of the particular subunits 
within the CNS, using in situ hybridisation to detect mRNA, and 
immunohistochemistry to detect proteins (Keinanen et a l, 1990; Sommer et al,
1990; Petralia and Wenthold et al, 1992; Martin et a l, 1993). Immunolabelling of 
the GluRl-4 subunits was consistent with the distribution of mRNA and with the 
overall pattern of [ H] AMPA binding, however there were regional differences in the 
pattern of the individual subunits (Petralia and Wenthold, 1992). For example, the 
pattern of GluRl immunostaining was heterogeneous, with marked contrast between 
densely and lightly stained structures. GluR2/3 exhibited the most widespread and 
densely immunostained pattern, and there were moderate levels of GluR4 
immunostaining. In the cortex, GluR2 is expressed uniformly throughout all layers, 
whereas GluRl and 4 are more abundant in layers I, V and VI; in the hippocampus, 
GluRl and 2/3 are abundant, but there is less GluR4. This differential pattern of 
immunostaining suggests that a large number of subunit combinations can be 
expressed by neurons, and single cell PCR studies confirm this (Lambolez et al, 
1992; Mackler and Eberwine, 1993). In the adult, the flop isoforms of AMPA 
receptors predominate, although there are regional variances, for example, 
hippocampal CA3 pyramidal cells express only flip subunits (Sommer et al., 1990; 
Monyer et al, 1991). In addition, within the mature nervous system, the majority of 
GluR2 subunits have undergone editing at the Q/R site, whilst virtually all GluR2-4 
subunits have undergone R/G editing (Sommer et a l, 1991; Lomeli et al, 1994).
At the cellular level, AMPA receptor subunits are located at the plasma membrane of 
cell bodies and dendrites of neurons, where they are localised predominantly at 
postsynaptic densities (Petralia and Wenthold, 1992). AMPA receptors with 
different subunit stoichiometry can co-exist on an individual neuron. They can also- 
coexist with kainate or NMDA receptors on individual neurons (Dingledine et al, 
1999). In addition to their presence on neurons, AMPA receptors have also been 
localised to glial cells such as astrocytes, microglia and oligodendrocytes (Noda et 
al, 2000; Gallo and Ghiani, 2000); this will be discussed in greater detail in section 
1.3.3.
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1.1.6 Function of AMPA receptors -  fast excitatory transmission and 
plasticity
Activation of AMPA receptors by glutamate is thought to be responsible for the 
majority of fast excitatory transmission with the brain. Given their ubiquitous 
distribution, AMPA receptors are involved in many of the functions of the CNS. The 
physiological relevance of AMPA receptor-mediated transmission can often be 
inferred by examining clinical disorders where glutamatergic transmission is 
disturbed, or where AMPA receptor ligands are therapeutically beneficial. Thus, the 
involvement of AMPA receptors in ischaemia, trauma, epilepsy, pain, schizophrenia, 
and potential roles in neurodegenerative diseases highlights the importance and 
ubiquitous nature of fast glutamatergic transmission at AMPA receptors.
AMPA receptors are also involved in long-lasting alterations in neuronal structure 
and function, known as synaptic plasticity. One example of this is long-term 
potentiation (LTP), a proposed cellular mechanism of memory formation. LTP 
describes the long lasting enhancement of synaptic transmission at a synapse 
following a short burst of presynaptic stimulation (Bliss and Lomo, 1973; Bliss and 
Collingridge, 1993). LTP depends on simultaneous electrical activity in both the 
pre- and post-synaptic neurons. The enhancement of synaptic transmission appears 
to involve both increased glutamate release and an enhanced post-synaptic response. 
Ca2+ entry through NMDA receptors, and the subsequent activation of protein 
kinases, calpains, phospholipases, and phosphatases are thought to contribute to the 
mechanism of LTP. Activity at AMPA receptors contributes to the induction of LTP 
by depolarising the postsynaptic membrane and relieving the Mg+ block of NMDA 
receptors to enable their activation. The contribution of AMPA receptors to LTP is 
inferred from the ability of AMPA receptor potentiators to augment LTP and 
enhance performance in rodent and human tests of cognition (Stuabli et al., 1994a, b; 
Ingvar et al., 1997); conversely, AMPA receptor antagonism results in cognitive 
deficits (Riedel et al, 1999). Aside from their role as a fast acting neurotransmitter 
that can relieve the Mg+ block of NMDA receptors, events at the AMPA receptor can 
also induce long lasting plastic changes that may contribute to LTP. Phosphorylation 
of AMPA receptors (see section 1.1.2), which can potentiate ion flux through the 
receptor, is thought to be one of the underlying mechanisms of LTP. Thus, 
electrical stimulation of neurons resulting in LTP causes phosphorylation of AMPA 
receptors mediated by CAM-KII (Barria, 1997). In addition to modulation of AMPA
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receptors, it has been hypothesised that phosphorylation of the AMPA receptor may 
increase the number of functional AMPA receptors in the postsynaptic membrane 
(Wenthold and Roche, 1998). Irrespective of the role of phosphorylation, it has been 
speculated that the induction of LTP may involve a switch from synapses containing 
only NMDA receptors (‘silent synapses’) to synapses containing both functional 
AMPA and NMDA receptors, via the insertion of new AMPA receptors into the 
membrane from intracellular stores (Luscher and Frerking, 2001; Henley, 2003).
Stimulation of AMPA receptors can trigger signal transduction cascades through the 
interaction of the AMPA receptor with the Src-family tyrosine kinase Lyn (Hayashi 
et al, 1999). Na+ and Ca2+ independent Lyn activation following AMPA receptor 
activity triggers mitogen-activated protein kinase (MAPK) signalling pathways 
which influence gene expression at the nucleus. For example, AMPA-receptor 
mediated MAPK pathways can cause the induction of brain-derived neurotrophic 
factor (BDNF) gene expression (Hayashi et al., 1999). BDNF expression may also 
be activated following AMPA receptor activation via Ca2+ influx through voltage 
activated Ca2+ channels. BDNF is thought to play a crucial role in synaptic 
plasticity, including the induction, expression and maintenance of LTP (McAllister et 
al., 1999; Poo, 2001).
1.2 Mechanisms of Brain Injury - Excitotoxicity
Glutamate can be considered a ‘Jekyll and Hyde’ molecule that serves essential roles 
as a neurotransmitter and metabolic intermediate whilst having potentially damaging, 
neurotoxic effects (Olney, 1990). Based on its role in metabolism, it was initially 
hypothesised that application of glutamate to the eye may alleviate retinal 
neurodegeneration. Instead however, it was unexpectedly discovered that it induced 
rapid neurodegeneration (Lucas and Newhouse, 1957). This neurotoxic property was 
later confirmed in the brain, and was subsequently named ‘excitotoxicity’ by John 
Olney (Olney, 1969; Olney and Sharp, 1969; Olney, 1971). These initial 
experiments focused on peripheral administration of high concentrations of 
glutamate, which was only toxic to neurons in certain brain areas of immature 
animals. However subsequent studies showed that intracerebral injection of 
glutamate or analogues of glutamate caused neuronal damage (Olney et al., 1975;
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Coyle and Schwarz, 1976; Simson et al, 1977). In addition, exposure of neuronal 
cell cultures to glutamate induces toxic effects (Choi et al, 1987).
1.2.1 Mechanisms of glutamate-induced excitotoxicity
High concentrations of glutamate or glutamate analogues are thought to kill neurons 
by over-activation of glutamate receptors. Thus, blockade of glutamate receptors 
prevents excitotoxicity in vivo and in vitro (Olney et al, 1979, 1981; Foster et al, 
1984; Rothman et al, 1984). Olney initially based his ‘excitotoxic’ theory on the 
correlation that existed between the excitatory actions of various glutamate agonists 
with their toxicity, suggesting that sustained depolarisation of the neuron by 
glutamate resulted in a lethal exhaustion of cellular energy reserves. Subsequent 
evidence suggested an important role for ionic imbalances and Ca2+ -mediated 
mechanisms, and suggested that there may be two phases in glutamate receptor- 
mediated toxicity. Initially, the sustained depolarisation associated with over 
activation of glutamate receptors results in Na+ and Cl' influx through monovalent 
ion channels. Because the vast Na+ and Cl' influx is larger than the K+ efflux, water 
enters neurons passively, causing cell swelling and oedema. Removal of Na+ or Cl' 
from the media of cultured neurons prevented the initial cell swelling caused by toxic 
levels of glutamate (Rothman 1985; Olney et al, 1986). Rapid Na+ entry is thought 
to be responsible for early glutamate-induced necrosis. Whilst removal of Na+ and
Cl' prevented initial cell swelling following glutamate exposure, neurons still
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degenerated at a later time point which was dependent on the presence of Ca in the 
medium, suggesting that a secondary, delayed Ca2+-dependent excitotoxic death 
occurred (Choi, 1987). Pre-treatment with Ca2+chelators can attenuate excitotoxic 
neuronal cell death in vivo and in vitro (Tymianski et a l, 1993). Elevated levels of 
intracellular Ca2+ initiate a complex cascade of inter-related intracellular events that 
ultimately result in cell death. For example, the activation of nucleases can result in 
DNA fragmentation; cytosolic proteases such as calpain can attack the cytoskeleton; 
kinases such as PKC can modify the phosphorylation states of proteins and disrupt 
cell function; whilst lipases can attack the cell membrane and intracellular 
organelles. In addition, Ca2+ can also activate enzymes involved in the production of 
reactive oxygen species (ROS) and nitric oxide (NO) (Kristian and Siesjo, 1997).
There are a number of hypothesised routes by which intracellular Ca2+ can become 
elevated following glutamate receptor activation (Choi, 1988). Glutamate receptor
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activation could cause a Ca2+ influx directly through NMDA or Ca2+ permeable 
AMPA receptors. Activation of glutamate receptors causes depolarisation in the 
postsynaptic cell, which activates voltage sensitive Ca2+ channels, causing further 
influx of Ca2+. The disruption of ionic homeostasis caused by sustained 
depolarisation may disturb the ion pumps that act to keep intracellular Ca2+ levels 
low; thus reversal of the Na+/Ca2+ exchanger and inactivation of the Ca2+-ATPase 
will result in elevated [Ca2+]i. Disrupted ionic homeostasis may also result in the 
release of Ca2+ from intracellular stores.
1.2.2 Excitotoxicity and acute neuronal degeneration
The potential role of excitotoxicity as a pathogenic mediator of CNS disorders was 
investigated when the neurotoxic potential of glutamate was established. A 
compelling role for excitotoxic mechanisms in the pathogenesis of cerebral 
ischaemia was recognized. Rothman (1984) was amongst the first to suggest a role 
for excitotoxicity in ischaemia when he showed that a glutamate receptor antagonist 
could attenuate anoxic neuronal death in vitro. Microdialysis techniques 
subsequently demonstrated that there was a massive increase in the extracellular 
concentration of glutamate following experimental focal or global cerebral ischaemia 
and CNS trauma (Benveniste et al, 1984; Butcher et al., 1990). Following focal 
cerebral ischaemia, the rise in extracellular glutamate positively correlated with the 
size of lesion that subsequently developed (Butcher et al., 1990). Microdialysis 
monitoring of patients with ischaemic stroke or head injury has extended these 
observations to humans, demonstrating elevated levels of glutamate in CSF (Persson 
et al., 1992; Castillo et al., 1997). However, perhaps the most compelling role for 
excitotoxicity in cerebral ischaemia is the significant attenuation of ischaemia cell 
damage following administration of glutamate receptor antagonists in experimental 
models of focal and global cerebral ischaemia. Due to the direct permeability of 
NMDA receptors to Ca2+ and the evidence suggesting the importance of Ca2+- 
mediated damage in excitotoxicity, NMDA receptors were thought to be the main 
mediators of excitotoxic damage and hence NMDA receptor antagonists were 
examined initially. NMDA receptor antagonists confer robust neuroprotection in 
animal models of focal cerebral ischemia (Ozyurt et al., 1988; Park et al., 1988a, b; 
Bullock et al., 1990). Initial, promising neuroprotective effects with NMDA receptor 
antagonism in models of global ischaemia may have been due to hypothermic
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affects, and the general consensus now is that they are less effective in global 
ischaemia models (Gill et al, 1987; Buchan and Pulsinelli, 1990). In contrast, 
AMPA receptor antagonism confers potent, neuroprotective effects in both focal and 
global models of cerebral ischaemia, confirming the fundamental role for this 
receptor in excitotoxicity (Gill et al., 1992; Buchan et a l, 1993; Sheardown et al, 
1990, 1993; Bullock et al, 1994; Xue et al, 1994). The superior neuroprotection 
conferred by AMPA receptor antagonists, combined with a longer therapeutic time 
window than NMDA receptor antagonists suggested they may be more efficacious in 
the clinic, however glycine site NMDA receptor antagonists may also have these 
attributes (Gotti et al, 1988).
Taken collectively, there is convincing evidence that excitotoxicity contributes to 
pathology underlying cerebral ischaemia. It is the metabolic inhibition and impaired 
ATP production that particularly predisposes ischaemic tissue to excitotoxic damage 
(see Fig. 1.6). Ionic membrane pumps such as the Ca2+ ATPase and the Na+/K+ 
ATPase cease functioning with lack of ATP. Consequently ionic gradients are 
disrupted, membrane potential is lost, and neurons depolarise. Glutamate 
transporters, which normally utilise ionic gradients to remove glutamate from the 
extracellular cleft, cease functioning and may reverse, leading to a build up of 
glutamate in the extracellular cleft, which in turn causes continued depolarisation. 
Thus, a vicious circle ensues, and once neurons become damaged, they release 
further glutamate by cell lysis, resulting in massive increases in extracellular 
glutamate, which affects increasing numbers of surrounding cells.
Excitotoxic mechanisms have also been implicated in the acute brain pathology 
resulting from seizures. For example, the infusion of glutamate or more potent 
glutamate analogues into the brain can cause convulsions, neuronal pathology and 
epileptiform activity measured electrophysiologically (Hayashi et al, 1952, Ben-Ari 
et al, 1980). The epileptogenic potential of glutamate analogues in humans was 
highlighted following an outbreak of poisoning that occurred in Canada in 1987. This 
was caused by the contamination of mussels with domoic acid, a potent agonist of 
kainate receptors. In some cases, seizures were reported, and one patient developed 
chronic temporal epilepsy. Neuropathological examination of three patients that died 
revealed pathology in limbic structures such as the hippocampus and amygdala, 
which is similar to the pattern of pathology following kainate administration in
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Figure 1.6 Excitotoxicity at AMPA receptors during ischaemia
W hen energy required to maintain ionic gradients is lost, cells depolarise, 
release more glutamate, which in turn causes further depolarisation, and 
hence a viscous circle ensues. This leads to vast influx o f  Na through 
AM PA receptors, which leads to cell swelling and necrosis. Ca2* also 
enters cells via voltage sensitive calcium channels (VSCC), or through Ca2* 
permeable AM PA receptors. Ca2 mediated mechanisms can cause cellular 
damage via a variety o f mechanisms.
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rodents (Ben-Ari et al, 1980; Perl et al., 1990; Teitelbaum et al., 1990; Cendes et al., 
1995). Elevated levels of glutamate are also reported in patients with epilepsy 
(During and Spencer, 1993). Accordingly, glutamate receptor antagonism has 
anticonvulsant properties (Yamaguchi et al., 1993; Chapman, 1998).
1.2.3 Excitotoxicity and chronic neurodegenerative disorders
Two chronic neurodegenerative diseases thought to be directly associated with 
excitotoxic mechanisms are neurolathyrism and amyotrophic lateral sclerosis on the 
Pacific island of Guam (Spencer et al., 1986,1987). Neurolathyrism and Guam 
disease are associated with dietary intake P-oxylylamino-L-alanine (BOAA) and p- 
methylamino-L-alanine (BMAA), both agonists of AMPA receptors (Bridges et al., 
1989; Smith and Meldrum, 1992; Willis et al., 1993;). Whilst the associations made 
between these two disorders and chronic consumption of glutamate analogues are by 
no means conclusive, they suggest that an excitotoxic mechanism may be the 
primary cause of neurodegeneration.
Evidence linking excitotoxicity with other chronic neurodegenerative diseases such 
as Parkinson’s or Alzheimer’s disease is less convincing than for acute neurological 
disorders such as cerebral ischaemia. For instance, there is no compelling, consistent 
data to suggest that EAA levels are elevated in the extracellular space in these 
disorders. However, it has been hypothesised that in situations of chronic 
degeneration, disruptions in normal cellular metabolism can predispose neurons to 
excitotoxic demise in the absence of elevations of extracellular glutamate. Therefore 
normal levels of glutamate can become toxic if the cell is unable to maintain ionic 
gradients and membrane potential. This hypothesis, known as ‘slow’, ‘weak’ or 
‘secondary’ excitotoxicity, was formed on the basis of in vitro experiments 
demonstrating that impaired energy metabolism increases the vulnerability of 
neurons to excitotoxic challenges (Novelli et al., 1988; Zeevalk and Nicklas, 1990). 
Flint Beal and colleagues have demonstrated this concept in vivo, showing that 
neuronal damage induced by ‘metabolic toxins’ such as malonate or 3-nitropropionic 
acid can be attenuated with glutamate receptor antagonists (Beal et al., 1993a, b; 
Henshaw et al., 1994). Secondary excitotoxicity may act as a common mechanism 
contributing to pathology in a number of neurological disorders (Lipton and 
Rosenberg, (1994).
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1.3 Effect of brain injury to white matter
1.3.1 Composition of white matter
Coronal sectioning o f the human cerebral cortex reveals a convoluted outer rim o f 
grey matter that overlies areas o f white matter (see Fig. 1.7). Grey matter contains 
neuronal cell bodies, dendrites, local ramifications o f axons and glial cells; whereas 
white matter is composed o f myelinated axons and glial cells. White matter is 
coloured white due to the high lipid content o f the myelin sheath. During the 
evolution o f  mammalian brains, the neocortex has expanded in size considerably. 
However, as brain size increases, the volume o f white matter beneath the cortex 
increases disproportionately faster than the volume o f cortical grey matter (Zhang 
and Sejnowski, 2000). Thus, white matter comprises 5% o f the cortical mantle o f 
rats, 35% in non-human primates, and nearly half in humans (Frahm et al., 1982). 
Myelinated axons contained within white matter are the conducting units o f neurons, 
conveying signals to other cells via the action potential. Therefore the normal 
functioning o f the CNS is critically dependent upon the components o f white matter.
Infarct
Figure 1.7 White matter in the human brain
Coronal section through a human brain revealing convoluted grey matter in the 
cortex overlying white m atter areas. This patient has suffered from  a stroke 
affecting the middle cerebral artery that has resulted in tissue damage 
(discoloured area on left hand side) that has affected both grey and white matter. 
Image courtesy o f  Professor D. I. Graham, departm ent o f  Neuropathology, 
University o f  Glasgow.
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A xonal structure
i
Axons emerge from the neuron cell body as slender threads that remain uniform in 
diameter and generally do not branch until they reach their target. Axons consist of a 
gelatinous core of neuronal cytoplasm known the axoplasm, which is surrounded by 
the neuronal membrane, referred to as the axolemma. CNS axons are generally 
myelinated by oligodendrocytes as a means of improving salutatory conduction. The 
myelin is laid down in segments, known as intemodes, with unmyelinated areas 
called Nodes of Ranvier between the intemodes. The axon contains a specialised 
architecture of ion channels and transporters that facilitate saltatory conduction. For 
example, voltage gated Na+ channels are clustered at high densities at the nodal 
membrane, whilst Na+/K+ATPase and Ca2+ATPase transporters and Na+/Ca2+ 
exchangers are present on the axolemma to maintain ionic gradients (Ritchie and 
Rogart, 1977; Waxman and Ritchie, 1993). The shape and integrity of the axoplasm 
is maintained by the cytoskeleton, a form of cellular scaffolding, which also forms 
the tracks required for axonal transport of mitochondria, vesicles and proteins (see 
Fig. 1.8). The cytoskeleton of axons is composed of distinct and interacting 
components; microtubules (MTs), neurofilaments (NFs) and actin microfilaments 
(MFs). NFs can be considered as the characteristic organelle of the axon; they 
comprise the bulk of axonal volume and outnumber microtubules. They are lOnm 
tubular structures that are arranged parallel to the long axis of the axon. Axonal NFs 
contain side arms that project from their surface and ensure that they are widely 
spaced within the axolemma. Axonal NFs are usually phosphorylated, unlike those 
in the neuronal perikarya (Stemberger and Stemberger, 1983). In the axon, NFs are 
composed of three subunit proteins; NF high molecular weight subunit (NF-H or NF 
200; ~200kDa); NF medium molecular weight subunit (NF-M or NF 150; ~150kDa) 
and NF light molecular weight subunit (NF-L or NF 68 ~68kDa). MTs are also 
arranged parallel to the long axis of the axon; they are 25nm hollow rod polymers 
composed of a- and p-tubulin. Microtubule associated proteins (MAPS) stabilise 
MTs against disassembly and mediate their interaction with other cellular 
components. There are several categories of MAPS: MAPla, MAPlb (MAP 5); 
MAP2 and the tau proteins. These have different cellular distributions; tau is 
enriched in axons; MAP 2 is found mainly in neuronal perikarya and dendrites; 
MAPla and MAP lb (MAP 5) occur in somato-dendrite regions and axons, however 
MAP lb (MAP 5) is expressed preferentially in axons (Sato-Yoshitake et al., 1989).
27
28
for
m 
the
 
tra
ck
s 
re
qu
ire
d 
for
 
ax
on
al
 t
ra
ns
po
rt.
 
A
nt
er
og
ra
de
 
tra
ns
po
rt 
is 
de
pi
ct
ed
 
he
re
, 
wh
er
e 
m
ito
ch
on
dr
ia
 
an
d 
pr
ot
ei
ns
 
su
ch
 
as 
am
yl
oi
d 
pr
ec
ur
so
r 
pr
ot
ei
n 
are
 
tra
ns
po
rte
d 
do
wn
 
the
 
ax
on
 
wi
th 
the
 
aid
 
of 
the
 
m
ot
or
 p
ro
te
in
, 
ki
ne
si
n.
 
M
ito
ch
on
dr
ia
 
are
 
pr
es
en
t 
in 
the
 
ax
op
las
m
 
to
 
pr
ov
id
e 
en
er
gy
. 
AM
PA
 
re
ce
pt
or
s 
are
 
pr
es
en
t 
on 
the
 
ol
ig
od
en
dr
oc
yt
e 
so
m
a 
an
d 
m
ye
lin
 
sh
ea
th
, 
as 
w
el
l 
as 
the
 
ne
ur
on
al
 p
er
ik
ar
ya
.
MFs are 3-5nm polymers composed of actin; they are commonly anchored at the 
axolemma by the protein spectrin.
As genetic material and protein synthesis machinery is located in the neuronal 
perikarya, the axon has a supply line that can deliver constituents essential for axonal 
function to the axon and the axon terminal. The delivery of proteins and organelles 
towards the nerve terminal is called anterograde transport, whereas the transport of 
constituents back to the neuronal perikarya is referred to as retrograde transport. 
Synaptic vesicles, mitochondria, enzymes, neuropeptides and membrane lipids move 
along the axon at the rate of 50 - 400mm a day (fast anterograde transport; Brady, 
1991; Steonien and Brady, 1999); whereas cytoskeletal components such as MTs and 
NFs are transported anterogradely at the slower rate of 0.2 - 8mm per day (slow 
anterograde transport; Steonien and Brady, 1999). Retrograde transport of trophic 
factors, exogenous material and old membrane constituents occurs at the rate of 200- 
300 mm per day (fast retrograde transport; Steonien and Brady, 1999). Axonal 
transport of constituents is thought to occur along microtubules, which serve as the 
‘tracks’, whilst motor proteins are thought to mediate the movement. Kinesin is the 
motor protein utilised for anterograde transport, whilst dynein is thought to mediate 
retrograde axonal transport.
Oligodendrocyte structure
Oligodendrocytes are responsible for production and maintenance of CNS myelin; 
they may also serve to influence axonal maintenance (Ludwin et al, 1997). They 
reside in white matter, where they are aligned in rows and are known as interfasicular 
oligodendrocytes; and in grey matter, where they are known as perineuronal 
oligodendrocytes (Peters et al., 1991). Another class of perineuronal oligodendrocyte 
that are not associated with myelin formation are satellite oligodendrocytes, which 
may serve to regulate the environment around the neuron (Ludwin et al., 1997). 
Oligodendrocytes can be distinguished from astrocytes due to their smaller size, 
absence of intermediate filaments and glycogen in their cytoplasm, and their 
enormously high content of microtubules (Baumann and Pham-Dinh, 2001). 
Oligodendrocytes are a heterogeneous cell type; numerous attempts have been made 
to classify these types based on the number of processes they possess, the thickness 
of myelin sheath they produce, or the density of their cytoplasm (Baumann and 
Pham-Dinh, 2001). On the same axon, adjacent myelin segments (intemodes) are
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ensheathed by different oligodendrocytes, therefore individual oligodendrocytes are 
capable o f myelinating numerous axons (see Fig. 1.9).
Myelin Sheath Structure
Multispiral myelin sheaths are formed from membranous processes o f 
oligodendrocytes that repeatedly envelope the axon and subsequently compact 
together. At the electron microscope level, cross sectioning o f the myelin sheath 
reveals concentric electron dense and light layers. The electron dense areas, known 
as the major dense lines, are formed from the cytoplasmic or intracellular surfaces o f 
the oligodendrocyte processes that are in close apposition with each other (see figure 
1.10). The electron light areas, known as intraperiod lines are formed by the fused 
extracellular membrane surfaces (Fig. 1.10). The myelin sheath is a phospholipid 
bilayer interspersed with proteins that are integral to its function (Fig. 1.10) 
Proteolipid protein (PLP) is a 30kDa integral membrane protein o f CNS myelin, 
accounting for approximately 50% o f all CNS myelin protein. Based on the 
phenotype o f PLP-deficient mice, PLP is thought to be important for stabilising 
intraperiod lines and for the maintenance o f axonal function (Boison and Stoffel, 
1994; Griffiths et al., 1998; Edgar et al., 2001). Myelin basic protein (MBP) is the 
second most abundant myelin protein, constituting up to 40% o f myelin proteins. 
MBP represents a family o f proteins o f which 6 isoforms exist, ranging from 14 -  
21kDa. Unlike PLP, MBP proteins are cytoplasmic, and are localised in the major 
dense line o f  myelin (Monuki and Lemke, 1995). The lack o f compact myelin, 
devoid o f the major dense line in MBP deficient mice (shiverer mice) suggests that
oligodendrocyte axons
Node of 
Ranvier
myelin
sheaths
Each oligodendrocyte extends 
processes to separate axons and 
repeatedly envelopes each axon with 
a myelin sheath. Image taken from 
w w w.science-education.nih.gov.
Figure 1.9 Myelinated 
axon fibres
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MBP is essential for the formation o f compact CNS myelin (Roach et al, 1983; 
Readhead et al., 1987). Other, minor protein components o f the myelin sheath 
include myelin associated glycogen protein (MAG), which comprises ~1 % of myelin 
protein and is thought to mediate axon-glial adhesion events that precede myelination 
(Trapp, 1990); and 2 ’,3’-cyclic nucleotide 3 ’-phosphodiestarase (CNP), which 
comprises 4% o f total myelin proteins and may play a role in anchoring cytoskeletal 
elements to cytoplasmic surface o f the plasma membrane (Laezza et al., 1997).
Axon
Oligodendrocyte
Myelin Sheath
Major D e n s e  Line
Extracel lular  su r fa ce
PLP
Intraperiod Line
ooooooooooooo
MBP
OOOOOO _  OOOOOO
Cyt op la sm
ooooo ooooo<
O O O O O O A iw w u C
o r  o o r > o t _ J o c O O
Intracellular interface
MAG
O OOOOOI OOOOOGi-----iGOOO
o o o o o o o o o o o o o o o  l o f o l o l o o o o o o ^ ^ ^ ^ o
Figure 1.10 Composition of the myelin sheath
The m yelin sheath is formed by a phospholipid bilayer interspersed by several 
proteins. M BP is a cytoplasmic protein; PLP transverses the membrane with 
intra- and extra-cellular portions and M AG has a membrane spanning domain 
w ith an extracellular region. Cross sectioning the myelin sheath at EM level 
reveals concentric electron dense (m ajor dense line) and electron light layers 
(intraperiod line), which are formed by apposition o f  the intracellular, 
cytoplasmic interface and the extracellular membrane, respectively.
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1.3.2 White matter is vulnerable to injury
Acute Brain Injury
Histological stains used to evaluate volume of pallor or neuronal perikaryal damage 
traditionally dominated the study of CNS tissue changes following experimental 
ischaemia. Using such methodology, it was historically assumed that white matter 
components were less vulnerable than grey matter to ischaemic damage, and that 
white matter changes were secondary to neuronal cell body damage (Marcoux et al., 
1982). In the past ten years, the use of alternative methodology has highlighted that 
white matter is highly vulnerable to ischaemia.
Isolated white matter tract preparations provide a useful model, devoid of neuronal 
perikarya, to examine the responses of white matter components to ischaemic-like 
insults. Exposure of in vitro optic nerve preparations to anoxia results in a rapid 
abolition of action potential conduction (Stys et al., 1990). The ultrastructural 
correlates of this white matter dysfunction are loss of axonal microtubules and 
neurofilaments, swollen mitochondria and the presence of intramyelinic spaces 
(Waxman et al., 1992). Similarly, exposure of in vitro optic nerve preparations to 
anoxia combined with glucose deprivation (oxygen/glucose deprivation) results in 
axonal swelling, degeneration and swollen axonal mitochondria (Garthwaite et al.,
1999). Subjecting spinal cord dorsal columns to anoxia results in myelin and axonal 
swelling and disruption (Li et al., 1999). Deprivation of oxygen and glucose results 
in cell death in oligodendrocyte cultures (Lyons and Kettenmann, 1998; McDonald 
et al., 1998a; Yoshioka et a l, 2000). Collectively, these studies highlight that white 
matter is vulnerable to energy/oxygen deprivation independently of neuronal 
perikaryal changes.
White matter damage has also been demonstrated following experimental cerebral 
ischaemia in vivo. Pantoni and colleagues (1996) used ultrastuctrual studies to 
demonstrate that oligodendrocyte swelling and myelin vacuolation occurred 30 
minutes following middle cerebral artery occlusion. The oligodendroglial changes 
were thought to occur independently from grey matter changes, as there was no 
evidence of neuronal perikaryal pathology until 3 hours following middle cerebral 
artery occlusion (MCAO; Pantoni et al., 1996). Similarly, there is ultrastructural 
evidence that microtubule accumulation and swelling occurs rapidly in 
oligodendrocytes following transient global ischaemia. Furthermore,
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oligodendrocytes are thought to be more sensitive to global ischaemia than neurons 
in certain brain areas (Petito et al, 1986, 1998).
Whilst electron microscope studies provide useful information about the temporal 
evolution and ultrastructural changes occurring in white matter tissue, they can only 
provide information about relatively small sample areas, and therefore cannot impart 
quantitative information about the effects of drug intervention. However, the use of 
immunocytochemical methods to detect and quantify white matter changes has added 
impetus to the study of white matter pathology. Antibodies raised against 
components of the axonal cytoskeleton (neurofilaments and microtubules) are 
commonly used to assess axonal loss or disruption following experimental brain 
injury (Yaghmai and Povlishock, 1992; Dewar and Dawson, 1997; Saatman et al., 
1998; Yam et al, 1998; McCracken et al, 2002). Under normal physiological 
circumstances, proteins such as amyloid precursor protein (APP) are transported 
along the axon by fast anterograde transport (Koo et a l, 1990). However, if the 
axonal transport system becomes disrupted, for example by cytoskeletal disruption, 
then APP can accumulate proximal to the disrupted segment. APP 
immunohistochemistry is a sensitive, quantifiable marker of axonal pathology 
following a number of acute brain insults (Gentleman et a l, 1993; Sherriff et al, 
1994a; Yam et al, 1997; Imai et al, 2002; Medana and Esiri, 2003). One of the 
advantages of APP immunohistochemistry is that it detects low, diffuse amounts 
under normal circumstances, but following axonal injury, APP immunostained axons 
are strikingly visible (figure 1.11; Sherriff et al, 1994a). Disruption of the 
cytoskeletal network of oligodendrocytes can also be assessed with 
immunohistochemistry. Increased immunoreactivity of the microtubule associated 
protein tau is a sensitive marker of oligodendrocyte damage following brain injury 
(figure 1.11; Dewar and Dawson, 1995; Irving et al, 1996b, 1997; Valeriani et al, 
2000).
These methods have been utilised to confirm the vulnerability of white matter 
following cerebral ischemia in vivo. Dewar and Dawson (1997) demonstrated 
axonal damage in striatal white matter tracts following focal cerebral ischaemia, 
using MAPla and MAP 5 immunohistochemistry. Similarly, Yam et al (1998) 
showed that there was a rapid disruption in the pattern of MAP 5 immunostaining in 
white matter tracts following MCAO, and that similar disruptions and axonal
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swellings were evident using antibodies raised against the light chain component o f 
neurofilaments (NF 68). In addition, they demonstrated impaired axonal transport 
following focal cerebral ischaemia, evident as accumulations o f SNAP 25, another 
protein that undergoes fast anterograde transport (Yam et al., 1998). Accumulation 
o f APP in damaged axons, generally located at the boundary o f infarction is also 
evident following focal cerebral ischaemia (Stephenson et al., 1992; Kalaria et al., 
1993; Yam et al., 1997; Dietrich et al., 1998). Alterations in tau immunoreactivity 
within oligodendrocytes were observed, as early as 40 minutes, following focal 
cerebral ischaemia; confirming the sensitivity o f  oligodendrocytes to ischaemic 
injury in vivo (Dewar and Dawson, 1995; Irving et al., 1997; Valeriani et al., 2000). 
Tau-1 and APP immunohistochemistry can also be used to assess longer term 
changes in white matter pathology (Irving et al., 2001) and to quantify changes in 
white matter pathology following intervention strategies (Yam et al., 1997; Valeriani 
et al., 2000; Yam et al., 2000; Imai et al., 2001; 2002).
Figure 1.11 APP and Tau-1 immunohistochemistry following focal 
cerebral ischemia
Perhaps the most compelling evidence for the vulnerability o f white matter to 
ischaemia is the high incidence o f white matter damage following human stroke. A 
large number o f strokes can affect both grey and white matter. For example, middle 
cerebral artery occlusion in man, a common cause o f human stroke, can cause both 
white and grey matter infarction (see Fig. 1.7). A retrospective study o f  stroke
A . Axonal swellings visualised in APP im m unostained sections at the 
boundary o f  an ischaemic lesion. The increased im m unostaining 
contrasts with the low level o f diffuse staining in the uninjured tissue
B. Tau-positive oligodendrocytes in the cerebral cortex following focal 
cerebral ischaemia. This section was im m unostained with the Tau-1 
antibody.
Images taken by Dr D. Dewar.
34
patients concluded that 44% of patients with strokes or transient ischaemic attacks 
had white matter changes, and that these were associated with a higher risk of 
mortality or dependency (Leys et al, 1999). The presence of tau positive 
oligodendrocytes and APP immunoreactive axons in humans has been confirmed in 
post mortem material from stroke patients (Irving et al, 1996b; Jendroska et al,
1997).
White matter pathology resulting from head injury is perhaps the most 
comprehensively examined form of acute white matter injury. Diffuse axonal injury 
(DAI) can occur following non-missile (rapid acceleration and deceleration of the 
brain inside the skull) head injury (Adams et al, 1982, 1989). The presence of 
damaged axons has been confirmed microscopically in post mortem tissue from 
patients that have died following head injury. Whilst antibodies to cytoskeletal 
components have been used to determine traumatically injured axons, APP 
immunohistochemistry is the most commonly deployed methodology (Gentleman et 
al, 1993; Grady et al, 1993; Blumbergs et al, 1994; Sheriff et al, 1994a, b; Geddes 
et al, 2000). The presence of axonal swellings in APP immunostained sections can 
occur rapidly (within 2-3 hours) following head injury, and axonal swellings are 
thought to increase in size with increasing survival time following head injury 
(Sheriff et al, 1994b; McKenzie et al, 1996; Wilkinson et a l, 1999). The presence 
of cytoskeletal disruption and APP immunoreactive axons is also observed following 
experimental traumatic brain injury (Yaghmai and Povlishock, 1992; Bramlett et al, 
1997; Saatman et al, 1998; Stone et al, 2001), and has allowed the underlying 
mechanisms of traumatic axonal injury to be examined. These studies have 
suggested that most axons are not principally tom at the moment of injury, but that 
axotomy occurs some hours following the initial injury (reviewed in Graham and 
Genarelli, 1997; Maxwell et al, 1997).
Other Neurological diseases and chronic neurodegenerative diseases
The use of immunohistochemical techniques such as APP immunostaining in 
conditions such as ischaemia and trauma has established that they are sensitive 
means of detecting axonal damage. These techniques have now been applied to a 
number of other CNS disorders, where they have been used to detect axonal damage
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and to highlight the importance and functional consequences of axonal pathology. A 
recent post mortem study has demonstrated that axonal injury, detected with APP 
immunohistochemistry, was associated with the impaired consciousness and cerebral 
dysfuction caused by complications of malaria infection (Medana et al, 2002). 
Widespread axonal damage has also been detected in the brains of HIV and AIDS 
patients (An et al, 1997; Raja et al, 1997; Gray et a l, 1998). In particular, APP 
immunoreactive axons were commonly correlated with areas of myelin pallor, a 
common autopsy finding in HIV patients (Raja et a l, 1997). Proximal axonal 
swellings detected with APP immunohistochemistry in post mortem tissue from 
Amyotrohpic lateral sclerosis (ALS) patients may be associated with early disease 
changes (Sasaki and Iwata, 1999).
The presence of axonal damage in the CNS of multiple sclerosis (MS) patients has 
been documented for over a century, however the development of new means to 
examine axonal pathology has expanded knowledge about this phenomenon. Using 
neurofilament and APP immunohistochemistry, it has been established that axonal 
damage occurs early in the disease progression, in acute plaques during 
demyelinating stages (Ferguson et al, 1997; Trapp et a l, 1998; Komek et al, 2000). 
The presence of early axonal pathology has also been confirmed in animal models of 
MS (EAE models), and in living MS patients using magnetic resonance spectroscopy 
(MRS) imaging to measure N-acetylaspartate (NAA, an index of axonal integrity) 
(Komek et al, 2000; Stefano et al, 2001; Bjartmar et a l, 2002; Filippi et al, 2003). 
Axonal pathology is also documented in a number of other myelin disorders 
(Bjartmar et al, 1999). Charcot-Marie-Tooth (CMT) disease is a peripheral 
neuropathy characterised by distal weakness, and decreased sensory and tendon 
reflexes. This disease encompasses a number of different forms, which are related to 
mutations in peripheral myelin proteins. Axonal loss and degeneration are 
characteristic of some forms of CMT (Dyck et a l, 1989; Hanemann et a l, 2001). 
Axonal loss, demonstrated by MRS imaging of NAA levels, has also been 
demonstrated in patients with Pelizaeus Merzbacher disease (PMD) caused 
specifically by PLP deficiency (Garbem et al, 2002). In addition, post mortem 
material from PLP deficient patients reveals the presence of degenerating axons at 
EM level (Garbem et al, 2002). Late onset axonal pathology has also been 
demonstrated in genetically engineered mice that lack MAG, CNP or PLP (Yin et al, 
1998; Griffiths et al, 1998; Uschkureit et al, 2000; Garbem et a l, 2002; Lappe-
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Siefke et al., 2003). Collectively, these studies suggest that axonal pathology is a 
common consequence o f myelin disorders, and highlights the importance o f normal 
glial-axonal relationships for maintaining normal axonal function.
1.3.3 AMPA receptors in white matter
In addition to their presence on neuronal perikarya and dendrites, AMPA/kainate 
receptors have been localised to white matter tracts (Petralia and Wenthold, 1992; 
Jensen and Chiu, 1993; Garcia-Barcina and Matute, 1998; Matute, 1998; reviewed in 
table 1.1). At a cellular level, functional AMPA/kainate receptors have been 
localised to astrocytes and microglia (Noda et al., 2000; Seifert and Steinhauser, 
2001). However, o f direct relevance to this thesis is the expression o f AMPA/kainate 
receptors in oligodendrocytes and myelin. Furthermore, a number o f  studies have 
determined that the oligodendrocyte lineage expresses functional AMPA receptors 
(reviewed in Verkhratsky and Steinhauser, 2000). AMPA and/or kainate receptors 
have been localised to oligodendrocytes from a variety o f anatomical locations, in 
both developing and mature oligodendrocytes. This is reviewed in table 1.2. AMPA 
receptors have also been localised to the myelin sheath. GluR4 has been detected in 
the myelin sheath o f rat spinal cord dorsal columns (Li and Stys, 2000); whilst KA-2 
has been localised at myelin sheaths in the mouse spinal cord, in close proximity to 
nodes o f Ranvier (Brand-Schieber and Werner, 2003).
Anatomical 
location / origin
Developmental
Stage
AMPA/kainate 
receptor subunit
Reference
Corpus Callosum 
Optic Nerve 
Fornix
Adult bovine Abundant G luR l-3  
Trace GluR4
Garcia-Barcina and 
Matute, 1998
Optic Nerve Adult rat A bundant G luR l,3 ,4 , 
GluR5, 6, 7 
KA1, 2
M atute, 1998
Optic Nerve Post natal day 15 
and adult rat
A bundant G luRl 
Trace GluR3
Jensen and Chiu, 1994
Table 1.1 Expression of AMPA I kainate receptor subunits in white 
matter homogenates
AM PA or kainate receptor subunits were detected in white m atter hom ogenates 
from various anatomical areas using reverse-transcription -  polym erase chain 
reaction (RT-PCR).
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Anatomical 
location / 
origin
Developmental
Stage
AMPA/kainate receptor 
subunit
Reference
I n  v i t r o
Cerebral Cortex 0 -2 A  progenitors 
E20-P1 rats
Abundant GluR2, 3, 4, 
GluR6, 7, KA-1, KA-2 
Trace G luRl
Patneau e t  a l ,  1994
Glial cell line CG-4 O L ’s Abundant GluR2, 3, 4, 
Abundant GluR 6, KA-2 
Trace GluR7, KA1
Patneau e t  a l . ,  1994
Glial cell line CG-4 O L ’s GluR2, 3, 4
GluR5, 6, 7, KA-1, KA2
Yoshioka e t  a l . ,  1995
Corpus
callosum
P6 rats 
OPCs
G luR l, 2, 3
GluR5, 6, 7, KA-1, KA-2
Yoshioka e t  a l . ,  1995
Coipus
callosum
P6 rats 
Mature O L ’s
G luR l, 2, 3
GluR5, 6, 7, KA-1, KA-2
Yoshioka e t  a l . ,  1995
Optic nerve P 12 rats
M ature O L ’s - Gal C / 
M BP expressing)
GluR3, 4,
GluR6, 7, KA-1, KA-2
Sanchez-Gomez and 
Matute, 1999
Optic Nerve P7-12 rats
M ature O L ’s - Gal C
GluR3, 4
GluR6, 7, KA1, KA-2
M atute e t  a l . ,  1997
Forebrain M ouse P I -3
Mature O L ’s
CNP, Gal C expressing
GluR2/3 M cDonald e t  a l . ,  
1998a
I n  s i t u  /  I n  v i v o
Subcortical 
white matter
Adult rat
RIP expressing O L ’s
GluR2/3 M cDonald e t  a l . ,  
1998a
Corpus
callosum, int & 
external capsule
P7 rat
Immature O L ’s 
01  expressing
GluR4 Follett e t  a l . ,  2000
Corpus
Callosum
Adult bovine 
Immature O L ’s
GluR4 Garcia-Barcina and 
M atute, 1998
Spinal cord 
dorsal columns
Adult rats 
M ature O L ’s
GluR3, 4 Li and Stys, 2000
Spinal Cord Mouse
CNP+ M BP- O L ’s
KA2 Brand-Schieber and 
W erner, 2003
Table 1.2 Expression of AMPA / kainate receptor subunits in 
immature and mature oligodendrocytes
Detected by RT-PCR, southern blotting or Im m unocytochemistry. O L ’s = 
oligodendrocytes, O PC ’s = oligodendrocyte progenitor cells
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1.4 Regeneration following brain injury
Historically, the CNS was viewed on as having only a limited capacity for 
regeneration. This idea has been challenged in recent years, in part by the studies 
described in the following sections.
1.4.1 Regeneration following entorhinal cortex lesioning
A well characterised in vivo model for examining degeneration and regeneration of 
the CNS is the entorhinal cortex lesion model (Deller and Frotscher, 1997; Savaskan 
and Nitsch, 2001, see figure 1.12). Glutamatergic neurons from the entorhinal cortex 
project via the perforant pathway to the dentate gyrus of the hippocampus. Neurons 
in the granule cell layer of the dentate gyrus extend their dendrites into the molecular 
layer of the dentate gyrus; entorhinal fibres project to the outer two thirds of this 
layer (Fig 1.12), where they form 80-90% of all synapses (Steward and Vinsant, 
1983). Commissural and associational fibres from the hippocampus project to the 
inner third of the molecular layer. The molecular layer of the dentate gyrus has a 
laminated appearance because of the segregation of these projections from different 
fibre systems, (Fig. 7.6) which enables changes in neuronal connectivity to be readily 
quantified. Lesioning the entorhinal cortex induces reorganisation of hippocampal 
circuitry (reviewed in Deller and Frotscher et al, 1997; Savaskan and Nitsch, 2001; 
Ramirez, 2001).
The temporal evolution of degeneration and regeneration in the dentate gyrus 
following entorhinal cortex lesioning has been extensively examined with electron 
microscopy. Lesioning the entorhinal cortex results in degeneration of entorhinal 
neurons and their axons, and a loss of synapses in the outer molecular layer of the 
dentate gyrus (Matthews et al, 1976; Savaskan and Nitsch, 2001). The degeneration 
appears to induce the sprouting of fibres, not from the lesioned entorhinal cortex, but 
from neighbouring, intact afferent fibre systems (Steward and Vinsant, 1983). 
Sprouting is thought to mainly occur between 4-12 days following lesioning, and the 
formation of new synapses, which has been named reactive synaptogenesis, proceeds 
slightly later (Lee et al, 1977; Cotman and Nadler, 1978; Steward and Vinsant, 
1983). The time course of degeneration and regeneration have also been examined 
using immunohistochemistry and light microscopy with molecular makers of 
sprouting and synatogenesis, GAP-43 and synaptophysin (Masliah et a l, 1991).
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Entorhinal Cortex B ML
GCL
Entorhinal Afferent
W'-
*
OML
MML
IML
GCL
Figure 1.12 Afferent projections from the entorhinal cortex to the 
molecular layer of the dentate gyrus
A. Digitised H & E sections dem onstrating the perforant pathw ay projection 
from  the entorhinal cortex to the dentate gyrus
B. Higher magnification view o f the dentate gyrus, illustrating the granule cell 
layer (GCL) and the m olecular layer (ML).
C. Neurons in the granule cell layer (GCL) extend there dendrites into the 
molecular layer, which has a laminated apperance com prising o f the inner 
molecular layer (IML), middle molecular layer (MML) and outer m olecular 
layer (OM L). Fibres from the entorhinal cortex project to the outer two 
thirds o f the m olecular layer where they form syapses with dendritic 
branches o f  the granule cell layers.
GAP-43 is a presynaptic membrane protein that may play a role in LTP, 
neurotransmitter release, and cytoskeletal organisation, however it is also expressed 
abundantly in the growth cones of sprouting axons (Skene et al, 1986; Benowitz and 
Routtenberg, 1997; Benowitz e ta l, 1998, 1990). Synaptophysin is a calcium binding 
glycoprotein localised in synaptic vesicles; synaptophysin immunohistochemistry 
can be used to label synapse density (Wiedenmann and Franke, 1985; Masliah et al, 
1991). GAP-43 and synaptophysin are useful markers of degeneration and 
regeneration in the CNS, as they can label both fibre degeneration and sprouting, and 
synapse loss and reactive synaptogenesis, respectively (Masliah et al., 1991).
Masliah and colleagues (1991) reported a significant decrease in both markers in the 
middle and outer molecular layers of the dentate gyrus 7 days following entorhinal 
cortex lesion in the rat, however, there was a 80% recovery of synaptophysin and a 
complete recovery of GAP-43 immunostaining by 30 days.
1.4.2 Neurogenesis
The discovery of a population of endogenous stem cells that divide and give rise to 
new neurons (neurogenesis) in adulthood in the mammalian CNS has further 
challenged the idea that the regenerative capacity of the CNS is limited. The dentate 
gyrus is one area of the brain where there is a population of dividing neuronal and 
glial progenitor cells (Cameron and McKay, 2001; van Praag et al., 2002). The S- 
phase marker 5-bromo-2’deoxyuridine (BrdU) is commonly used to label 
proliferating stem cells in the dentate gyrus; using this marker it has been suggested 
that approximately 10 000 new cells are generated in the dentate gyrus each day 
(Miller and Nowakowski, 1988; Cameron and McKay, 2001). Many of these newly 
generated cells go on to die 1-2 weeks following generation, however a proportion 
may survive and go on to form functional neurons (Gould et al., 1999; Shors et al, 
2001; vanPraag et al., 2002). Enhanced levels of stem cell proliferation and 
neurogenesis in the dentate gyrus have been demonstrated following brain injury, 
such as global and focal cerebral ischaemia, seizures and entorhinal cortex lesion 
(Gould and Tanapat, 1997; Parent et al., 1997; Liu et al, 1998; Arvidsson et al., 
2002; Kokaia and Linvall, 2003).
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1.5 Therapeutic Potential of AMPA receptor 
antagonists and AMPA receptor potentiators
Overwhelming evidence suggests that excitotoxic mechanisms contribute to the 
pathophysiology of cerebral ischaemia (discussed in section 1.2.2). Based on their 
efficacy in animal models of ischaemia (McCulloch et al., 1992), NMD A receptor 
antagonists were advanced to clinical trials in human stroke, however they showed 
no evidence of efficacy (Dyker and Lees, 1998; Devuyst and Bogousslavsky, 1999; 
Lees et al., 2001). Their inability to improve functional outcome in the clinic is 
multifactorial (Gladstone et al., 2002), but may partly be related to an inability to 
protect white matter. Compared to rodents, which are generally used to demonstrate 
pre-clinical efficacy, humans have evolved larger amounts of white matter (see 
section 1.3.1). Whilst MK-801 can protect grey matter following focal cerebral 
ischaemia in the cat, there is no concomitant protective effect on the axons in white 
matter (Yam et al, 2000). This is consistent with the lack of evidence for functional 
NMDA receptors in white matter (Verkhratsky and Steinhauser, 2000). It seems 
obvious that improved functional outcome following stroke should be dependent on 
the protection of neuronal perikarya in addition to axons and white matter 
components as the latter are critical for the normal functioning of the nervous 
system.
AMPA receptor antagonism may represent a promising approach for the treatment of 
ischaemic stroke. Based on the presence of functional AMPA receptors in white 
matter (reviewed in section 1.3.3) it seems more likely that AMPA receptor 
antagonists may be capable of salvaging the cellular components of both white and 
grey matter. Considerable evidence suggests a role for AMPA receptors in mediating 
white matter pathology. Thus, oligodendrocytes are vulnerable to AMPA receptor 
mediated toxicity in vitro and in vivo, and AMPA receptor antagonism can attenuate 
in vitro white matter preparations from ischaemic-like insults (reviewed in chapter 
3). The role of AMPA receptors in mediating white matter pathology in vivo, and in 
particular, axonal pathology will be investigated further in this thesis.
In contrast to glutamate receptor antagonists, the clinical potential of AMPA receptor 
potentiators (described in section 1.1.4) has only become evident within the past ten 
years. Based on the role of AMPA receptors in plasticity and LTP (reviewed in
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section 1.1.6), potentiating activity at AMPA receptors may have beneficial effects in 
a number of clinical disorders. Deficits in glutamatergic transmission have been 
hypothesised in the aged brain, in Alzheimer’s disease and in schizophrenia, which 
are often associated with cognitive deficits (Tamminga, 1998; Carlsson et a l, 1999; 
Segovia et al, 2001; Farber et al, 2002). The ability of AMPA receptor potentiators 
to enhance action potential discharge rate, LTP and performance in rodent and 
human models of cognition suggests that they may have positive effects in these 
clinical conditions (Staubli et al, 1994,a,b; Davies et a l, 1997; Ingvar et a l, 1997; 
Vandergriff et al, 2001; Quirk and Nisenbaum, 2002). Pre-clinical animal studies 
have also suggested that AMPA receptor potentiators may possess anti-depressant 
effects (Li et al, 2001; Knapp et al, 2002). Whilst AMPA receptor potentiators 
such as LY404187 are known to enhance AMPA induced currents in prefrontal 
cortical, hippocampal and spinal neurons (Baumbarger et a l, 2001; Vandergriff et 
al, 2001), there is little other information regarding the anatomical site of action of 
AMPA receptor potentiators or the functional consequences of AMPA receptor 
potentiation. This will be investigated in this thesis.
Activation of AMPA receptors is known to promote BDNF synthesis (Zafra et al, 
1990; Bessho et al, 1993; Wetmore et al, 1994; Hayashi et a l, 1999). Furthermore, 
AMPA receptor potentiators can enhance the expression of BDNF protein and 
mRNA in vitro (Lauterbom et al, 2000; Legutko et al, 2001). Administration of 
CX-546, or LY404187 or its active isomer LY451646 results in increased expression 
of BDNF mRNA and protein in the hippocampus of rats (Lauterbom et al, 2000; 
Mackowiak et a l, 2002). BDNF is proposed to play a role in brain injury, as 
endogenous BDNF is upregulated following brain injury (Kokaia et a l, 1995,1998; 
Goutan et a l, 1998; Hicks et al, 1999; Dougherty et al, 2000) and exogenously 
administered BDNF is neuroprotective (Beck et a l, 1994; Schabitz et a l, 1997). 
Furthermore, BDNF has been shown to enhance regeneration following brain injury. 
For example, exogenous administration of BDNF can promote axonal sprouting 
following spinal cord or optic nerve injury, or neurotoxin-induced lesion of cortical 
serotonin neurons (Mamounas et a l, 2000; Coumans et a l, 2001; Klocker et al, 
2001; Takano et al, 2002). The inability of BDNF to cross the blood brain barrier 
precludes its development as a treatment to enhance regeneration in the human CNS; 
therefore means of enhancing endogenous BDNF levels may be therapeutically 
beneficial. Based on the ability of AMPA receptor potentiators to enhance BDNF
43
levels in vivo, it can be hypothesised that they may enhance regenerative processes
following brain injury. This was investigated in this thesis, using the entorhinal
cortex model of degeneration and regeneration.
1.5.1 Aims of Thesis
1. To determine if AMPA receptor mediated excitotoxicity results in axonal 
damage in vivo. To determine if AMPA receptor antagonism can protect both 
grey and white matter damage following focal cerebral ischaemia in vivo.
2. To establish a mouse model of AMPA-induced axonal damage. To compare 
AMPA-induced pathology with malonate (a mitochondrial inhibitor)-induced 
pathology in the mouse.
3. To determine if PLP and MBP deficient mice exhibit an altered sensitivity to 
AMPA-induced axonal and neuronal damage in vivo.
4. To determine the anatomical site of action of the AMPA receptor potentiator, 
LY404187.
5. To determine if the AMPA receptor potentiator, LY404187 can enhance 
regeneration following brain injury.
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CHAPTER 2 
MATERIALS AND METHODS
2.1 In vivo rat model of AMPA toxicity
2.1.1 Stereotaxic Surgery
Adult male Sprague Dawley rats (Harlan Olac, Bicester, UK) used in these studies 
were housed in groups prior to surgery, fed with the same diet and housed in 
identical conditions. The rats were anaesthetised initially in a perspex box containing 
5 % halothane in a nitrous oxide and oxygen gas mixture (70:30), and then 
transferred to a David K opf stereotaxic frame, where the incisor bar was set at 
-3.5mm (Clark, Electromedical). A facemask was fitted over the snout, and halothane 
was reduced to 1.5-2.5% for the remainder o f the surgical procedure. Rectal 
temperature was monitored throughout the period o f anaesthesia and maintained 
close to 37°C with the aid o f heating lamps.
A midline incision was made in the scalp, and the skin and muscle retracted to reveal 
the surface o f the skull and Bregma. A 26g, blunt ended 2pl Hamilton syringe 
attached to the stereotaxic frame was aligned over Bregma, and then moved to the 
appropriate coordinates (AP -0.26m m , ML 2mm; from the stereotaxic atlas o f 
Paxinos and Watson, 1986) where an ink mark was made on the skull. A small 
burrhole was then made using a dental drill cooled with saline, and the dura was 
pierced with a dural hook. The Hamilton syringe was lowered 3mm from the surface 
o f the brain into the external capsule (Fig. 2.1), where injections o f 0.5pl o f S-AMPA 
(Sigma) or
Figure 2.1 Stereotaxic injection 
into the rat external 
capsule
Digitised H&E stained section 
depicting the injection site, at 
the co-ordinates AP=-0.26,
M L=2mm, DV=3m m relative 
to Bregma
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vehicle (PBS, lOmM, pH7.4) were made at the rate of 0.1 pi per minute. When the 
injection was complete, the syringe was left in place for 10 minutes to allow 
diffusion of the injectate from the needle tip. Following removal of the needle, the 
scalp was sutured with 4 /0 silk thread (Tyco Healthcare, UK), and 2 mis of saline 
was administered subcutaneously. A topical antibiotic (Auremycin) was applied 
liberally over the wound to minimise infection. Anaesthesia was withdrawn, and 
animals were housed individually for a survival period of 24 hours on post-operative 
pads in cages containing soft diet.
2.1.2 Intravenous administration of the AMPA antagonist SPD 502
Male Sprague Dawley rats (Harlan Olac, Bicester, UK) were initially anaesthetised 
in a perspex box with 5% halothane in a 30% oxygen / 70% nitrous oxide mix.
When deeply anaesthetised, rats were intubated by introducing a 16 gauge intubation 
tube, which contained a blunted needle within the tube, into the trachea (Quick-Cath 
II; 51mm L, Baxter). Once in place, the needle was removed and rats attached to a 
ventilator delivering anaesthetic containing between 1-2% halothane.
The left femoral artery and vein were cannulated to allow for blood pressure 
monitoring and drug infusion, respectively. Cannulae were prepared at least 24 
hours prior to surgery, consisting of a 2cm length of polythene cannula (external 
diameter 0.96 mm, internal diameter 0.58mm diameter; SIMS Portex Ltd) inserted 
into a 20cm length of wider diameter cannula (external diameter 1.4mm, internal 
diameter 0.63 mm, SIMS Portex Ltd), and secured with a small amount of superglue 
(RS Components). The femoral vessels were exposed by blunt dissection using 
forceps, the artery and vein were isolated, and blood flow was temporarily restricted 
by holding the vessels taut with 4/0 silk thread (Tyco Healthcare, UK). A small 
incision was made in each vessel using microscissors, and the cannulae, containing 
heparinised saline, were inserted and advanced 1cm into the vessels. Following 
insertion into the artery and vein, the cannulae were secured with 4/0 silk thread 
(Tyco Healthcare, UK), and a small amount of superglue (RS Components). By blunt 
dissection, a small incision was made at the nape of the neck, and the cannulae, 
sealed using small metal stoppers, were advanced through the subcutaneous tissue to
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the neck, and externalised with the aid of a hollow stainless steel rod. Lignocaine gel 
(Biorex Labs Ltd) was applied to the femoral incision site, which was then sutured.
Animals were assigned into drug or vehicle groups by Mrs Joan Stewart, and I was 
blinded to the Animals received an intravenous bolus of drug (SPD 502, formerly 
known as NS 1209, Neurosearch, 16 mg/kg) (n=5) or vehicle (24 mM NaOH in 
isotonic saline) (n=6), 15 minutes prior to intracerebral injection of AMPA (25nmol) 
into the external capsule as described in section 2.1.1. All animals received identical 
volumes of bolus containing drug or vehicle (1 ml/kg) administered over 2 minutes. 
Rats then received continual infusion of SPD 502 (16mg/kg/hr) or vehicle (6mM 
NaOH in isotonic saline) for 1 hour. Again, rats received identical volumes of drug 
or vehicle infusions (4ml/kg/hr). All infusions were made with a Harvard infusion 
pump (Harvard apparatus syringe pump model ‘22’). Following the infusion, 
cannulae were trimmed until just surpassing the incision site at the neck, sealed using 
blunted 1cm metal stoppers made from needle tips (23 gauge, 0.6mm diameter, 
Microlance), and then held in place by suturing. Anaesthetic was withdrawn and the 
endotracheal tube was removed once the animals were capable of spontaneous 
respiration. Animals were then administered saline and housed in individual cages 
with soft diet. All animals used in these studies were perfuse fixed 24 hours 
following the stereotaxic injection.
2.1.3 Perfusion Fixation
Animals were deeply anaesthetised in a perspex box containing 5% halothane in a 
30% oxygen / 70% nitrogen mixture, and then transferred to a facemask where 
halothane levels were reduced to 3% until the end of the saline step of the procedure. 
An incision was made below the sternum to reveal the diaphragm, which was 
excised. The ribs were cut at either side of the midline to expose the heart. A blunt 
needle attached to the perfusion fixation equipment was inserted in the left ventricle 
and advanced up the aorta. The needle was clamped in place, and the right atrium 
was pierced to allow for drainage of blood. Between 300 -  400 ml of heparinised 
saline (1000units/100ml) was administered to the animal until the perfusate ran clear. 
The animal was then administered 300-400 ml of 4% paraformaldehyde in a 50 mM 
phosphate buffer solution (Sigma, see appendix 2) until the carcass became rigid.
The heads were removed and immersed in paraformaldehyde solution for 24 hours.
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The brains were then removed from the skull, and post-fixed in paraformaldehyde for 
a further 24 hours.
|
i
2.1.4 Tissue processing and cryostat cutting
Following post-fixation in paraformaldehyde, the brains were transferred to 30% 
sucrose in 10 mM phosphate buffered saline. The brains initially floated in this 
solution, and gradually sank over the course of 3 or 4 days. The brains were then 
frozen in isopentane cooled to -42°C in dry ice for 2 minutes, mounted on a chuck 
using cryomatrix (Shandon) and stored at -20°C until ready for sectioning. Sections 
(30pm) were cut in a cryostat (Bright) at -20°C, and stored in individual cell wells 
i containing cryoprotectant (see appendix 2) at -20°C until further use.
2.2 Focal cerebral ischaemia
Dr Eileen McCracken performed all surgical procedures and tissue processing for 
this experiment. Male Sprague-Dawley rats were deeply anaesthetised in a perspex 
| box with 5% halothane and 30% oxygen/70% nitrous oxide, intubated and
| mechanically ventilated on 1-2% halothane in 30% oxygen/70% nitrous oxide for the
duration of surgery. Both arterial and venous lines were cannulated to allow blood 
pressure monitoring and for drug infusion, respectively. Mircovascular clips were 
placed on the left common carotid artery (CCA) and internal carotid artery (ICA) and 
the external carotid artery (ECA) was electro-coagulated distal from the bifurcation 
of the ECA and ICA. A heat blunted 3.0 monofilament was inserted in the ECA and 
advanced up through the ICA for approximately 22mm until resistance was felt, to 
block the origin of the middle cerebral artery (MCA) (Longa et al., 1989). Vehicle 
(saline 24mmol/L NaOH in isotonic saline)(n=8) and drug (SPD 502) (n=7) was 
administered as an intravenous bolus (16mg/kg) 15 minutes prior to monofilament 
insertion, and then as a continuous infusion for 4 hours (16mg/kg/hr) with a Harvard 
infusion pump. Drug cerebrospinal fluid levels were estimated to be 300nM based 
upon the pharmacokinetics and brain entry of the drug (Morrison, unpublished data, 
Shire Pharmaceuticals development Ltd, U.K). After 3 hours of ischaemia the 
monofilament was removed, animals were allowed to recover and placed in a 
controlled environment for 21 hours. Animals treated with SPD 502 appeared more 
lethargic than the vehicle treated animals in the initial post-operative period. In the
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latter 12 -24 hours of the recovery period both groups of animals behaved in a similar 
manner. Twenty-four hours after the onset of ischaemia animals were perfused 
transcardially with 0.9% saline and 4% paraformaldehyde. Rat brains were processed 
for paraffin embedding and 6pm sections cut for histology and 
immunohistochemistry. The inclusion criteria for analysis of the tissue were the 
absence of an intracranial haemorrhage and the presence of neuronal damage.
2.3 In vivo mouse model of AM PA toxicity
2.3.1 Stereotaxic surgery
All mice used in these studies were housed in groups prior to surgery, fed with the 
same diet and housed in identical conditions. The mice were initially anaesthetised in 
a perspex box containing 3% halothane in an oxygen and nitrous oxide mix (20:50), 
then transferred to a David Kopf stereotaxic frame (Clark, Electromedical). A mouse 
facemask was fitted over the snout, and anaesthesia maintained with 3-3.5%  
halothane for the remainder of the surgical procedure. Rectal temperature was 
monitored throughout the surgical procedure and maintained at 37°C by the use of 
heating lamps. A midline incision was made which exposed the skull and Bregma.
A 2pi Hamilton syringe was aligned over Bregma, and then moved to the appropriate 
coordinates (-0.25mm AP, 2mm ML; from the stereotaxic atlas of Franklin and 
Paxinos, 1997, Fig. 2.2), where an ink mark was made on the skull. A burr hole was 
drilled over this spot, using saline to cool the skull. The dura was pierced using a 
dural hook, and the syringe was slowly lowered 3.5mm from the surface of the brain. 
Injections of 0.7pl S-AMPA (Sigma), malonate (Sigma) or vehicle (PBS, lOmM, 
pH7.4) were made into the caudate nucleus at the rate of 0.1 pi per minute. The 
needle was left in place for 5 minutes to allow for diffusion of the injectate from the 
needle tip. The syringe was then gradually removed from the brain, and the scalp 
sutured with 6/0 silk thread (Tyco Healthcare, UK). Following subcutaneous 
administration of 1ml of sterile saline, anaesthesia was withdrawn and the animals 
were housed in individual cages for 24 hours with soft diet.
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Figure 2.2 Stereotaxic 
Injection into the 
mouse caudate 
nucleus
Digitised H&E stained section 
dem onstrating the injection site, at the co­
ordinates AP—0.5, M L=2mm, DV=3.5mm 
relative to Bregma
2.3.2 Perfusion Fixation
The mice were deeply anaesthetised in a perspex box containing 3% halothane in a 
20% oxygen / 50% nitrous oxide mixture, then transferred to a face mask where 
anaesthesia was maintained. An incision was made in the abdomen to reveal the 
diaphragm, which was excised. The ribs were cut at either side o f the midline to 
expose the heart. A needle, attached by tubing to a 20ml syringe, was placed in the 
heart through the left ventricle, clamped in place, and the right atrium was pierced. 
Twenty mis o f heparinsed saline, then 20ml o f 4% paraformaldehyde (appendix 2) 
was infused continually at the rate o f 3.24ml per minute using a Harvard infusion 
pump. The heads were removed, and post-fixed in paraformaldehyde for 24 hours. 
The brains were removed from the skull, post-fixed in paraformaldehyde for a further 
2 hours, then placed in 50 mM phosphate buffer until paraffin processing.
2.3.3 Paraffin processing and sectioning
The whole mice brains were dehydrated through a series o f alcohols, cleared with 
xylene, then submerged in liquid paraffin at 60°C by an automated tissue processor 
(VIP, appendix 1). The brains were then embedded in small containers containing 
liquid paraffin, left to cool, then removed and mounted onto wooden blocks.
Sections (6pm) sections were cut using a microtome (Leica RM 2135), and mounted 
onto poly-L-lysine slides (see appendix 2).
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2.4 In vivo rat entorhinal cortex lesion model
2.4.1 Stereotaxic Surgery
Adult male Sprague Dawley rats (Harlan Olac, Bicester, UK) used in these studies 
were housed in groups prior to surgery, fed with the same diet and housed in 
identical conditions. The rats were anaesthetised initially in a perspex box containing 
5 % halothane in a nitrous oxide and oxygen gas mixture (70:30), then transferred to 
a David K opf stereotaxic frame (Clark, Electromedical). A facemask was fitted over 
the snout, and halothane was reduced to 1.5-2.5% for the remainder o f the surgical 
procedure. Rectal temperature was monitored throughout the period o f anaesthesia 
and maintained close to 37°C with the aid o f heating lamps.
Figure 2.3 Stereotaxic 
Injection into the 
rat entorhinal 
cortex
Digitised H&E stained section 
dem onstrating the injection site, at the co­
ordinates AP=-8.3, M L^6.8m m , relative to 
Bregma. The needle was at an angle o f  15°; 
lowered 3.5mm from  the surface o f  the 
brain.
A midline incision was made in the scalp, and the tissue and muscle were retracted to 
reveal the surface o f the skull, bregma and the interaural line. Muscle was retracted 
to reveal the right occiptal bone, down to the base o f the skull. A 2pl Hamilton 
syringe attached to the stereotaxic frame was aligned over bregma, and then moved 
to the appropriate coordinates (AP -8.3mm, ML 6.8mm, angle 15°C from vertical,
Fig. 2.3) where an ink mark was made on the skull. A burr hole was drilled over this 
area with a dental drill, using saline to cool the skull, and then the dura was pierced 
with a dural hook. The needle was lowered 3.5 mm ventrally from the surface o f the 
brain. Ibotenic acid (a-amino-3-hydroxy-5-isoazoleacetic acid, Sigma, lOmg/ml) 
made in PBS (lOmM, pH 7.4) was injected into the entorhinal cortex, at the rate o f
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0.1 pi per minute. A total volume o f 0.5pl was injected, and then the needle was left 
in place for a further 10 minutes to allow diffusion o f the injectate. The skin was 
then sutured, anaesthesia discontinued, and 2 ml o f sterile saline was administered 
subcutaneously. Animals were housed individually following surgery, initially on 
post-operative pads in cages containing soft diet. The following day, animals were 
transferred to individual cages containing sawdust and returned to the animal unit.
2.4.2 Experimental design and drug administration
The experimental design is illustrated in figure 2.4. Animals were divided into two 
groups o f  either 2 (Group A) or 3 (Group B) weeks survival time following the 
entorhinal cortex lesion (ECL). Drug or vehicle treatment commenced 7 days 
following ECL. On day 6 post ECL, all animals administered intraperitoneal 
injection o f BrdU (lOOmg/kg in 0.007NaOH/0.9% saline; lm g/80pl). Animals from 
each group were randomly assigned to drug (LY404187, 0.5mg/kg) or vehicle (10% 
ethanol, 3.75% hydroxy-propyl-p-cyclodextrin) treatment. Each animal received 
subcutaneous injections o f LY404187 (0.5mg/kg) or vehicle twice daily. All animals 
received identical volumes o f either drug or vehicle (lm g/4m l).
Inject BrDU 
(100mg/kg)s.c
Odays 7 days 14 days 21 days
I______________________!____________________I_____________________ I
Vehicle or drug treat (0.5mg/kg LY404187) 
animals twice daily for 7 or 14 days (s.c)
i i
Group A Group B
14 day 21 day
survival survival
animals animals
Figure 2.4 Experimental design for entorhinal cortex lesion study
t
Lesion entorhinal 
cortex (10mg/ml 
ibotenic acid)
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2.4.3 Perfusion Fixation
At the end of the appropriate survival period outlined in figure 2.4, animals were re­
anaesthetised and transcardially perfuse fixed with 4% paraformaldehyde as 
described in section 2.1.3.
2.4.4 Tissue processing and sectioning
Following perfusion fixation, animals were decapitated and the heads immersed in 
paraformaldehyde solution for 24 hours. The brains were then removed from the 
skull, and post-fixed in paraformaldehyde for a further 24 hours. The whole rat 
brains were dehydrated through a series of alcohols, cleared with xylene, then 
submerged in liquid paraffin at 60°C by an automated tissue processor (VIP, 
appendix 1). The brains were then embedded in small containers containing liquid 
paraffin, left to cool, then removed from the and mounted onto wooden blocks. 
Sections (6pm) were cut using a microtome (Leica RM 2135), and mounted onto 
poly-L-lysine slides (see appendix A). Sections were initially taken from the 
entorhinal cortex area to confirm lesion placement, then further sections were cut 
from the hippocampus at the level of the lateral habenula.
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2.5 Immunohistochemistry
2.5.1 General Principle
The immunohistochemistry technique takes advantage of basic immunological 
principles to enable the detection and localisation of specific tissue constituents 
(antigens). Antibodies, raised in animals against a particular antigen, will bind 
specifically to the antigen located in the tissue of interest. The avidin-biotin 
detection method was used in many of the studies in this thesis to improve the 
sensitivity and resolution of the technique (Fig. 2.5). As well as using the enzymatic 
reaction between peroxidase and DAB described in figure 2.5, the incorporation of a 
fluorescent signal into the avidin (ie, texas red, avidin D) was also used for antibody 
detection in this thesis.
2.5.2 Immunostaining of free-floating sections
Sections were removed from storage in the -20° C freezers, and transferred from 
cyroprotectant to individual cell wells using a paintbrush, where they were washed in 
PBS (lOmM solution). Pasteur pipettes were used at all stages during the 
experiments to remove and add the various solutions to the sections in the cell wells. 
Three hundred pi of each solution was required per section. The cell wells were 
placed on a shaker (Luckham R100) at all times, except for the overnight incubation 
in primary antibody. Immunostaining was then performed using the protocol 
described in figure 2.6. Optimal working dilutions were determined for each 
antibody using serial dilution curves. Details of the primary antibody concentrations, 
blocking sera and secondary antibodies used are shown in table 2.1. When the 
immunostaining was complete, the sections were floated onto glass slides coated 
with poly-L-lysine (Appendix 2) with the aid of Tris buffer and a paintbrush. After 
air drying overnight, the sections were then rinsed in tap water for 20 minutes, then 
dehydrated through a series of alcohols, placed in histoclear (National Diagnostics), 
and coverslips mounted using DPX (R.A. Lamb Lab Supplies). Negative controls 
underwent the same procedure as above except for omission of the primary antibody. 
No significant staining was detected in these controls.
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Brown c h r o m a g e n  
fo rm ed  th a t  labels  
th e  an t igen
Add s u b s t r a te  for 
p e ro x id a se  - DAB
ABC C om plex
Antigenic Epitope
Prim ary  Antibody
Biotinylated 
S e c o n d a r y  Antibody
Biotin
Avidin
P e ro x id a s e
5)
Prim ary  an t ibody  b inds  to th e  an t igen
S e c o n d a r y  an t ibody  with biotin a t ta c h e d ,  ra ised  
a g a in s t  th e  s p e c i e s  of th e  prim ary  an tibody, b inds  to 
the  prim ary an t ibody
A co m p lex  of avidin an d  biotinylated p e ro x id a se  is 
fo rm ed  in s u c h  proportion tha t  s o m e  biotin-binding 
s i te s  on  th e  avidin m o lecu le  a r e  still f ree  to re a c t  with 
the  biotin in th e  s e c o n d a r y  an t ibody
W h e n  th e  ABC c o m p lex  is a d d e d  to th e  t is sue ,  th e  
biotin on th e  s e c o n d a r y  an t ibody  r e a c ts  with free  
biotin binding s i te s  on  th e  ABC com plex
An e n z y m a t ic  reac tion  b e tw e e n  d iam inobenz id ine  
(DAB) a n d  p e r ix o d a s e  p r o d u c e s  a  brown c h ro m a g e n  
tha t  is readily  visible in t i s su e
Figure 2.5 The ABC detection method used in immunostaining
This indirect method for antibody detection improves the sensitivity and 
resolution o f  the technique. The ABC technique takes advantage o f  the very 
high affinity that avidin, a large glycoprotein from egg whites, has for biotin, 
a low m olecular weight protein from  egg yolks.
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W ash sections with PBS
PRE- 0
TREATMENT
0.2%  PBS -T riton  X-100 (Sigma) 
30 minutes
© 3% H20 2 in PBS 20 minutes
2 x 5  mins PBS washes
© 10 % normal sera + 0.5%  Bovine Serum Albumin (BSA) in PBS 
1 hour
PRIMARY
ANTIBODY ©
Prim ary antibody diluted in PBS at 
appropriate concentration 
overnight  at -4°C
3 x 5  mins PBS washes
XT
SECONDARY
ANTIBODY © Biotinylated secondary antibody made in PBS 1 hour
2 x 5  mins PBS washes
A V ID IN -B IO T IN ^  
COMPLEX (£)
ABC com plex (Vector labs) made 
according the manufacturers 
intructions in PBS 1 hour
2 x 5  mins  PBS washes
VISUALISATION 
STEP 0
DAB (Vector Labs) made up in 
distilled water according to 
m anufacturer instructions 
2-10 mins
Rinse sections in Tris buffer and 
m ount onto Poly-L-lysine slides
To perm eabilise the 
sections
To quench endogenous 
peroxidases
Blocks non-specific 
binding sites with normal 
sera from the species the 
secondary antibody was 
raised in
Primary antibody raised 
in an animal against the 
antigen o f  interest
Secondary antibody, 
raised against the species 
o f animal the primary 
anitbody was made in
Com plex o f  avidin and 
biotinylated peroxidase 
added which is made in 
such a proportion that 
there are still biotin 
binding sites on the 
avidin to bind to biotin on 
the secondary antibody
Enzym e reaction with 
peroxidase to produce a 
visible chromagen
Figure 2.6 Flow chart demonstrating the protocol for 
immunostaining of free floating sections
2.5.3 Double labelling with free floating sections
Sections were immunostained with the first antibody as outlined in steps 1-6 o f 
figure 2.6. Instead o f using DAB in the visualisation step however, SG (Vector 
Labs, UK) was used to react with peroxidase to produce a grey colour. The sections 
were rinsed with water, followed by 3 x 5 minute PBS washes and then incubated 
with the appropriate blocking solution for the second antibody for 1 hour. The 
sections were then placed in the second primary antibody made in PBS overnight at - 
4°C. The following day, sections were treated as outlined in steps 5 and 6 in the 
protocol in figure 2.6. For the visualisation step with the second antibody, VIP 
(Vector Labs) was used to produce a pink chromagen. Sections were then rinsed in 
water, and treated in the same way following the DAB visualisation step described in 
section 2.5.2.
Prim ary
Antibody
S p e c i e s  , 
type
S o u rc e  of 
Prim ary
Dilution Blocking S e r a S e c o n d a r y
Antibody
MAP-5
(clone
AA6)
Mouse
M onoclonal
Sigma 1:2000 10% horse 
serum, 0.5% 
BSA in PBS
Biotinylated Anti- 
M ouse 1:100 
(Rat Adsorbed)
NF-200
(Clone
NE14)
Mouse
M onoclonal
Sigma 1:15000 10% horse 
serum, 0.5%  
BSA in PBS
Biotinylated Anti- 
M ouse 1:100 
(Rat Adsorbed)
SMI-32 Mouse
M onoclonal
Stem berger
M onoclonals
Inc.
1:1500 10% horse 
serum, 0.5% 
BSA in PBS
Biotinylated Anti- 
M ouse 1:100 
(Rat Adsorbed)
PLP Mouse
M onoclonal
CN
Biosciences
1:1000 10% horse 
serum, 0.5% 
BSA in PBS
Biotinylated Anti- 
M ouse (Rat 
Adsorbed) 1:100
Tau-1 M ouse
M onclonal
Chemicon 1:5000 10% horse 
serum, 0.5% 
BSA in PBS
Biotinylated Anti- 
M ouse 1:100 
(Rat Adsorbed)
MAG Goat
Polyclonal
Santa-Cruz 1:100 10% horse 
serum, 0.5%  
BSA in PBS
Biotinylated Anti- 
Goat 1:100
GFAP M ouse
M onclonal
Sigma 1:1000 10% horse 
serum, 0.5% 
BSA in PBS
Biotinylated Anti- 
M ouse 1:100 
(Rat Adsorbed)
mrf-1
(M icroglial 
response 
factor-1)
Rabbit
Polyclonal
Gift from 
Dr S. Tanaka
1:50 10% goat 
serum, 0.5% 
BSA in PBS
Biotinylated Anti- 
Rabbit 1:100
Neu-N Mouse
M onoclonal
Chemicon 1:1000 10% horse 
serum, 0.5% 
BSA in PBS
Biotinylated Anti- 
M ouse 1:100 
(Rat Adsorbed)
Table 2.1 Primary antibodies used in free floating 
immunohistochemistry experiments
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2.5.4 Double labelling with the Tau-1 antibody and a marker of DNA 
fragmentation
For Tau-1 and Fluorescein-FragEL™ double labelling, sections were rinsed in PBS, 
then incubated in 0.2% Triton X-100 in PBS, followed by 1 hour in blocking solution 
(10% normal horse serum, 0.5% bovine serum albumin in PBS), and then overnight 
with Tau-1 (1:1000, Chemicon). Following washes, sections were incubated for 1 
hour with biotinylated rat adsorbed horse anti-mouse secondary antibody (1:100, 
Vector Labs), followed by 1 hour with fluorescent avidin D (Texas red, Vector Labs,
1:100), then washed again. Sections were then mounted onto glass slides and left to 
dry in the dark overnight. Detection of DNA fragmentation the following day was 
carried out with a Fluorescein-FragEL™ kit (Oncogene Research Products), 
according to the manufacturer’s instructions. Briefly, sections were rehydrated with 
TBS (20mM Tris pH7.6, 140mM NaCL) for 15 minutes, permeabilized with 2mg/ml 
proteinase K in lOmM Tris pH8 for 12 minutes and then equilibrated in 5X 
Equilibration Buffer. DNA Fragmentation was detected by incubating sections with 
TdT enzyme diluted with Fluorescein-FragEL™ TdT labelling reaction mix for 2 
hours at 37°C. At this stage, only 60pl of solution was used per section. To ensure 
that this covered all the sections evenly, a small section of film (Nescofilm) was 
placed onto the solution on each section. Sections were then rinsed and mounted 
using Fluorescein-FragEL™ mounting media.
2.5.5 Immunohistochemistry on paraffin sections
Paraffin sections were placed in histoclear for 2 x 10 minutes to remove the wax, and 
then two changes of absolute alcohol (for 5 then 10 minutes). The sections were then 
microwaved in citric acid buffer (10 mM, pH6.0) for 2 x 5 minutes on full power to 
increase the antigenicity of the tissue (optional). Following a 40-minute cooling 
period, the sections were placed in 3% hydrogen peroxide (BDH lab supplies) in 
methanol for 30 minutes, and then thoroughly washed in running water for 40 
minutes. Following 2 x 5  minute washes in PBS, the sections were removed from 
their racks, dried and ringed with a hydrophobic pen (Vector Labs) before 
proceeding with the same protocol outlined in steps 3 -7  of figure 2.6. Details of the 
primary antibody concentrations, source, and appropriate blocking solution and
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secondary antibody are shown in table 2.2. After the DAB visualisation step, the 
sections were rinsed in water, then placed in running water for 20 minutes. 
Following dehydration through a series o f  graded alcohols, the sections were cleared 
with histoclear (National Diagnostics) then mounted with coverslips using DPX 
(R.A.Lamb Lab Supplies).
Antibody S p e c ie s ,
Type
S o u rc e  of 
Prim ary
Dilution Blocking
S e ra
S e c o n d a r y
Antibody
NF 200
(clone
NE14)
Mouse,
monoclonal
Sigma Rat tissue = 
1:8000 
Mouse tissue 
-1 :8000
10% horse 
serum, 
0.5% BSA 
in PBS
Biotinylated Anti- 
M ouse (Vector) 
(Rat Adsorbed) 
1:100
APP
(clone
22CC11)
Mouse,
monoclonal
Chemicon Rat tissue =
1:500
M ouse
tissue-1:2000
10% horse 
serum, 
0.5% BSA 
in PBS
Biotinylated Anti- 
M ouse (Vector) 
(Rat Adsorbed) 
1:100 (rat)
1:300 (mouse)
MBP Rat,
monoclonal
Chemicon Rat tissue = 
1:12000 
Mouse
tis su e -1 :10000
10% rabbit 
serum, 
0.5%  BSA 
in PBS
Biotinylated Anti- 
Rat (Chemicon) 
1:100
PLP Mouse,
monoclonal
Oncogene
Reasearch
Products
Rat tissue = 
1:1000
10% horse 
serum, 
0.5% BSA 
in PBS
Biotinylated Anti- 
Mouse (Vector) 
(Rat Adsorbed) 
1:100
MAG Goat
polyclonal
Santa-Cruz Rat tissue -  
1:100
M ouse tissue -  
1:150
10% horse 
serum, 
0.5% BSA 
in PBS
Biotinylated Anti- 
Goat (Vector) 
1:100
Synapto-
physin
Mouse,
monoclonal
Sigma Rat tissue = 
1:100
10% horse 
serum, 
0.5% BSA 
in PBS
Biotinylated Anti- 
Mouse (Vector) 
(Rat Adsorbed) 
1:100
GAP-43 Rabbit,
polyclonal
Chem icon Rat tissue- 
1:1000
10% goat 
serum, 
0.5%  BSA 
in PBS
Biotinylated Anti- 
Rabbit (Vector) 
1:100
BrdU Mouse,
monoclonal
Sigma Rat tissue -  
1:100
10% horse 
serum, 
0.5%  BSA 
in PBS
Biotinylated Anti- 
M ouse (Vector) 
(Rat Adsorbed) 
1:100
Table 2.2 Primary antibodies used in paraffin embedded tissue 
immunohistochemistry experiments
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2.5.6 Quantification of axonal damage following intracerebral injection 
of AMPA in the rat
Every seventh section throughout the entire extent o f the histological lesion (see 
section 2.6.3) was stained using an antibody raised against MAP 5, a microtubule 
associated protein present in axons. MAP 5 immunostained sections were captured 
and digitised with a standard 8-bit CCD video camera connected to an MCID-M4 
image analyser (Imaging Research, Canada). The image o f  each coronal section was 
printed, at a fixed magnification, onto A4 paper using a laser printer. Areas o f axonal 
damage, which contained axonal bulbs and swellings, were identified in the external 
capsule using a conventional light microscope, and transcribed onto the digitised 
images. These areas o f axonal damage were then quantified by placing a 2mm 
spaced transparent grid over each digitised image, and counting the number o f grid 
intersections that fell within the area containing damaged axons. A MAP 5 score for 
each animal was obtained by summing the scores for each coronal plane through the 
lesion. The reproducibility o f the MAP 5 scoring system was examined and 
described in appendix 3.
Figure 2.7 AMPA-induced axonal damage in the external 
capsule in MAP 5 immunostained sections
A. Representative image from  the external capsule contralateral to 
the injection site, where axons appeared smooth, and ordered.
B. Axonal swellings and disruption following intracerebral injection 
o f  AM PA
Scale bar = 50/xm.
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2.5.7 Quantification of oligodendrocyte damage following intracerebral 
injection of AMPA in the rat
Increased tau immunoreactivity is present in oligodendrocytes in the brains of rats 
after focal cerebral ischaemia (Dewar and Dawson, 1995; Irving et a l , 1997, 
Valeriani et al., 2000) and following intracerebral injection of glutamate (Irving et 
a l , 1996a). Every fourteenth section throughout the lesion was immunostained with 
Tau-1. The boundary between areas containing intensely stained tau-positive 
oligodendrocytes and those containing none or a few faintly stained oligodendrocytes 
could be easily identified. Each Tau-1 immunostained section was captured using a 
standard 8-bit CCD video camera and digitised, and the resultant image was printed 
on A4 paper. With the aid of a light microscope, the area of tissue containing tau- 
positive oligodendrocytes was delineated on the printed image. The area of tissue 
containing tau-positive cells was determined, with the aid of the delineated printed 
diagrams, using the MCID-M4 image analyser that had been calibrated for distance 
with a 1cm graticule. The volume of tissue containing oligodendrocyte damage was 
calculated using the integration of the damaged areas with the distance between the 
sections.
2.5.8 Quantification of myelin damage following intracerebral injection 
of AMPA in the rat
Every fourteenth section throughout the histological lesion was immunostained using 
an antibody raised against proteolipid protein (PLP). The boundary between 
damaged myelin and normal appearing myelin was identified on the PLP 
immunostained sections. The area of myelin damage was determined using the 
MCID-M4 image analyser with the aid of a light microscope. The MCID-M4 
analyser was calibrated for distance with a 1cm graticule. The volume of myelin 
damage was calculated using the area of myelin damage on each section integrated 
with the distance between the sections.
2.5.9 Quantification of axonal damage following intracerebral injection 
of AMPA in the m ouse
Serial sections were taken throughout the lesion according to the cutting schedule 
described in section 2.6.4. Adjacent sections to those used to examine histological 
damage were stained using antibodies raised against amyloid prescusor protein (APP,
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Chemicon) or the heavy chain, phoshorylated component o f neurofilaments (NF 200, 
Sigma). Each APP or NF 200 immunostained slide was then examined by light 
microscopy, and the appropriate coronal plane was identified using a stereotaxic 
mouse atlas (Franklin and Paxinos, 1997). Areas o f focal axonal damage were then 
transcribed onto a copy o f  the appropriate area from the stereotaxic atlas. Using an 
MCID-M4 image analyser, calibrated for distance using the scale bar in the 
stereotaxic atlas (Imaging Research, Canada), the areas o f  axonal damage were then 
calculated from each coronal level throughout the lesion. The volume o f axonal 
damage was then calculated based on the distances between each section calculated 
from the stereotaxic atlas.
2.5.10 Quantification of plasticity using GAP 43 and synaptophysin 
following entorhinal cortex lesion in the rat
To quantify the GAP 43 and synaptophysin immunoreactivity, T iff images were 
captured in grey scale from the molecular layer o f the dentate gyrus at xlO 
magnification, using a Leica microscope and Image ProPlus software. Two images 
each were captured from the contralateral and ipsilateral dentate gyrus per section, as 
illustrated below. Two sections were examined per animal, from the anterior and 
posterior portion o f the lateral habenula. Images were also taken from a reference 
region in each section.
Figure 2.8 Representative diagram of dentate gyrus, illustrating 
where images were captured for quantification of 
immunostaining
Two images were captured from the dentate gyrus contralateral and ipsilateral to 
the ECL. The red boxes illustrate the areas where the images were captured.
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For synaptophysin immunostained sections, the reference region was the corpus 
callosum, which exhibited minimal levels of immunostaining. For GAP 43 
immunostained sections, the optic tract was taken as the reference region, as this 
anatomical area contained the lowest levels of immunostaining at the level of the 
hippocampus (Benowitz et al., 1988). All images were captured for each antibody 
on the same day at the same light intensity. Relative optical density was then 
measured in the inner, middle and outer molecular layers using an MCID/M4 image 
analyser (Imaging Research, Canada). Ten optical density readings were taken per 
layer for each image, using a measuring frame with a constant size. To ensure that 
there were consistent levels of immunostaining, 10 optical density readings were also 
taken from the appropriate reference region from each section. The optical density 
readings for the outer, middle and imier molecular layer from each animal were then 
averaged; and the ipsilateral values were expressed as percentage of the contralateral 
optical density readings. In addition the average optical density values from the 
contralateral dentate gyrus were compared for drug and vehicle treated animals to 
ensure that the drug had no effect on this region.
2.6 Histology
2.6.1 Haematoxylin and Eosin staining
Free floating sections, mounted onto poly-L-lysine slides (Appendix 2), were firstly 
rehydrated in water for 20 minutes, dehydrated through a series of alcohols, then 
rehydrated back through a series of graded alcohols and finally back into water. 
Paraffin sections were placed in the oven at 60°C for 20 minutes, then in histoclear 
for 2x 5 minutes to remove the wax, dehydrated through graded alcohols, and then 
into water.
Sections were placed in haematoxylin (Surgipath) for 2-5 minutes, differentiated in 
acid alcohol, rinsed in water, placed in Scott’s tap water for 1 minute, rinsed and 
placed in eosin (Surgipath) for 3-5 minutes. Sections were then dehydrated through 
a series of alcohols, cleared in histoclear and mounted with coverslips using DPX.
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2.6.2 Counter staining with Haematoxylin
Paraffin embedded sections immunostained using the APP antibody were 
counterstained with haematoxylin to enable the identification of anatomical 
landmarks. Following the DAB visualisation stage, sections were rinsed in water for 
20 minutes and then placed in haematoxylin (Surgipath) for 30 seconds, and 
differentiated in acid alcohol. Sections were then placed in Scott’s tap water for 1 
minute, rinsed in water, dehydrated through a series of alcohols, cleared in histoclear, 
and mounted with coverslips using DPX.
2.6.3 Quantification of tissue damage following intracerebral injection 
of AMPA in the rat
Serial sections (30pm) were cut coronally through the lesion, and every seventh 
section was stained with haematoxylin and eosin (H & E). Each H & E section was 
captured with an 8-bit standard CCD video camera and the area of pallor was 
measured using an MCID-M4 image analyser (Imaging Research, Canada). This 
was integrated using the distance between each section to obtain a volume of tissue 
damage for every animal.
2.6.4 Quantification of neuronal damage following intrastriatal injection 
of AMPA or malonate in the mouse
Sections (6pm) were cut coronally through the mice brains using a microtome (Leica 
RM2135). Twenty sections (2 per slide) from every 40 sections cut were floated onto 
poly-L-lysine slides for histology and immunostaining. From each cycle in this 
cutting schedule, the first slide was stained with H & E to examine histological 
damage. Each H & E slide was then examined microscopically, and the co-ordinates 
were identified using a stereotaxic mouse atlas (Franklin and Paxinos, 1997). Areas 
of focal histological damage were then transcribed onto a copy of the appropriate 
coronal level from the stereotaxic atlas. Using an MCID-M4 image analyser 
(Imaging Research, Canada), the areas of grey matter damage were then calculated 
from each level throughout the lesion. The volume of neuronal cell body damage 
was then calculated based on the distances between each section, calculated from the 
stereotaxic atlas.
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2.7 In vivo [14C]-2-deoxyglucose autoradiography
2.7.1 Theory
The [ l4C]-2-deoxyglucose autoradiographic technique ([l4C]-2-DG) allows the 
quantification o f function-related glucose utilisation within anatomically discrete 
regions o f the CNS. Two principles provide the conceptual basis for this approach. 
Firstly, under normal conditions, the metabolic requirements o f the central nervous 
system are derived almost exclusively from the aerobic metabolism o f glucose. 
Secondly, local functional activity is intimately related to local energy metabolism 
and use (Sokoloff et al, 1977). Regional measurement o f rates o f glucose 
phosphorylation therefore enables energy generation and energy consuming 
functional events within individual CNS structures to be determined.
d-GLUCOSE 2-DEOXY-d-GLUCOSE
Figure 2.9 The structural difference between glucose and 2- 
deoxyglucose
2-deoxyglucose differs from glucose only by the replacem ent o f  a hydroxyl group 
on the second carbon atom by a hydrogen atom, yet this structural difference is 
responsible for the properties that make this technique possible.
The unique properties o f 2-deoxyglucose, which differs from glucose only in the 
replacement o f the hydroxyl group on the second carbon by a hydrogen atom (Fig. 
2.9), account for the ability o f this technique to quantify glucose utilisation in 
anatomically discrete regions in the CNS. The same carrier transports glucose and 2- 
deoxyglucose across the blood brain barrier to CNS tissue, where they become
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substrates for metabolism, and are both phosphorylated by their respective hexose-6- 
phosphates. Glucose-6-phosphate is subsequently metabolised and therefore does not 
accumulate within cerebral tissues. However, 2-deoxyglucose-6-phosphate is not a 
substrate for the next enzyme in the glycolytic cycle (isomerase), and so it 
accumulates progressively during the experimental phase. An alternative pathway for 
2-deoxyglucose-6-phosphate is glucose-6-phosphatase metabolism, however this 
does not present a problem in this technique as glucose-6-phosphatase is only present 
at low levels. 2-deoxyglucose-6-phosphate is effectively trapped in the tissue for the 
duration of the experiment. Regions within the CNS that have larger rates of glucose 
utilisation will accumulate more 2-deoxyglucose-6-phosphate. The 2-deoxyglucose 
used in this technique is isotopically labelled with 14C to enable the quantification of 
accumulated [14C]-2-deoxyglucose-6-phosphate in discrete anatomical regions with 
autoradiography.
Sokoloff et al (1977) developed a theoretical model based on the biochemical 
properties of glucose and 2-deoxyglucose (Fig. 2.10), which allows the rate of 
glucose utilisation to be calculated using an ‘operational equation’ (Fig. 2.11). The 
operational equation calculates the rate of cerebral glucose utilisation in terms of the 
arterial plasma concentration of glucose (Cp) and [14C]-2-deoxyglucose (Cp*) during 
the experimental period, and the total concentration of 14C tracer within cerebral 
tissue at the end of the experiment (Q*). The operational equation depends on the 
following assumptions:-
(1) Plasma glucose concentration and the rate of glucose consumption remain 
constant during the experimental period
(2) Tissue is homogeneous within which the concentrations of [14C] -2- 
deoxyglucose and glucose are uniform and exchange directly with the 
plasma
(3) [14C]-2-deoxyglucose is present in a tracer amount
66
Plasma | | Brain Tissue
[14C]2-Deoxyglucose- 
(CP*)
Glucose
(C p)
K,
Precursor Pool
«o
I I  k 2 (0
i U
i r
I
I
I I_____
[ C]2-Deoxyglucose
(CE )
Glucose
(C e)
k3
Metabolic Products
Ki
[14C]2-Deoxyglucose-6 
-Phosphate 
(Civ,*)
Hydrolysis by 
glucose-6-phosphate
Glucose-6-phosphate
(CM)
I  
I  
I
CO2+H 2 O
Total Tissue 14C Concentration = Ci"=CE +C M
Figure 2.10 Diagrammatic representation of the theoretical model that 
formed the basis for the 2-deoxyglucose method
Cj represents the total l4C concentration in a single homogenous tissue of the brain 
CP and Cp* represent the concentrations of glucose and [l4C]-2-deoxyglucose in the 
arterial plasma
CE and CE* represent the concentrations of glucose and [l4C]-2-deoxyglucose in
tissue pools serving as substrates for hexokinase
Cm* represents the tissue concentration of [14C]-2-deoxyglucose
K]* is the rate constant for carrier-mediated transport of [,4C]-2-DG from plasma to
tissue
K2 is the constant for carrier-mediated transport back from tissue to plasma 
K3* is the constant for phosphorlyation by hexokinase 
K) K2 and K3 are the equivalent rate constants for glucose
(from Sokoloff et al, 1977)
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Figure 2.11 The operational equation of [14C]-2-deoxyglucose method
This equation is used to calculate the rate of glucose utilisation in any region 
cerebral tissue.
T represents the time at the end of the experiment
X  represents the ratio of the distribution space of deoxyglucose in the tissue to that 
of glucose
O is the fraction of glucose which, once phosporylated, continues down the 
glycolytic pathway
Km* and Vm* and Km and Vm represent the Michaelis-Menten kinetic constants for 
hexokinase and deoxyglucose, respectively.
Other symbols are defined in figure 2.10.
(from Sokoloff et al, 1981)
2.7.2 Rat surgical technique
Professor J. McCulloch performed the surgical techniques used in the 2- 
deoxyglucose experiments. Adult male Sprague Dawley rats were anaesthetised 
initially in a perspex box filled with 5% halothane in a 30% oxygen/70% nitrous 
oxide mixture. When deeply anaesthetised, rats were transferred to a facemask 
where anaesthetic was maintained at 2-2.5% halothane. The right femoral vessels 
were exposed using blunt dissection, and the femoral artery and vein were separated 
from the surrounding connective tissue. A small incision was made in each vessel 
whilst they were held taunt with silk thread to briefly reduce flow. Polythene 
catheters (external diameter 0.96 mm, internal diameter 0.58mm diameter; SIMS 
Portex Ltd; 15 cm long) containing heparinised saline were inserted 1cm into the 
vein and artery and then secured with 2/0 silk suture. Local anaesthetic gel 
(xylocaine) was applied to the incision site, which was sutured and then held in place 
with gauze pads and masking tape. The rat’s body was then inserted into a 20 cm
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length of bandage. A moistened Plaster of Paris was carefully wrapped loosely 
around the body and hind limbs to immobilise the animal. The animal’s body and 
hind limbs were then taped to a lead brick. A rectal probe was inserted to allow 
temperature to be monitored. At this stage, the anaesthetic was discontinued and the 
animals were left for 2 hours before the start of the 2-deoxyglucose procedure to 
allow the majority of the anaesthetic to clear. Animals were maintained at 37°C 
during the procedure with the aid of heating lamps. Prior to drug administration, the 
femoral artery cannula was connected to a blood pressure transducer, to allow the 
monitoring of blood pressure.
2.7.3 The 2-deoxyglucose technique -  rats
Local cerebral glucose utilisation was measured in conscious rats using an 
experimental design based on the theoretical considerations outlined in section 2.7.1, 
and the original method described by Sokoloff et al (1977). At time zero, 50pCi 
[14C]-2-deoxyglucose dissolved in 0.5ml of saline (specific activity 51 mCi/mol. 
Sigma) was administered into the venous catheter at a constant rate for 30 seconds. 
Fourteen arterial blood samples (approximately lOOpl) were taken over the 45 
minute experimental period, beginning at the onset of the administration of 14C-2- 
DG. Arterial samples were taken more frequently during the early phase of the 
experiment, then at less frequent intervals later in the experimental phase. Arterial 
samples were immediately centrifuged (Beckman Microfuge E). Plasma samples 
were then assayed for glucose levels, using a semi-automated glucose oxidase 
enzyme assay (Glucose Analyser 2, Beckman), and for 14C concentration by means 
of liquid scintillation counting. At approximately 45 minutes, the animal was 
decapitated using a guillotine, and the brain was dissected and frozen in isopentane 
maintained at -42°C for 10 minutes. The brain was mounted onto a cryostat chuck 
using mounting media (Cryomatrix, Shandon), and embedding matrix (Thermo 
Shandon, Shandon) was poured over the brain to provide a protective coating. The 
brain was then stored at -20°C (maximum of 24 hours) until it was sectioned. 
Sections (20pm) were cut in a cryostat at -15°C. As a general rule, 3 sections were 
retained from every 13 sections cut, however, extra sections were retained from 
regions of interest. The entire brain and cerebellum was sectioned according to this
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cutting schedule. Triplicate sections were retained on coverslips, which were secured 
against a piece of card. These were then exposed to X-ray film (Kodak BioMax MR- 
1 film, Sigma), with a set of 14 pre-determined [14C]methacrylate standards, which 
contain different 14C concentrations (equivalent to brain concentrations in 20/xm 
section of 44-2500nCi/g) for 3 days. The films were then developed using an 
automated film developer.
2.7.4 Densitometric analysis and calculation of cerebral glucose  
utilisation in rats
An MCID/M4 image analyser (Imaging Research, Canada) was used to determine 
local levels of 14C-2-DG that had accumulated in 51 anatomical areas, by quantitative 
densitometry. These areas were identified by visual inspection of the films on a light 
box prior to densitometry. Optical density measurements taken from the 52 brain 
areas were converted into 14C levels by reference to the optical density of the 14 
[14C]methacrylate standards on the autoradiograms, which were used to calibrate the 
machine. The size of measuring frame used to capture the optical densities varied 
for certain anatomical regions depending on the size of the structure, however it 
remained constantly sized for all treatments for a defined region. The history of the 
plasma glucose and isotope levels from the duration of the 45 minute 2-deoxyglucose 
procedure was also entered into the MCID-M4 machine. Cerebral glucose utilisation 
was then calculated using the operational equation outlined in figure 2.11 by the 
MCID-M4. For each structure analysed, cerebral glucose utilisation was calculated 
from an average of 12 densitometric readings (right and left side from 6 sections).
2.7.5 The 2-deoxyglucose technique -  mice
Cerebral glucose utilisation was estimated in mice following stereotaxic injection of 
AMPA (6nmol), malonate (1.35jtimol) or vehicle (PBS, lOmM, pH7.4) as described 
in section 2.3.1. The entire procedure was timed to take exactly 38 minutes (see 
figure 4.1), then anaesthesia was discontinued, and mice received an intraperitoneal 
injection of 4.5pCi of 14C-2-deoxyglucose in 400pl of sterile saline. Exactly 42.5 
minutes later, mice were re-anaesthetised for 2.5 minutes, decapitated, and a terminal 
blood sample taken by torso inversion and immediately centrifuged. Brains were 
dissected from the skull and frozen in isopentane at -42°C for 5 minutes. Plasma
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samples were assayed for glucose levels using a semi-automated glucose oxidase 
enzyme assay (Glucose Analyser 2, Beckman); and for 14C concentration by means 
of liquid scintillation counting. Coronal sections (20pm) were cut through the brain 
and cerebellum in a cryostat at -15°C, collected in triplicate on coverslips, and dried 
quickly on a hotplate at 60°C. Three sections from every six cut were retained, and 
autoradiograms produced by exposing the sections to X-ray film for 3 days with pre­
determined 14C standards (44-2500nCi/g).
2.7.6 Densitometric analysis and estimation of local cerebral glucose  
utilisation in mice
The technique described in section 2.7.3 for rat 14C-2- DG experiments involved 
taking 14 blood samples over the 45-minute experimental procedure, and using this 
information in the operational equation to calculate LCGU. However, in the mouse, 
only a terminal blood sample was taken, therefore local cerebral glucose utilisation 
was estimated using a semi-quantitative technique. Levels of 14C in 17 anatomical 
areas were determined based on the densitometric measurements from the X-ray 
film. Optical density measurements from the 17 brain areas were converted into 14C 
levels with reference to the 14 [14C] methacrylate standards on the autoradiograms, 
which were used to calibrate the machine. The levels of 14C were calculated in 6 
sections for each anatomical region, both in the hemisphere ipsilateral to the 
stereotaxic injection, and the contralateral hemisphere. LGCU was estimated based 
on the ratio of 14C in the region of interest with 14C in a reference region, the 
hypothalamus.
Tissue 14C in region of interest
Estimated LCGU = _____________________________
Tissue 14C in reference region 
(Hypothalamus)
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2.8 Western Blotting
2.8.1 Tissue homogenisation and preparation
Western blotting techniques were used to determine the levels of glutamate receptor 
subunits in PLP knockout and wild type littermates. Whole mouse brains (post natal 
day 20) were dissected and a membrane-enriched fraction was prepared according to 
the protocol of Norton and Poduslo (1973), by Dr Mark McLaughlin. The brains 
were homogenised in 7 mis of solution A (see appendix A) using a Polytron 
homgeniser at high speed for 10 seconds. The homogenates were then placed in a 
Beckman SW41 centrifuge tube, and 3mls of solution B (see appendix 2) was 
layered on top of the samples and centrifuged at 70000g (25000rpm) for 90 minutes 
at 4°C, yielding a pellet, supernatant and myelin fraction. The supernatant and 
myelin fraction were removed, then the pellet fraction was homogenised in solution 
B and snap frozen in liquid nitrogen and stored at -80°C until further use. The pellet 
fraction is membrane enriched and was selected for western blot analysis of the 
glutamate receptor subunits GluRl-4.
2.8.2 Quantification of protein content of sam ples
The protein concentration of the samples was determined using a BCA protein assay 
reagent (Pierce). This assay is based on the biuret reaction where proteins reduce 
Cu2+to Cu1+to generate a purple product. The intensity of the colour is proportional 
to the protein concentration and can be measured using spectrophotometry. A series 
of protein (bovine serum albumin) standards ranging from 0.1 -  0.8 mg/ml were 
reacted with the protein assay reagent, to produce solutions with a spectra of 
different colours from pale green through to purple. Light absorbency measurements 
from these standards were then determined in a spectrophotometer (Cecil) at a 
wavelength of 562 nm. From these values, a graph was constructed (figure 2.12). 
The homogenates for the western blotting were simultaneously reacted with the 
protein assay reagent, and absorbency was measured in the spectrophotometer. 
Samples were assayed in duplicate then averaged. Using linear regression analysis, 
the protein content of the samples was determined from their relative absorbencies.
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Figure 2.12 Standard Curve for determining protein concentration
The relative absorbancy of BSA standards at 562 nm increases with increasing 
concentration of BSA. Linear regression was used to determine protein 
concentration of the homogenates for the western blotting experiments.
2.8.3 SDS-PAGE electrophoresis
Once the protein concentration of each of the homogenates had been determined, the 
samples were prepared for gel electrophoresis. Equal amounts of sample were 
prepared by adding the appropriate volume of water and laemelli buffer (240pl of 3x 
sample buffer, 30pl of 1M DTT) to the homogenates to obtain 25pi of sample. 
Samples were mixed thoroughly, heated to 90°C for 4 minutes to denature the 
proteins, then spun briefly.
Mini gel apparatus was used in these experiments. The glass plates were thoroughly 
cleaned with ethanol, and the gaskets were clamped in place. A 10% resolving gel 
(see appendix 2) was prepared and immediately poured between the glass plates. A 
small amount of 0.1% SDS was poured onto of the gel to ensure that it polymerised 
evenly. When the resolving gel had set, the SDS was washed off, and a stacking gel 
(see appendix 2) was prepared. This was poured on top of the resolving gel, the 
combs inserted (to allow wells to form for the samples), and left to set. When set, 
the combs were removed, and the wells were rinsed thoroughly with PAGE buffer
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(see appendix 2). The rubber gaskets were then removed, and the gel was transferred 
to the electrophoresis apparatus, which was filled with PAGE buffer. Each sample 
was then loaded (25pi per lane) into the individual wells, with broad range colour 
markers (Sigma) also being loaded periodically. The gel was run for 1.5 hours at a 
constant current of 20 mA (Biorad).
2.8.4 Western Blotting
The gel was carefully removed from the glass plates, the stacking gel discarded, and 
excess gel trimmed from the sides. A small diagonal segment was removed from the 
left-hand comer so that the correct orientation of the gel could be determined. The 
gel was then incubated in cathode buffer for 5 -  10 minutes. The methanol in the 
cathode buffer fixes the proteins. A section of PVDF membrane (Hybond P, 
Amersham) and 6 pieces of 3MEM blotting paper per gel were prepared with the 
same dimensions as the gel (7cm x 10cm). The PVDF membrane was hydrated in 
methanol for 10 seconds, then incubated in distilled water for 5 minutes followed by 
anode II buffer (appendix 2) for at least 10 minutes. One, two and three sheets of 
3MEM blotting paper were soaked in anode I buffer, anode II buffer and cathode 
buffer, respectively (Fig. 2.13, appendix 2). Each piece of blotting paper, PVDF 
membrane and gel was then placed on the transfer equipment, according to the order 
shown in figure 2.13. Proteins were then transferred from the gel onto the membrane 
at a constant current of 100mA for 1 hour (Biorad powerpack).
Following the protein transfer, the PVDF membrane was rinsed in IX TBS-tween, 
then incubated with blocking solution (5% Marvel in IX TBS-tween) for 1 hour to 
block non-specific binding sites. The blots were then incubated in primary antibody 
(see table 2.3) on a shaker overnight at 4°C. The following day, the blots were rinsed 
for 3 x 20 minutes in IX TBS, then incubated with the appropriate HRP conjugated 
secondary antibody diluted in blocking solution for 1 hour. Following 3 x 20 minute 
washes with IX TBS-Tween, antibody detection was performed using enhanced 
chemiluminescence (ECL, Pierce), prepared according to the manufacturers 
instructions. The ECL reagents contain luminol, which reacts with the horseradish 
peroxidase in the secondary antibody producing light emission, which can be
74
detected using X-ray fdm. The membranes were removed from the IX  TBS-tween, 
excess solution blotted off, then placed in ECL solution for 1 minute. Excess ECL 
solution was removed by placing the membranes between two sheets o f blotting 
paper, then they were wrapped with cling film and secured in X-ray cassettes with 
tape. The blots were exposed to X-ray radiographs in the dark for 1-5 minutes 
depending on each antibody. Following development in a automatic X-ray 
processor, the proteins detected with the appropriate antibody appeared as dark bands 
on the X-ray film.
LID
PVDF
m e m b r a n e
To
p o w e rp a c k
3 x blotting p a p e r  
s o a k e d  in c a th o d e  
buffer
2 x blotting 
p a p e r  s o a k e d  in 
a n o d e  II buffer
1 x blotting 
p a p e r  s o a k e d  in 
a n o d e  I buffer
Figure 2.13 Arrangement of blotting paper, gel and PVDF membrane 
on semi-dry transfer system
As each layer was placed on the transfer equipment, it was rolled with a glass 
pipette to remove air bubbles
75
2.8.5 Quantification of protein levels
The films were scanned using a Hewlitt Packard scanner (ScanJet 6200C), and 
proteins were quantified for differences in light intensity using NIH imaging 
software.
Prim ary
Antibody
S p e c ie s ,
Type
S o u rc e  of 
P rim ary
Dilution of 
Prim ary
Blocking
S e r a
S e c o n d a r y
Antibody
G luRl Rabbit
Polyclonal
Chemicon 1:100 5 %  M arvel 
in TBS
HRP Anti-Rabbit 
(Sapu) 1:4000
GluR2/3 Rabbit,
polyclonal
Chemicon 1:66 5% Marvel 
in TBS
HRP Anti-Rabbit 
(Sapu) 1:4000
GluR2 Rabbit,
Polyclonal
Chemicon 1:200 5% Marvel 
in TBS
HRP Anti-Rabbit 
(Sapu) 1:4000
GluR4 Rabbit,
Polyclonal
Chemicon 1:50 5% Marvel 
in TBS
HRP Anti-Rabbit 
(Sapu) 1:4000
Actin Mouse,
M onoclonal
Sigma 1:100 000 5% Marvel 
in TBS
HRP Anti-M ouse 
(Sigma) 1:5000
Table 2.3 Primary antibodies used in the western blotting 
experiments
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CHAPTER 3
THE ROLE OF AMPA RECEPTORS IN MEDIATING 
AXONAL DAMAGE IN VIVO
3.1 Introduction
AMPA receptor-mediated excitotoxicity causes neuronal perikaryal death in vitro and 
in vivo, and AMPA receptor antagonists attenuate neuronal perikaryal damage 
following cerebral ischaemia (Meldrum and Garthwaite, 1990; Gill, 1994). In addition 
to their presence on neuronal perikarya, functional AMPA receptors are also present in 
the cellular components of white matter, such as oligodendrocytes and myelin.
Considerable evidence suggests a role for AMPA receptor-mediated excitotoxicity in 
causing oligodendrocyte death. Exposure of oligodendrocyte cultures to AMPA or 
glutamate results in cell death (Oka et al, 1993; Yoshioka et al., 1995; McDonald et 
al., 1998a, b; Sanchez-Gomez and Matute, 1999; Alberdi et al., 2002), whilst 
intracerebral injection of AMPA into the external capsule of rats results in a 60% 
reduction of oligodendrocytes (McDonald et al, 1998a). Chronic and acute in vivo 
administration of the AMPA receptor agonist kainate onto the rabbit optic nerve 
results in oligodendrocyte cell death and myelin disruption (Matute et al., 1997; 
Matute, 1998).
Myelinated axons are dependent upon interactions between the 
oligodendrocyte/myelin sheath and the axon cylinder for normal functioning. 
Excitotoxic events at the oligodendrocyte may have detrimental effects on axons, and 
hence the functioning of the nervous system. In vitro evidence suggests that AMPA 
receptor-mediated mechanisms may cause axonal damage. Exposure of spinal cord 
segments to anoxia and trauma results in a loss of compound action potential and 
structural damage to the axon cylinder, which is attenuated by AMPA-receptor 
antagonists, and exacerbated by the addition of AMPA or kainate (Agrawal and 
Fehlings, 1997; Li et al., 1999). However, while application of glutamate to spinal 
cord dorsal column segments in vitro does not affect the structural integrity of axons, 
functional integrity of the tract is impaired, demonstrated by reduced compound action 
potential (Li and Stys, 2000). This is attenuated by the AMPA receptor antagonists 
NBQX and GYKI52466, suggesting that AMPA-receptor mediated mechanisms cause 
axonal dysfunction (Li and Stys, 2000). In contrast to the spinal cord, exposure of rat 
brain slices to oxygen glucose deprivation results in both a loss of axonal compound 
action potential and neurofilament derangement, and both are prevented by blockade 
of AMPA receptors with NBQX or GYKI52466 (Baltan Tekkok and Goldberg, 2001).
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It remains to be established if axons in the brain are vulnerable to AMPA receptor- 
mediated damage in vivo.
3.1.1 Aims of study
The aims of the present study were firstly to determine if intracerebral injection of 
AMPA causes structural damage to the axonal cytoskeleton, and to confirm if this 
occurs through AMPA receptor-mediated mechanisms. The effects of AMPA on 
myelin, oligodendrocytes and neurons were also examined. In addition, it was 
determined if AMPA receptor antagonism has the potential to salvage axons as well as 
neuronal perikarya following focal cerebral ischaemia.
3.2 Methods
3.2.1 Intracerebral injection of AMPA
Male Sprague-Dawley rats (Harlan Olac, UK) weighing 300-425g received stereotaxic 
injections of 0.5jnl of S-AMPA (Sigma, UK) (2.5nmol, n=19) (25 nmol, n=5) or 
vehicle (10 mM PBS pH 7.4, n = ll)  into the external capsule according to the protocol 
outlined in section 2.1.1. To further characterise the response of myelin to 
intracerebral injection of AMPA, a separate set of animals received intracerebral 
injection of 0.5pl of S-AMPA (2.5nmol, n=5) (25nmol, n=5) or vehicle (n=4).
3.2.2 Intracerebral injection of AMPA with intravenous administration of 
the AMPA receptor antagonist, SPD-502
Male Sprague Dawley rats (340-375g) received an intravenous bolus of drug (SPD- 
502, 16 mg/kg; n=5) or vehicle (saline; n=6), 15 minutes prior to intracerebral 
injection of S-AMPA (25nmol) into the external capsule as described in section 2.1.1. 
Rats then received a continual infusion of SPD 502 (16mg/kg/hr) or vehicle for 1 hour, 
according to the protocol in section 2.1.2. All drug administration and subsequent 
analysis was performed whilst blinded to the treatment.
3.2.3 Intracerebral injection of AMPA with the NMDA receptor 
antagonist, MK-801
To determine if axonal damage induced by intracerebral injection of AMPA occurred 
through NMDA receptor mediated mechanisms, the NMDA receptor antagonist MK-
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801 was co-injected with AMPA into the external capsule as described previously 
(McDonald et al., 1998). Male Sprague-Dawley rats (295-335g) received stereotaxic 
co-injection of 0.5pl S-AMPA (25nmol) andMK-801 (5nmol, n=6); S-AMPA 
(25nmol, n=5); or vehicle (n=5) into the external capsule and were allowed to recover 
for 24 hours as described in section 2.1.1. All drug administration and subsequent 
analysis was performed whilst blinded to the treatment given for each animal.
3.2.4 Immunohistochemistry and histology following stereotaxic 
injection
Animals were re-anaesthetised 24 hours following the stereotaxic injection, then 
perfused transcardially with 0.9% heparinised saline followed by 4% 
paraformaldehyde in 50mM phosphate buffer as described in section 2.1.3. Brains 
were then processed with sucrose, then 30pm sections were cut in a cryostat, as 
described in section 2.1.4. Immunohistochemistry was performed on the free floating 
sections as described in section 2.5.2. MAP 5, NF 200 and SMI 32 immunostaining 
was used to examine axonal pathology; Tau-1 and PLP immnostaining was used to 
examine oligodendrocyte and myelin pathology respectively. Double labelling with 
Tau-1 and either GFAP (a marker of astrocytes), neuN (a marker of neurons) or mrf-1 
(a marker of microglia) was carried out according to the protocol outlined in section 
2.5.3. Double labelling with Tau-1 and TUNEL was also performed according to the 
protocol in section 2.5.4. with sections from animals that had received intracerebral 
injection of AMPA (25nmol; n=5). Free floating sections were also mounted onto 
poly-L-lysine slides and stained using conventional H & E staining to examine 
histological damage (2.6.1). Quantification of axonal, oligodendroglial, myelin and 
tissue damage is outlined in sections 2.5.6., 2.5.7., 2.5.8., and 2.6.3., respectively.
3.2.5 Focal cerebral ischaemia
Dr Eileen McCracken performed all surgical procedures and tissue processing for this 
experiment. Male Sprague-Dawley rats were deeply anaesthetised, and the right 
middle cerebral artery was occluded using the intraluminal thread technique, as 
described in section 2.2. Vehicle (saline)(n=8) and drug (SPD 502) (n=7) were 
administered as an intravenous bolus (16mg/kg) 15 minutes prior to monofilament 
insertion and then as a continuous infusion for 4 hours (16mg/kg/hr). Twenty-fours 
hours following the MCAO, animals were perfuse fixed, then brains were processed 
and paraffin embedded (section 2.2).
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3.2.6 Immunohistochemistry and histology on ischaem ic tissue
Sections (6/rm) from 8 pre-determined coronal levels throughout the brain (Osborne et 
al., 1987) were stained with H & E to determine neuronal cell body damage (section 
2.6.1). The volume of neuronal perikaryal damage was quantified by Dr Eileen 
McCracken, using a protocol described by Osborne et al., 1987. Adjacent sections 
were immunostained with APP and NF 200 to examine axonal pathology according to 
the protocol outlined in section 2.5.5. Dr Eileen McCracken performed APP 
immunostaining and quantification of axonal damage in APP immunostained sections. 
Axonal damage visible in APP immunostained sections was quantified using a scoring 
system based on the presence or absence of damaged axons in 65 individual regions of 
white matter (Imai et al., 2002). I performed the analysis of the NE 200 
immunostaining. The area of axonal damage visible in each NF 200 immunostained 
section was plotted onto a copy of the appropriate coronal level from a rat stereotaxic 
atlas (Paxinos and Watson, 1998). The volume of axonal damage in the NF 200 
immunostained sections was calculated by integration of the areas of damage on each 
coronal plane with the distance between each level. For descriptive analysis of 
damage to myelinated fibre tracts, sections were immunostained using antibodies 
raised against myelin basic protein (MBP), proteolipid protein (PLP) and myelin 
associated glycoprotein (MAG), according to the protocol outlined in section 2.5.5.
3.2.7 Statistical Analysis
To determine if there was any significant difference between the AMPA (2.5nmol or 
25nmol) or vehicle-injected animals, one-way analysis of variance was used with post- 
hoc Student’s Mest and Bonferonni corrections for multiple comparisons. To 
determine if there was any significant difference between vehicle, AMPA or AMPA 
and MK-801 treatement, one-way analysis of variance was used with post-hoc 
Student’s r-test and Bonferonni corrections for multiple comparisons. To determine if 
there was any significant difference between SPD 502- and saline- treated animals 
following intracerebral injection of AMPA, two-tailed, unpaired Student’s t-test was 
used. Data are presented as mean ± standard error of the mean (SEM).
To determine if there were any differences in the volume of axonal (NF 200) or 
neuronal damage between vehicle treated and SPD 502 treated animals following focal 
cerebral ischaemia, two-tailed unpaired Student’s f-test was used. Data are presented 
as mean ± SEM.
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3.3 Results
3.3.1 AMPA-induced axonal damage
In the external capsule contralateral to the site of injection, axons in MAP-5 
immunostained sections ran in a smooth, organised manner (Fig. 3.1 A). In contrast, 
the ipsilateral external capsule of animals that received injection of AMPA contained 
damaged axons, visualised in MAP 5 stained sections as swollen and bulbous like 
profiles (Fig. 3.IB). SMI 32 and NF 200 immunostaining also revealed the presence of 
axonal swellings and bulbs in the ipsilateral external capsule of AMPA-treated 
animals (Fig. 3. ID and 3. IF), which had a rougher, disorganised appearance compared 
to the contralateral hemisphere (Fig. 3.1C and 3.IE). Animals that received 
intracerebral injection of vehicle exhibited minimal axonal damage confined to a small 
area immediately adjacent to the injection site (Fig. 3.3A). Quantification of axonal 
damage in the external capsule of MAP 5 immunostained sections showed that AMPA 
caused significantly more axonal damage compared to injection of the vehicle (Fig. 
3.3B), and this was dose-dependent. The presence of damaged axons and dendrites, 
often with a characteristic beaded appearance, in the cortex overlying the injection 
site, was observed in AMPA treated animals in MAP 5 immunostained sections (Fig. 
3.2B). SMI 32 and NF 200 immunostained sections also revealed axonal swellings 
and bulbs in the cortex overlying the injection site (Fig. 3.2D and 3.2F).
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Contralateral Ipsilateral
Figure 3.1 Immunohistochemical staining in the external capsule 
following intracerebral injection of AMPA (25nmol)
In the external capsule contralateral to the injection site, axons in M AP 5, SMI 32 
and NF 200 im m unostained sections appeared to be running in smooth, organised 
networks (A, C and E respectively). Following intracerebral injection o f  AMPA, 
axonal disruption was evident in M AP 5, SMI 32 and NF 200 im m unostained 
sections (B, D and F respectively).
Scale Bar = 50/rm.
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Contralateral Ipsilateral
Figure 3.2 Immunohistochemical staining in the cortex following 
intracerebral injection of AMPA (25nmol)
In the cortex contralateral to the injection site, axons in M AP 5, SMI 32 and NF 200 
im m unostained sections appeared to be running in smooth, organised networks (A,
C and E respectively). Following intracerebral injection o f AM PA, axonal 
disruption was evident in M AP 5, SMI 32 and NF 200 imm unostained sections (B, 
D and F respectively).
Scale Bar = 50^m
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Figure 3.3 Axonal damage in MAP 5 immunostained sections 
following intracerebral injection of AMPA
A. Digitised M AP 5 im m unostained sections from a single coronal level o f 
representative animals following injection o f  vehicle or AM PA (2.5 or 
25nmol). The extent o f axonal dam age in the external capsule is 
represented within the solid black line.
B . Quantification o f  axonal damage in the M AP 5 im m unostained sections. 
Data are presented mean ± SEM. *P<0.05, ***P<0.001, for com parison 
with vehicle treated group (one way ANOVA with p o s t  h o c  S tudent’s t  test 
and Bonferonni correction). Vehicle, n= l 1; 2.5nmol, n=9; 25nmol, n=5.
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3.3.2 AMPA-induced oligodendrocyte pathology
Tau-1 immunoreactivity in the hemisphere contralateral to the site of injection had a 
diffuse pattern of staining, with minimal staining of cell bodies in both white (Fig. 
3.4C) and grey matter (Fig. 3.4A). AMPA-treated animals exhibited intensely stained 
cells with the characteristic morphology of oligodendrocytes (figure 3.4B) in tau 
immunostained sections. Tau-positive cells were not observed to be double labelled 
with either GFAP (a marker of astrocytes), mrf-1 (a marker of microglia)or neu-N (a 
marker of neurons) (Fig. 3.5).
Tau-positive oligodendrocytes were present predominantly in the cortex overlying the 
external capsule, but only occasionally within the external capsule itself following 
injection of the lower dose of AMPA (2.5nmol, Fig. 3.6A). Following injection of the 
higher dose of AMPA (25nmol), tau-positive oligodendrocytes were observed in an 
anatomically more extensive area of cortex, often being localised to the boundary of 
the lesion. Tau-positive cells were rarely observed in the external capsule following 
injection of the higher dose of AMPA (25nmol; Fig. 3.4D, 3.6A). Animals that 
received an injection of vehicle contained few tau-positive cells, which were confined 
to the area adjacent to the needle tract (Fig. 3.6A). Quantification of the volume of 
tissue containing tau-positive oligodendrocytes showed that AMPA caused 
significantly more oligodendrocyte damage compared to the vehicle, and that this 
damage increased in a dose dependent manner (Fig. 3.6B).
Tau-positive cells were not observed to be double labelled with TUNEL, a marker of 
DNA fragmentation (TdT FragEL) (Fig. 3.7).
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Figure 3.4 Oligodendrocyte and myelin damage in the cortex and 
external capsule of immunostained sections following 
intracerebral injection of AMPA (25nmol)
There was diffuse Tau-1 im m unoreactivity, with minimal staining o f  cell bodies in the 
cortex (A) and external capsule (C) contralateral to the injection site. Tau-positive 
oligodendrocytes were present in the cortex overlying the injection site (B), but were 
rarely observed in the external capsule (D) following injection o f  AM PA (25nmol). 
M yelinated fibres im m unostained w ith PLP formed organised profiles in the cortex (E) 
and external capsule (G) in the hem isphere contralateral to the injection site. AMPA 
(25nmol) caused disruption o f  PLP im m unostained fibres in the cortex (F), and in the 
external capsule there was a loss o f im m unostaining accom panied by the presence o f 
intensely stained swollen fibres. Scale bar = 50/xm
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Figure 3.5 Double labelling immunohistochemistry
A. Tau-1 (grey, closed arrow heads) and mrf-1, a m arker o f
m icroglia (pink, open arrow heads).
B. Tau-1 (grey, closed arrow heads) and GFAP, a m arker o f
astrocytes (pink, open arrow  head).
C. Tau-1 (grey, closed arrow heads) and Neu-N, a marker o f
neurons (pink, open arrow head).
All images were taken from the cortex overlying the injection 
site (x400 magnification).
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Figure 3.6 Oligodendrocyte pathology following intracerebral 
injection of AMPA
A. Digitised representative Tau-1 im m unostained sections from a single 
coronal level. Tissue containing tau-positive oligodendrocytes are 
contained within the solid black line.
B . Quantification o f  the volume o f tissue containing tau-positive 
oligodendrocytes following intracerebral injection o f  vehicle or AM PA 
(2.5 or 25nrnol). Data are presented mean ± SEM. *P<0.05,
***p<0 oo i for com parison with vehicle treated group. (One way 
ANOVA followed by S tudent’s t-test with Bonferroni correction). 
Vehicle, n= l 1; 2.5nmol, n=9; 25nmol, n=5.
Figure 3.7 Double labelling with Tau-1 and a marker of DNA 
fragmentation (TUNEL)
A. Tau-positive cell (red, closed arrow head).
B. TUNEL positive cells (green, open arrow head)
C. Com bined channel showing that tau-positive cells (red. closed arrow head)
are not visibly double labelled with TUNEL positive cells (green, open 
arrow head).
All images were taken from the cerebral cortex overlying the injection site 
(x400 magnification).
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3.3.3 AMPA-induced myelin pathology
A separate set of animals were used to examine the responses of myelin to 
intracerebral injection of AMPA. PLP immunostained sections showed uniform, 
smooth staining of the myelin in the external capsule contralateral to the injection site 
(Fig. 3.4G). AMPA caused a loss of PLP immunostaining, accompanied by the 
presence of intensely stained swollen myelinated fibres in the external capsule (Fig. 
3.4H). PLP immunostained sections revealed organised networks of myelinated fibres 
in the cortex overlying the injection site (Fig. 3.4E). Following injection of AMPA, 
there was a loss of this organised appearance of myelinated fibres in the cortex, with 
fibres severely disrupted and swollen (Fig. 3.4F). Quantification of the volume of 
tissue containing myelin damage on PLP immunostained sections revealed that there 
was significantly more myelin damage following injection of AMPA (25nmol) 
compared to injection of vehicle (Fig. 3.8).
These data show that intracerebral injection of AMPA causes damage to axons and 
myelin; however, explicit comparisons were not made between the amounts of axonal 
and myelin damage as these were assessed in different groups of animals.
3.3.4 AMPA-induced tissue damage
H & E staining of the external capsule contralateral to the injection site revealed that 
oligodendrocyte-like cells ran in organised profiles (Fig 3.9A). Following injection of 
AMPA, the oligodendrocytes appeared abnormal and disorganised, and vacuolation 
was evident in the external capsule (Fig. 3.9B). In the cortex, AMPA caused neuronal 
cell body necrosis, indicated by the presence of shrunken, eosinophilic cells (Fig. 
3.9D). The lower dose of AMPA (2.5nmol) caused neuronal perikaryal damage in the 
cortex surrounding the injection site (Fig. 3.10A), whereas the higher dose of AMPA 
caused neuronal damage in a larger area of cortex, as well as a small area in the dorsal 
caudate nucleus beneath the injection site (Fig. 3.10A). The H & E sections of 
vehicle-treated animals revealed minimal neuronal cell body damage limited to a small 
area overlying the external capsule at the injection site (Fig. 3.10A) The dose- 
dependent increase in neuronal perikaryal damage induced by AMPA is reflected in 
the volume of tissue damage (Fig. 3.10B).
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Figure 3.8 Myelin damage in PLP immunostained sections
A. Representative PLP imm unostained sections from a single 
coronal level showing the extent o f  m yelin damage within the 
black line following injection o f  AM PA (2.5nmol or 25nmol) or 
vehicle
B . Quantification o f  myelin dam age in PLP im m unostained sections. 
Data are presented as mean ± SEM ***P<0.001 for com parison 
w ith vehicle treated gourp (One way ANOVA followed by 
Student’s /-test w ith Bonferroni correction). Vehicle, n=4; 
2.5nmol, n=5; 25nmol, n=5. Direct com parisons cannot made 
between the am ount o f m yelin damage with the am ount o f  axonal 
damage (Fig. 3.3), as these were assessed in separate groups o f 
animals.
Contralateral Ipsilateral
External Capsule
Figure 3.9 Histological changes in the external capsule 
and cortex following intracerebral injection of 
AMPA (25nmol).
Oligodendrocyte-like cells (white arrows) ran in an organised 
manner in the external capsule contralateral to the injection site (A). 
In contrast, oligodendrocytes appeared abnormal (black arrows) and 
vacuolation was present in the external capsule following 
intracerebral injection o f  AM PA (B). Neurons (white arrows) 
appeared m orphologically normal in the cortex overlying the 
injection site (C). Following injection o f AM PA, neurons appeared 
shrunken and eosinophilic (black arrows) in the cortex overlying the 
injection site (D). Sections were stained with H & E.
Scale bar = 25/nm.
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Figure 3.10 Tissue damage following intracerebral injection of 
AMPA
A. Digitised H & E stained section showing the area o f  tissue dam age 
within the solid black line, following injection o f  AM PA (2.5nm ol or 
25 nmol) or vehicle.
B. Quantification o f  the volume o f  tissue dam age in the H & E stained 
sections. Data are presented m ean ± SEM. **P<0.01 ***P<0.001 
for com parison with vehicle treated groups (One way ANOVA 
followed by S tudent’s M est w ith Bonferroni correction). Vehicle, 
n= l 1; 2.5nmol, n=9; 25nmol, n=5.
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3.3.5 Stereotaxic injection of AMPA with intravenous administration of 
the AMPA receptor antagonist SPD 502
Axonal damage was evident in MAP 5, NF 200 and SMI 32 immunostained sections 
in the external capsule following injection of AMPA (25nmol) with intravenous 
administration of vehicle. Following SPD 502 treatment, axonal damage was 
anatomically less extensive. Quantification of AMPA- induced axonal damage in 
MAP 5 immunostained sections showed that SPD 502-treated animals contained 
significantly less axonal damage when compared to saline treated control animals (Fig. 
3.11 A). Tau-positive oligodendrocytes were evident in the cortex of AMPA-treated 
control animals, however SPD 502 administration significantly reduced the volume of 
tissue containing AMPA-induced tau-positive oligodendrocytes (Fig. 3.1 IB). The 
extent of myelin damage in PLP immunostained sections was significantly reduced 
following administration of SPD 502 compared with saline-treated control AMPA 
animals (Fig. 3.11C). The volume of tissue damage quantified from H & E stained 
sections was significantly reduced following pre-treatment with SPD 502 (Fig. 3.1 ID) 
compared to controls.
3.3.6 Co-injection of AMPA (25nmol) with the NMDA receptor antagonist 
MK-801 (5nmol)
Intracerebral injection of AMPA (25nmol) or AMPA (25nmol) with MK-801 (5nmol) 
caused a significantly greater amount of axonal damage compared to injection of the 
vehicle. However, there was no significant change in the pattern or anatomical extent 
of axonal damage between the AMPA (25nmol) and AMPA (25nmol) with MK-801 
(5nmol) groups (Fig 3.12A). Tau-positive cells were rarely observed in the vehicle 
treated animals; however, tau-positive cells were detected in the cortex following 
administration of AMPA (25nmol) or AMPA (25nmol) and MK-801 (5nmol). There 
were no significant differences in the volume of tissue containing tau-positive 
oligodendrocytes in the AMPA (25nmol) compared to the AMPA (25nmol) with MK- 
801 (5nmol) treated animals (Fig. 3.12B). Similarly, there were no significant 
differences in the amount of myelin damage between the AMPA (25nmol) and AMPA 
(25nmol) with MK-801 (5nmol) groups (Fig. 3.12C). Co-injection of AMPA 
(25nmol) with MK-801 (5nmol) had no significant effects on the amount of tissue 
damage quantified from H & E stained sections compared to injection of AMPA 
(25nmol; Fig. 3.12D).
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3.3.7 Effect of SPD 502 on axonal damage visualised in NF 200 
immunostained sections following focal cerebral ischaemia
In the hemisphere contralateral to the occluded MCA, NF 200 immunostained axons 
were evident running in a smooth, regular pattern (Fig. 3.13A, C, E, G). In contrast, in 
the hemisphere ipsilateral to the occluded MCA, axons appeared swollen and 
disrupted, indicating disrupted cytoskeletal structure (Fig. 3.13B, D, F, H). The 
anatomical extent of axonal damage visualised in a representative animal following 
vehicle treatment is presented in Fig. 3.14. Axonal damage was often observed in the 
cortex, external and internal capsule, caudate nucleus, globus pallidus, hypothalamus, 
thalamus and median forebrain bundle following vehicle treatment. Treatment with 
the AMPA receptor antagonist, SPD 502 (16mg/kg) reduced the anatomical extent of 
axonal damage visualised in NF 200 immunostained sections (Fig. 3.15). 
Quantification of the amount of axonal damage demonstrated that SPD 502 
significantly reduced the amount of total hemispheric axonal damage (Fig. 3.16A). 
Subdividing this into cortical and subcortical damage revealed that SPD 502 
significantly reduced the amount of cortical axonal damage (Fig. 3.16B), however 
there was no significant concomitant protective effect on axons in the subcortex (Fig. 
3.16C).
3.3.8 Effect of SPD 502 on axonal damage visualised in APP 
immunostained sections following focal cerebral ischaemia
In the hemisphere contralateral to the occluded MCA, APP immunoreactivity was 
present at a diffuse, low level (Fig. 3.17B). In the ipsilateral hemisphere, intense APP 
immunoreactivity was present in swollen axons and bulbs (Fig. 3.17C). APP- 
immunoreactive axons were present predominately within the myelinated fibre tracts 
of the caudate nucleus, internal and external capsules, median forebrain bundle and 
fornix (Fig. 3.14). The anatomical extent of APP immunoreactive axons was reduced 
following SPD 502 treatment (Fig. 3.15). Quantitative analysis of the axonal damage 
in the APP-immunostained sections demonstrated that treatment with SPD 502 
significantly reduced that amount of axonal damage (Fig. 3.17A).
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Figure 3.13 NF 200 immunostaining following transient focal cerebral 
ischaemia
In the hem isphere contralateral to the occluded hemisphere, axons ran in smooth, 
organised profiles in the cortex (A) and subcortical regions such as the caudate 
nucleus (C), internal capsule (E) and thalam us (G), which contrasts with the axonal 
swellings and bulbs evident in ipsilateral hem isphere (B, D, F, H).
Scale Bar =  25/tm.
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Figure 3.16 Quantification of axonal damage observed in 
NF 200 immunostained sections following 3 
hours of focal cerebral ischaemia, 21 hours of 
reperfusion and treatment with vehicle or the 
AMPA receptor antagonist SPD 502
A. Hemisphere B. Cortex C. Subcortex
Data are expressed mean ± SEM. Vehicle, n=8; SPD 502, n=7.
*P=<0.05, two-tailed Student’s t -test
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Figure 3.17 Axonal pathology assessed in APP immunostained
sections following 3 hours of focal cerebral ischaemia and 
21 hours of reperfusion
A. Axonal damage quantified from APP imm unostained sections according to 
the protocol outlined by Imai et al., 2002. Vehicle, n=8; SPD 502 n=7. 
**P<0.01, two-tailed M ann-W hitney test
B. Representative images from  APP im m unostained sections in the 
hem isphere contralateral to the M CA occlusion, where no dam aged axons 
were evident.
C. APP accum ulation in dam aged axons in the ipsilateral hemisphere.
Scale bar = 25/xm.
(data presented in M cCracken et al, 2002)
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3.3.9 Effect of SPD 502 on myelin-protein immunostaining following 
focal cerebral ischaemia
In the hemisphere contralateral to the occluded MCA, PLP and MBP immunostaining 
revealed individual networks of fibres running in organised networks in the cortex 
(Fig. 3.18A, C), whilst subcortical white matter tracts had a smooth, organised profile 
(Fig. 3.19A, C). In the ipsilateral hemisphere, PLP and MBP immunostained fibres 
appeared swollen and disrupted in the cortex (Fig. 3.18B, D), and subcortical white 
matter tracts appeared disrupted and vacuolated (Fig. 3.19B, D). In the SPD 502 
treated animals, the extent of myelin disruption was anatomically less extensive 
compared with the vehicle treated group. Myelinated fibres stained with MAG 
appeared ordered and even in the contralateral hemisphere (Fig. 3.18E; Fig. 3.19E), 
however there was a reduction of MAG immunostaining in the occluded hemisphere, 
particularly within the core of MCA territory (Fig. 3.18F; Fig. 3.19F). Although the 
appearance of MAG immunostaining was similar in the SPD 502 treated animals; the 
loss of immunostaining was less extensive in these animals.
3.3.10 Effect of SPD 502 on neuronal damage following focal cerebral 
ischaemia
In the hemisphere ipsilateral to the occluded MCA, the cerebral cortex, caudate 
nucleus and anterior hypothalamus clearly exhibited the characteristics of ischaemic 
neuronal necrosis, whereas the contralateral hemisphere showed no evidence of 
neuronal pathology (Fig. 3.20B, C). The anatomic extent of neuronal damage in a 
representative animal from the vehicle and SPD 502 treated groups are presented in 
figures 3.14 and 3.15. Treatment with SPD 502 significantly reduced the anatomical 
extent of neuronal damage in the hemisphere and cortex, however there was no 
difference between SPD 502 and vehicle treated groups in the subcortex (Fig. 3.20A).
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Figure 3.18 Immunostaining of myelin proteins in the 
cerebral cortex following 3 hours of focal 
cerebral ischaemia and 21 hours of reperfusion
Representative images from  the cerebral cortex in the hem isphere 
contralateral to the M CA occlusion in M BP (A), PLP (C) and MAG
(E) im m unostained sections. In the cortex ipsilateral to the M CA 
occlusion, there was a disruption o f  the pattern o f  M BP (B) and PLP
(D) and MAG (F) im m unostaining. PLP im m unostained sections 
have been counterstained with haem atoxylin 
Scale bar = 25pm.
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Figure 3.19 Immunostaining of myelin proteins in the 
caudate nucleus following 3 hours of focal 
cerebral ischaemia and 21 hours of reperfusion
Representative images from  the caudate nucleus in the hem isphere 
contralateral to the MCA occlusion in MBP (A), PLP (C) and MAG
(E) im m unostained sections. In the caudate nucleus ipsilateral to the 
M CA occlusion, there was a disruption o f  the pattern o f  M BP (B) 
and PLP (D) imm unostaining, and a loss o f  MAG im m unostaining
(F). PLP im m unostained sections have been counterstained with 
haematoxylin.
Scale bar = 25pm.
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Figure 3.20 Effects of SPD 502 on neuronal damage following 3 
hours of focal cerebral ischaemia and 21 hours of 
reperfusion
A. Neuronal Damage. Data are expressed m ean ± SEM. Vehicle, 
n=8; SPD 502 n=7. **P<0.01, two-tailed Students /-test
B. Representative images illustrating m orphologically normal 
neurons (closed arrow head) in the hem isphere contralateral to 
the occluded M CA
C. Ischaem ic neurons (open arrow head) in the hem isphere 
ipsilateral to the occluded MCA.
Scale bar -  25/rm
(data presented in M cCracken et al, 2002).
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3.4 Discussion
In the present study, it was demonstrated that intracerebral injection of AMPA causes 
damage to the cytoskeleton of axons in vivo. The AMPA-induced axonal damage was 
attenuated with systemic administration of an AMPA-receptor antagonist, SPD 502, 
suggesting that AMPA receptor-mediated mechanisms cause axonal damage. 
Furthermore, intracerebral injection of AMPA also induced oligodendrocyte, myelin, 
and neuronal perikaryal damage in vivo. Myelinated axons and oligodendrocytes 
contained within grey matter of the cortex are also vulnerable to AMPA mediated 
toxicity. These data indicate the importance of AMPA receptor-mediated mechanisms 
in causing damage to multiple cellular elements. The AMPA receptor antagonist SPD 
502 significantly reduced the amount of axonal and neuronal damage following focal 
cerebral ischaemia, suggesting that AMPA receptor antagonism has the potential to 
salvage the cellular components of white and grey matter.
AMPA causes cytoskeletal disruption in axons
Excitotoxic lesions were thought historically to cause “axon sparing” lesions (Simson 
et al., 1977). This view reflects an era when damage was evaluated using conventional 
histological staining. The more sensitive immunocytochemical methods used in this 
study reveal that intracerebral injection of AMPA causes damage to microtubules and 
neurofilaments, cytoskeletal components of the axon. Application of kainate, an 
agonist of both AMPA and kainate subtypes of glutamate receptor, onto the rabbit 
optic nerve in vivo also causes damage to the axonal cytoskeleton, evident as axonal 
swellings, and disrupted neurofilaments (Matute, 1998).
AMPA-induced oligodendrocyte damage - significance o f increased Tau-1 
immunoreactivity
Oligodendrocyte pathology, demonstrated by increased Tau-1 immunoreactivity in 
oligodendrocytes within the cortex, was observed following intracerebral injection of 
AMPA in this model. However, tau positive-oligodendrocytes were not observed 
within the external capsule at the injection site of these animals. The reasons for this 
discrepancy between the responses of the oligodendrocytes in the cortex and external 
capsule are unknown. Whilst increased immunoreactivity of tau in oligodendrocytes 
has been demonstrated as a sensitive marker of oligodendrocyte damage following 
intracortical perfusion of glutamate (Irving et al., 1996a), experimental focal cerebral
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ischaemia (Dewar and Dawson, 1995; Irving et al., 1997; Valeriani et al, 2000) and 
human stroke or head injury (Irving et al., 1996b), at present it remains unclear if this 
is indicative of a restorative, protective function, or if it signifies oligodendroglial 
degeneration. If tau positive-oligodendrocytes were involved in a protective response, 
oligodendrocytes near the injection site may be too severely injured for this response 
to occur. In support of this, intracerebral injection of AMPA (20nmol) has previously 
been shown to reduce the amount of Rip-positive oligodendrocytes by 60%
(McDonald et al., 1998a), suggesting oligodendroglial death in this region. This 
hypothesis is also supported by the demonstration that tau-positive oligodendrocytes 
were not double labelled with a marker of DNA fragmentation. In addition, the lack of 
tau-positive oligodendrocytes in the external capsule may also reflect the temporal 
progression of pathology, and it remains possible that tau positive oligodendrocytes 
may have been present in the external capsule at earlier time points than 24 hours. 
However, this discrepancy may also be explained by differences in intrinsic properties 
of oligodendrocytes in these diverse environments. For example, they may contain 
different AMPA receptor subunit compositions, and oligodendrocytes within grey 
matter in the cortex may also react differently to excitotoxins when compared to those 
in the white matter (Jamin et al., 2001).
Mechanisms o f AMPA-induced axonal damage -  involvement o f oligodendrocytes and 
the myelin sheath
At present, there is no evidence that functional AMPA receptors are located on axonal 
cylinders therefore it seems unlikely that AMPA is directly toxic to axons. Instead, 
axonal pathology is likely to result from actions occurring at the AMPA receptors 
located on the myelin sheath and/or the oligodendrocyte. Axonal dysfunction caused 
by application of AMPA or glutamate onto isolated spinal cord preparations in vitro is 
thought to be mediated through Ca2+ permeable GluR4 subunits localised in the 
myelin sheath (Li & Stys, 2000). In the present study we also demonstrate that AMPA 
causes myelin and oligodendrocyte pathology in vivo. Previous studies have also 
shown that intracerebral injection of AMPA into a similar anatomical area causes 
oligodendrocyte damage in vivo (McDonald et a l, 1998a).
It is currently unclear how AMPA receptor-mediated excitotoxicity at the myelin 
sheath and oligodendrocyte results in axonal damage. The integrity of myelinated
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axons is dependent on their stable interactions with oligodendroglia and myelin 
sheaths, and disruption of these interactions is associated with axonal damage. This is 
illustrated by the high prevalence of axonal damage associated with myelin disorders 
(Bjartmar et al, 1999). For example, over-expression or lack of expression of MAG or 
PLP in the myelin sheath causes axonal damage in humans (PLP, Garbem et al., 2002) 
and rodents (Griffiths et al., 1998; Yin et al, 1998). Similarly, axonal damage is 
prevalent in multiple sclerosis and Charcot Marie Tooth disease (Dyck et a l, 1989; 
Ferguson et al, 1997; Trapp et al, 1998; Hanemann et a l, 2001; Stefano et al, 2001). 
Disruptions in the cytoskeleton of mice containing mutant PMP 22 (trembler) or MBP 
deficiency further reinforce the constant influence that myelinating glial have over 
axonal integrity (deWaugh et al, 1992; Brady et al, 1999; Kirkpatrick et a l, 2001). 
AMPA receptor-mediated damage to the oligodendrocyte and myelin could therefore 
impact on the structural integrity of the axon cylinder.
In support of this, studies have recently been performed in an in vitro Campenot 
chamber, where axons can be separated from oligodendrocytes, allowing axonal- 
oligodendroglial relationships to be examined. Axons cultured in the absence of 
oligodendrocytes are not damaged by exposure to kainate, whereas axons co-cultured 
with oligodendrocytes are damaged by kainate (Underhill et a l, 2001; 2002a). These 
in vitro data suggest axonal damage is mediated through over-activation of AMPA 
receptors on oligodendrocytes. This may be caused by the diffusion of toxic 
substances released as a consequence of oligodendroglial excitotoxicity. For example, 
oligodendrocyte progenitors have been shown to produce free radicals following 
exposure to AMPA (Liu et a l, 2002), and free radical-mediated mechanisms are 
known to cause axonal damage in vivo (McCracken et a l, 2000, 2001). A recent 
study has suggested that AMPA-induced axonal damage is mediated by free radical 
mediated mechanisms arsing at the oligodendrocyte, which can be blocked with 
catalase, which breaks down H2O2 (Underhill et al, 2002b). Oligodendrocytes also 
express inducible nitric oxide in pathological situations (Merrill et al, 1997; Gahm et 
al, 2002;) and by-products of nitric oxide, such as peroxynitrite, also cause axonal 
damage in vivo and in vitro ( Smith et al, 2001; Touil et a l, 2001; Garthwaite et al, 
2002).
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Mechanisms o f AMPA-induced axonal damage -  involvement o f the neuronal cell 
body and NMD A receptor mediated mechanisms
In addition to AMPA-receptor mediated axonal damage in the external capsule, axonal 
damage in the overlying cortex was also demonstrated. Neuronal damage was also 
present in the cortex; therefore the possibility that axonal damage is secondary to 
neuronal perikaryal damage cannot be excluded. This could occur by diffusion of 
toxic substances from neurons, or by axonal degeneration resulting from damage to 
the perikarya. However, the protective effect of AMPA receptor blockade on axons 
following oxygen/glucose deprivation in situ was not an indirect consequence of 
neuronal perikarya protection, as no concomitant protective effect on neuronal 
perikarya was demonstrated (Baltan Tekkok and Goldberg, 2001). Instead, the 
protection of axons was likely to reflect the local protection of cellular elements in 
white matter tracts (Baltan Tekkok and Goldberg, 2001). Myelin damage induced by 
kainic acid is detected prior to neuronal perikaryal damage, suggesting that the 
pathological processes at these two sub cellular sites occur independently (Hopkins et 
al, 2000). Thus, it would appear unlikely that the AMPA-induced axonal damage 
observed in the present study is a consequence of neuronal cell body damage in the 
overlying cortex. Time course studies may establish if axonal and neuronal perikaryal 
damage occur as independent events.
Another possibility is that AMPA may have induced secondary NMDA receptor 
excitotoxicity. However, it was demonstrated in the current study that co-injection of 
AMPA with the NMDA receptor antagonist MK-801 did not significantly reduce the 
amount of axonal damage. Similarly, co-injection of AMPA (20nmol) with MK-801 
(5nmol) did not reduce the amount of oligodendroglial loss in the external capsule 
(McDonald et al., 1998a). Intracerebral injection of NMDA does not induce 
oligodendrocyte death (McDonald et a l, 1998a), and NMDA receptor antagonism 
does not reduce axonal or oligodendrocyte damage after cerebral ischaemia (Irving et 
al, 1997; Yam et al, 2000). Therefore, it seems unlikely that NMDA receptor- 
mediated mechanisms contribute to AMPA-induced axonal damage.
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AMPA receptor blockade with SPD 502 protects axons and oligodendrocytes from  
focal cerebral ischaemia in vivo
The in vivo AMPA toxicity studies indicated that AMPA induces damage to the 
cellular components of both white and grey matter in vivo. The in vivo cerebral 
ischaemia study therefore provided ‘proof of concept’ that AMPA receptor 
antagonism can protect against grey and white matter damage. In addition to the 
protection of axons and neurons, SPD 502 also significantly reduced the anatomic 
extent of ischaemically-damaged oligodendrocytes, determined by Tau-1 
immunoreactivity (McCracken et al., 2002). The protective effect of AMPA blockade 
was demonstrated in the cerebral cortex, however axons and neurons were not 
protected in the deep subcortical areas, where the reduction in cerebral blood flow is 
most pronounced (Komjati et al, 2001). The protective effect of AMPA blockade on 
oligodendrocyte pathology was also significant in the cortex but minimal in 
subcortical areas (McCracken et al., 2001).
Interestingly, the anatomical distribution of damaged neurons and axons labelled with 
APP or NF 200 immunostaining were comparatively different following focal cerebral 
ischaemia (see Fig. 3.14 and 3.15). APP immunoreactive axons were the least 
anatomically widespread, and usually located at the boundary of the lesion. This is 
perhaps expected, considering that the accumulation of APP is dependent on normal 
axon function and energy dependent axonal transport. In contrast, areas of damaged 
axons visible in NF 200 immunostained sections were anatomically more extensive, 
and coincidental with neuronal damage. In addition, swollen axons were also evident 
in NF 200 immunostained sections in anatomical areas where neurons appeared 
morphologically normal, particularly the thalamus. The lack of APP immunopositive 
axons in these areas highlights the sensitivity of NF 200 immunostaining, and 
emphasises the need for multiple markers for the evaluation of axonal damage. Similar 
findings have been reported using APP and NF 200 immunohistochemistry in another 
model of focal cerebral ischaemia (Bingham et al., 2003). Sherriff and colleagues 
(1994a) carried out a comparison of the sensitivity of APP and NF 68 
immunohistochemistry on post mortem head injured patients, and concluded that APP 
immunostaining was the most sensitive marker of damaged axons. However, only one 
anatomical area was examined in this study (corpus callosum) in contrast to the many 
areas examined in the current study. In addition, the heavy chain component of
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neurofilament examined in the current study may be a more sensitive marker than NF 
68. It is unclear if the presence of swollen axons in areas such as the thalamus, which 
contained morphologically normal neurons, signifies reversible or irreversible axonal 
damage. It is possible that they may be mildly swollen and damaged, but that this may 
be resolved beyond 24 hours. Time course studies would be useful to further examine 
this phenomenon. If they do represent irreversibly damaged axons, two possibilities 
exist. They may signify axons degenerating as a result of neuronal perikaryal damage, 
for instance cortico-thalamic fibres degenerating as a consequence of neuronal 
perikaryal damage in the overlying cortex.
Mechanisms o f AMPA induced excitotoxicity in vivo
The current study, combined with in vitro and in situ experiments, which have shown 
that AMPA receptor antagonism can protect axons and oligodendrocytes from oxygen 
and/or glucose deprivation, provide compelling evidence for the role of AMPA- 
mediated mechanisms in causing white matter ischaemic damage. However, one 
question remains -  what is the endogenous source of glutamate that causes white 
matter excitotoxicity in the absence of neuronal glutamatergic synapses? Stys and 
colleagues have examined this phenomenon in isolated white matter preparations 
devoid of neuronal cell bodies. Exposing dorsal column segments to anoxia or 
trauma, they demonstrated a loss of axonal function, which could be attenuated with 
AMPA receptor antagonists (Li et al, 1999). However, inhibitors of Na+-dependent 
glutamate transport also attenuated the axonal pathology, and prevented the depletion 
of cytosolic glutamate from axon cylinders and oligodendrocytes (Li et a l, 1999). 
Therefore, it seems likely that under anoxic conditions, ionic imbalances may result in 
reverse operation of the Na+ dependent glutamate transporter that could cause elevated 
levels of glutamate within white matter (Stys, 1998; Li et a l, 1999). This hypothesis is 
consistent with the presence of glutamate transporters within white matter (Li et al, 
1999). A diagrammatic representation of mechanisms of white matter damage during 
ischaemic conditions is presented in figure 3.21.
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Figure 3.21 Hypothesised mechanisms of hypoxic-ischaemic 
white matter damage
Disruption o f  energy supplies results in a depletion o f  ATP, which causes 
ionic imbalances due to m alfunctioning o f  the N a7K '-A T P ase. This results 
in Na* influx through activation o f  N a channels, and Ca2 influx through 
voltage sensitive Ca2 channels and reversal o f Na /C a2 exchange. This 
results in axonal malfunctioning, swelling and the activation o f  Ca2* 
mediated destruction. In addition, the ionic im balances can lead to release 
o f  glutamate through reversal o f Na -dependent glutam ate transporters. 
This can cause excitotoxicity at the myelin sheath and oligodendrocyte, 
which results in axonal dysfunction.
From Baltan Tekkok and Goldberg (2001).
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The data presented in this chapter provide compelling evidence that AMPA receptor 
mediated mechanisms cause white matter damage. The next chapter describes the 
characterisation of an in vivo model of AMPA-induced axonal damage in mice. This 
was a prerequisite for the studies investigating the effects of AMPA -induced axonal 
damage in transgenic mice, which are described in chapter 5.
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CHAPTER 4
ESTABLISHING A MOUSE MODEL OF AMPA 
RECEPTOR-MEDIATED EXCITOTOXICITY & 
COMPARISON WITH MALONATE-INDUCED 
PATHOLOGY IN THE MOUSE
4.1 Introduction
The myelin sheath is interspersed with proteins that have an integral role in myelin 
formation and maintenance. Proteolipid protein (PLP) and myelin basic protein 
(MBP) are the two major protein components of CNS myelin. In addition to 
supporting the architecture of the myelin sheath, these proteins have an integral role 
in glial-axonal interactions. Evidence supporting this came from the discovery of 
axonal abnormalities in transgenic mice that are deficient in P IP  or MBP, which will 
be described in more detail in chapter 5. Pip gene knockout mice and MBP deficient 
mice (shiverer mice) are currently under investigation at the Glasgow University Vet 
School campus, by a group led by Professor Ian Griffiths. The abnormal glial-axonal 
relationships that PLP and MBP deficient mice contain provide a useful model to 
examine the role of oligodendrocytes and myelin in AMPA-induced axonal damage. 
It may also be possible that the degeneration exhibited by these mice may arise from 
‘secondary’ excitotoxicity. Therefore, investigations were undertaken to determine if 
Pip gene knockout and shiverer mice exhibit altered sensitivity to AMPA-induced 
axonal damage compared with wild type mice. These studies will be described in 
chapter 5. Preceding these investigations however, a model of AMPA induced 
axonal pathology was characterised in the mouse (C57/BU), and this work will be 
described in detail in the current chapter.
At the same time that the mouse model of AMPA-mediated axonal damage was 
established, Mr Dan Cuthill carried out contemporaneous studies in this department 
to establish a mouse model of malonate-mediated energy failure. Malonate 
competitively inhibits succinate dehydrogenase (SDH), a mitochondrial enzyme that 
plays a central role in energy metabolism. Energy failure due to mitochondrial 
dysfunction contributes to the pathology observed following cerebral ischaemia and 
head injury, and may also contribute to the pathogenesis of chronic 
neurodegenerative diseases (Fiskum et al., 1999). Irreversible inhibition of SDH with 
the plant myotoxin 3-Nitropropionic acid produces striatal neuronal damage 
(Ludolph et al., 1991; Beal et al., 1993a) and axonal damage, assessed with APP 
immunohistochemistry (McCracken et al., 2001). Infusion of malonate into the 
caudate nucleus of rats also produces neuronal damage (Beal et al., 1993b; Greene et 
al, 1993) and accumulation of APP in damaged axons at the boundary of the lesion 
(Dewar et al., 2000).
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4.1.1 Aims of study
The primary aim of this study was to establish an in vivo mouse model of AMPA 
receptor mediated axonal and neuronal damage. The effects of intrastriatal 
injection of malonate on axonal and neuronal damage were also evaluated and 
compared with AMPA-induced damage. As interesting discrepancies were observed 
in the pattern of pathology observed in AMPA and malonate injected animals, the 
acute effects of either toxin on cerebral glucose utilisation were examined 1 hour 
post-injection.
4.2 Methods
4.2.1 Stereotaxic Surgery
Adult C57/BU (23-33g) mice received stereotaxic injection of AMPA (1.5nmol, 
n=5; 3nmol, n=6 or 6nmol, n=5) or vehicle (10 mM PBS, pH 7.4, n=5); and malonate 
(0.34pmol, n=5; 0.68pmol, n=5 or 1.35pmol, n=5) or vehicle (10 mM PBS, pH 7.4, 
n=5) into the caudate nucleus as outlined in section 2.3.1. Mr Daniel Cuthill 
performed all the stereotaxic injections of malonate in the pathology experiment. 
Twenty-four hours later, animals were perfused transcardially with saline (0.9%) 
then paraformaldehyde (4%); post-fixed, processed and paraffin embedded (section 
2.3.2).
4.2.2 Histology and Immunocytochemistry
Sixteen sections (6fim) from every forty sections cut were retained on poly-L-lysine 
slides (2 sections per slide) for histology and immunostaining. One slide from each 
cycle was stained with H & E to examine neuronal perikaryal damage (section 2.6.1), 
and adjacent sections were immunostained using antibodies raised against NF 200 
and APP to examine axonal pathology (section 2.5.5). Mr Daniel Cuthill performed 
all histological and immunostaining procedures for malonate-injected brains. All 
malonate-lesioned brains were quantified by Mr Daniel Cuthill, while I performed 
the analysis of the AMPA-lesioned brains. Inter-rater variability was assessed in 
eight animals from each group (See appendix 4). Quantification of axonal and 
neuronal damage is outlined in section 2.5.9 and 2.6.4. In addition to the focal area of 
neuronal and axonal damage induced by AMPA, widespread damage was also
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observed, for instance in various thalamic nuclei in the hemisphere ipsilateral and 
contralateral to the injection site. This widespread damage, which could clearly be 
differentiated from the focal damage caused by AMPA, was not included in the 
volumetric quantification of damage. The rostral and caudal limit for integration of 
the lesion induced by AMPA were 2.8mm and -4.26mm respectively from Bregma. 
The rostral and caudal limit for integration of the lesion induced by malonate were 
1.98mm and -1.58mm respectively from Bregma.
4.2.3 In vivo 14C-2-deoxyglucose autoradiography
To further characterise the acute affects of intrastriatal injection of AMPA or 
malonate, the effects of these toxins on glucose utilisation were investigated one hour 
post-injection. The protocol for stereotaxic injection of AMPA, malonate or vehicle 
followed by 14C-2-deoxyglucose autoradiography is illustrated in figure 4.1. Fifteen 
C57/BU (26-32g) were anaesthetised and received stereotaxic injection of AMPA 
(6nmol, n=5), malonate (1.35jnmol, n=5), or vehicle (PBS, lOmM, pH, 7.4, n=5) into 
the caudate nucleus as previously described (section 2.3.1). Each animal was then 
administered 14C-2deoxygucose as described in section 2.7.5. The subsequent 14C-2- 
deoxyglucose protocol is described in section 2.7.5 and 2.7.6. Levels of 14C were 
calculated in 17 brain areas, in both the hemispheres ipsilateral and contralateral to 
the injected caudate nucleus. Local cerebral glucose utilisation was estimated as the 
ratio of 14C in the region of interest to that in the hypothalamus. The hypothalamus 
was chosen as reference region as it has few direct afferent and efferent connections 
with the injection site. To validate the use of the hypothalamus as a reference area, 
the relationship between 14C in this region with plasma 14C and plasma glucose was 
examined.
4.2.4 Statistical analysis
To determine if there was any significant difference between AMPA (1.5, 3 and 
6nmol) and vehicle treated animals, one-way analysis of variance was used with post 
hoc Student’s t test and Bonferonni corrections for multiple comparisons. To 
determine if AMPA (6nmol) induced altered levels of glucose utilisation in the 
hemisphere ipsilateral and contralateral to the injected caudate, two-tailed, paired 
Student’s t test was used.
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4.3 Results
4.3.1 AMPA-induced axonal damage a ssessed  in NF 200 
immunostained sections
Injection Site
In the caudate nucleus and overlying external capsule contralateral to the injection 
site, NF 200 immunostained axons within white matter tracts appeared uniform and 
organised, and individual axons in the overlying cortex ran in organised networks 
(Fig. 4.2A, C, E). The caudate nucleus of animals that received injection of AMPA 
contained a rougher, disrupted pattern of immunostaining. Disrupted, severely 
swollen axons were evident in the centre of the lesion (Fig. 4.2B), whereas the 
surrounding areas contained vacuolated, disrupted white matter tracts with less 
severely swollen axons (Fig. 4.2D). A disorganised pattern of immunostaining was 
also observed in the overlying cortex (Fig. 4.2F) and external capsule, where bulbous 
like axonal profiles were evident. Increasing AMPA dosage caused axonal damage in 
an anatomically more extensive area of caudate and cortex (Fig. 4.4B-D). Animals 
that received intrastriatal injection of vehicle exhibited minimal axonal damage, 
mainly confined to a small area immediately adjacent to the needle tract in the 
caudate nucleus and overlying external capsule and cortex (Fig. 4.4A).
Distant Brain Areas
Disrupted, swollen axons immunostained with NF 200 were also observed in the 
globus pallidus, internal capsule and substantia nigra (Fig. 4.3) following intrastriatal 
injection of AMPA. In the volumetric analysis of axonal damage, the damage in 
these areas could not be differentiated from the local damage caused by AMPA in 
the caudate; therefore they were included in the quantification. Quantification of 
axonal damage in NF 200 immunostained sections revealed that AMPA caused a 
dose dependent increase in axonal damage compared to injection of vehicle (Fig. 
4.4E). AMPA also induced scattered axonal damage in several thalamic nuclei that 
were distant from the focal lesion, in the hemispheres ipsilateral and contralateral to 
the injection site. These areas were not included in the volumetric quantification of 
axonal damage because of their diffuse nature. There was an increased frequency of 
axonal damage in these distant brain areas with increasing AMPA dosage (Table 
4.1). Contralateral axonal damage in the caudate nucleus, globus pallidus, internal 
capsule or substantia nigra was not observed.
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Figure 4.2 NF 200 immunostaining in the caudate nucleus and
cortex following intrastriatal injection of AMPA (6nmol)
In the caudate nucleus and cerebral cortex contralateral to the injection site, 
axons ran in a smooth, organised profile (A, C, E). Axonal swellings and a 
disrupted pattern o f  imm unostaining were evident in the core (B) and boundary 
o f  the lesion (D) in the caudate nucleus, and the overlying cerebral cortex (F). 
Scale bar = 25pm.
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Figure 4.3 NF 200 immunostaining in extrastriatal brain areas 
following intrastriatal injection of AMPA (6nmol)
In the globus pallidus, internal capsule, thalam us and substantia nigra 
contralateral to the injection site o f  this animal, axons ran in a smooth, 
organised profile (A, C, E, F). Axonal swellings were evident in these areas in 
the hem isphere ipsilateral to the injection site (B, D, F, H).
Scale bar = 25pm.
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A Vehicle C AMPA (3nmol)
B AMPA (1.5nmol) D AMPA (6nmol)
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Figure 4.4 Axonal damage assessed in NF 200 immunostained 
sections following intrastriatal injection of AMPA
Digitised NF 200 im m unostained sections (A-D), dem onstrating the 
anatomical extent o f  axonal damage following stereotaxic injection o f 
Vehicle (PBS) or AM PA (1 ,5-6nmol). The area o f  disrupted 
imm unostaining is contained within the dashed line.
Quantification o f  the volume o f  axonal dam age in NF 200 
imm unostained sections. One way ANOVA followed by Student’s t  test 
with Bonferonni correction). ***P<0.001 for com parison with vehicle 
treated group. Vehicle, n=5; A.MPA (1.5nm ol), n=5; AM PA (3nmol), 
n=6; AM PA (6nmol), n=5.
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Anatomical Area
AMPA
Vehicle 1.5nmol 3nmol 6nmol
Globus Pallidus (ipsilateral) 1 of 5 3 of 5 6 of 6 5 of 5
Internal Capsule (ipsilateral) 1 of 5 3 of 5 6 of 6 5 of 5
Thalamus (ipsilateral) Oof 5 1 of 5 4 of 6 5 of 5
Thalamus (contralateral) Oof 5 Oof 5 1 of 6 3 of 5
Substantia Nigra 1 of 5 3 of 5 6 of 6 5 of 5
Table 4.1 The incidence of damaged axons a ssesse d  in NF 200 
immunostained sections in 4 brain areas following 
intrastriatal injection of AMPA
4.3.2 AMPA-induced axonal damage a sse sse d  in APP immunostained 
sections
Injection Site
In the hemisphere contralateral to the injection site, APP immunoreactivity was 
present at a low, diffuse level. Intracerebral injection of AMPA caused increased 
APP immunoreactivity in swollen axons (Fig. 4.5). However, this was confined to a 
small area in the caudate nucleus and external capsule adjacent to the needle tract, in 
a similar pattern to vehicle treated animals (Fig. 4.7). APP immunoreactive axons 
were rarely observed in the overlying cortex of any animal. This contrasted with the 
pattern of axonal disruption and swellings evident in NF 200 immunostained sections 
(Fig. 4.4).
Distant Brain Areas
Increasing AMPA dosage did not increase the anatomical extent of APP 
immunoreactive axons (Fig. 4.6,4.7). Occasionally, small APP immunoreactive 
swellings were observed in the globus pallidus, internal capsule, thalamus, and 
substantia nigra following injection of AMPA. These were rarely present, and 
contrasted starkly with number of swellings evident in the same areas of NF 200 
immunostained sections. These intermittent, distant APP immunoreactive axons 
were not included in the volumetric analysis of axonal damage in APP 
immunostained sections. Quantification of the volume of tissue containing damaged 
axons in APP immunostained sections demonstrated that there was no significant 
difference between AMPA and vehicle treated animals (Fig. 4.7E).
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Figure 4.5 APP immunostaining in the caudate nucleus and cortex 
following intrastriatal injection of AMPA (6nmol)
In the caudate nucleus and cerebral cortex contralateral to the injection site, 
APP imm unoreactivity was present at a low, diffuse level (A, C, E). APP 
imm unoreactive swollen axons were present at the centre o f  the lesion in the 
caudate, (B) but not in the boundary o f the lesion (D) in the caudate nucleus, or 
the overlying cortex (F). The arrows in (A) and (B) indicate white matter tracts 
in the caudate nucleus. All sections were counterstained w ith haematoxylin. 
Scale bar = 25pm.
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Figure 4.6 APP immunostaining in 4 brain areas following 
intrastriatal injection of AMPA (6nmol)
In the globus pallidus, internal capsule, thalam us and substantia nigra 
contralateral to the injection site, APP im m unoreactivity was present at a low, 
diffuse level (A, C, E, G respectively). APP im m unoreactive axons were rarely 
present in these structures in the hem isphere ipsilateral to the injection (B, D, F, 
PI), in contrast to the changes observed in NF 200 im m unostained sections (Fig 
4.3). All sections were counterstained with haem atoxylin 
Scale bar = 25pm.
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Figure 4.7 Axonal damage assessed in APP immunostained sections 
following intrastriatal injection of AMPA
Digitised APP imm unostained sections (A-D), dem onstrating the anatom ical extent 
o f  axonal damage following stereotaxic injection o f  Vehicle (PBS) or AM PA (1.5- 
6nmol). The area o f disrupted im m unostaining is contained within the dashed line. 
Quantification o f  the volume o f  axonal dam age in APP im m unostained sections (E). 
One way ANOVA followed by S tudent’s t  test w ith Bonferonni correction) P>0.05 
for com parison with vehicle treated group. Vehicle, n=5; AM PA (1 .5nmol), n=5; 
AM PA (3nmol), n=6; AM PA (6nmol), n=5.
The data are presented on a graph with the same Y-axis to that used in Figure 4.4E, 
to highlight the discrepancies between NF 200 and APP immunostaining.
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4.3.3 AMPA-induced neuronal damage
Minimal neuronal damage was observed in H & E stained sections from vehicle 
treated animals, confined to a small area in the caudate nucleus and cortex. Injection 
of AMPA caused neuronal perikaryal damage, evident in the caudate nucleus and 
overlying cortex. The anatomical extent of neuronal damage in the caudate nucleus 
and cortex increased with increasing doses of AMPA (Fig. 4.8B-D), and the lesion 
often extended into the globus pallidus and thalamus. Quantification of the neuronal 
damage within the focal lesion demonstrated that AMPA caused a dose-dependent 
increase in neuronal damage (Fig. 4.8E). In addition to the neuronal damage 
associated with the focal lesion, AMPA caused widespread neuronal damage in 
many other areas (Fig. 4.9), such as the hippocampus, thalamic nuclei and the dorsal 
endopiriform nuclei, in both the hemisphere ipsilateral and contralateral to the 
injection site. Damaged neurons in these areas were shrunken with an intensely 
eosinophilic cytoplasm, and were usually intermingled with morphologically normal 
neurons. The incidence of distant neuronal damage following intrastriatal injection 
of AMPA is described in figure 4.9A.
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Figure 4.8 Neuronal damage following intrastriatal injection of 
AMPA
Digitised H & E sections (A-D) dem onstrating the anatom ical extent o f 
histological damage following stereotaxic injection into the caudate nucleus o f 
Vehicle (PBS) or AM PA (1.5-6nmol). Damage in the cerebral cortex overlying 
the injection site is likely to be due to diffusion o f  AM PA along the needle tract. 
Quantification o f  the volume o f neuronal dam age (E). Data are presented mean ± 
SEM. One way ANOVA followed by S tudent’s M est with Bonferonni 
correction). **P<0.01 for com parison with vehicle treated group. Vehicle, n=5; 
AM PA (1.5nmol), n=5; AM PA (3nmol), n=6; AM PA (6nmol), n=5. 12o
A
A natom ical Area
AM PA
Vehicle 1.5 nmol 3nmol 6nmol
Globus Pallidus (ipsilateral) 1 o f  5 3 o f 5 5 o f  6 5 o f  5
Thalam us (ipsilateral) O o f 5 1 o f 5 4 o f  6 5 o f  5
Thalam us (contralateral) O o f 5 O of 5 1 o f  6 5 o f  5
Hippocam pus (ipsilateral) O o f 5 O of 5 2 o f  6 3 o f  5
Hippocam pus (contralateral) 0 o f  5 O of 5 1 o f  6 3 o f  5
A m ydala (ipsilateral) O o f 5 O of 5 1 o f  6 2 o f  5
Am ydala (contralateral) O o f 5 O of 5 1 o f  6 1 o f  5
Endopiriform  cortex (ipsi) O o f 5 O of 5 2 o f  6 2 o f  5
Endopiriform  cortex (contra) O o f 5 O of 5 1 o f  6 1 o f  5
Pirifom i cortex (ipsilateral) O o f 5 O of 5 2 o f  6 4 o f  5
Substantia Nigra (ipsilateral) O o f 5 O of 5 5 o f  6 5 o f  5
Figure 4.9 Selective neuronal damage in widespread brain areas 
caused by intracerebral injection of AMPA
Table (A) illustrating the num ber o f  animals that contained selective neuronal 
damage in 6 brain areas following injection o f  vehicle or AM PA (1.5nmol, 3nmol, 
6nmol).
Representative images illustrating m orphologically normal neurons in the C A 1 
sector o f  the hippocam pus (B) and thalam us (D) o f  vehicle treated animals; and 
shrunken, eosinophilic neurons in the CA1 sector o f  the hippocam pus (C) and 
thalamus (E) following intrastriatal injection o f  AM PA (6nmol).
Closed arrow heads point to m orphologically normal neurons, open arrow heads 
point to damaged neurons.
Scale bar = 25pm. 129
4.3.4 Malonate-induced axonal damage a ssesse d  in NF 200 
immunostained sections
In contrast to the organised pattern of immunostaining observed in the hemisphere 
contralateral to the injection site, malonate (0.34pmol) resulted in the occurrence of 
axonal swellings and bulbs in the injected caudate nucleus and overlying external 
capsule (Fig. 4.10). In the centre of the lesion, there was generally an area of 
increased immunostaining, where axons appeared less severely disrupted (Fig. 
4.10B), in contrast to the boundary of the lesion where axons were severely swollen 
and disrupted following injection of malonate (0.68, 1.34pmol) (Fig. 4.10D). 
Disorganised, swollen axons were increasingly evident in the globus pallidus and 
external capsule following injection of the higher doses of malonate (Fig. 4.11; Table 
4.2). There was minimal disruption of axons in the overlying cerebral cortex 
following injection of malonate (Fig. 4.10F; 4.12A), except for mechanical damage 
caused by the needle tract and an occasional, small rim of damage overlying the 
external capsule in animals that had received the higher doses of malonate (0.68, 
1.35pmol). Animals that received stereotaxic injection of vehicle contained minimal 
disruption of immunostaining, confined to a small area adjacent to the needle tract in 
the caudate nucleus and overlying cortex. Quantification of the volume of tissue 
containing damaged axons in the NF 200 immunostained sections revealed that 
malonate caused a dose-dependent increase in axonal damage (Fig. 4.12B)
Anatomical Area
Malonate
Vehicle 0.34pmol 0.68pmol 1.34jxmol
Globus Pallidus Oof 5 2 of 5 5 of 5 5 of 5
Internal Capsule Oof 5 1 of 5 5 of 5 5 of 5
Thalamus (ipsilateral) 0 of 5 Oof 5 Oof 5 Oof 5
Thalamus (contralateral) Oof 5 0 of 5 Oof 5 Oof 5
Table 4.2 Incidence of axonal damage a sse sse d  in NF 200 and APP 
immunostained sections in two brain structures following 
intrastriatal injection of malonate
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Figure 4.10 NF 200 immunostaining in the caudate nucleus and 
cortex following intrastriatal injection of malonate 
(1.35nmol)
In the caudate nucleus and cerebral cortex contralateral to the injection site, axons 
ran in a smooth, organised profile (A, C, E). In the core o f  the lesion, less axonal 
swellings were evident (B) than in the boundary o f  the lesion (D). Minimal 
disruption o f  axons was evident in the cortex overlying the caudate nucleus (F). 
Scale bar = 25pm.
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Figure 4.11 NF 200 immunostaining following intrastriatal injection of 
malonate (1.35^imol)
In the globus pallidus (A), internal capsule (C) and thalam us (E) contralateral to 
the injection site, axons ran in a smooth, organised profile. Swollen, disrupted 
axons were evident in the ipislateral globus pallidus (B) and internal capsule (D), 
however swollen axons were rarely observed in the thalam us (F).
Scale bar = 25pm.
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Figure 4.12 Quantification of axonal and neuronal damage following 
intrastriatal injection of malonate
Digitised NF 200 (A), APP (C) and H & E (E) stained sections, dem onstrating the 
anatomical extent o f axonal and neuronal dam age (within the dashed line) following 
intrastriatal injection o f malonate (1.35/rmol).
Quantification o f axonal damage in N F200 (B) and APP (D) im m unostained sections 
revealed that there was a dose dependent increase in axonal dam age using both these 
markers (in contrast to AMPA, see figures 4.4 and 4.7). Quantification o f neuronal 
dam age (F) revealed that there was a dose dependent increase in neuronal damage. 
One-way ANOVA followed by S tudent’s t  test with Bonferroni correction. n=5 per 
group. **P<0.01, ***P<0.001 for com parison with vehicle treated group.
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4.3.5 Malonate-induced axonal damage a ssessed  in APP 
immunostained sections
In the hemisphere contralateral to the injection site, APP immunoreactivity was 
present at a low, diffuse level (Fig. 4.13 A, C, E). Intrastriatal injection of malonate 
resulted in the presence of intense APP immunoreactivity in swollen and bulbous 
axons in the caudate nucleus (Fig. 4.13D) and overlying external capsule. The 
anatomical extent of APP-immunoreactive axons increased with increasing malonate 
dosage. Following intrastriatal injection of malonate at the highest doses (0.68, 
1.35|nmol), APP immunoreactive fibre bundles were predominantly present in the 
boundary of the lesion, whilst the core of the lesion contained relatively few 
immunoreactive axons (Fig. 4.13A). APP immunoreactive axons were also present 
in the external capsule overlying the lesion, and occasionally spread across the 
corpus callosum following malonate administration (0.68,1.34jLimol; Fig. 4.12C). 
The incidence of axonal damage in the internal capsule and globus pallidus was the 
same as that observed in NF 200 immunostained sections (Table 4.2). Animals that 
received intrastriatal injection of vehicle contained minimal APP immunoreactive 
axons confined to a small area adjacent to the needle tract. Malonate caused a dose- 
dependent increase in axonal damage quantified from APP immunoreactive sections 
(Fig. 4.12D).
4.3.6 Malonate-induced neuronal damage
Vehicle treated animals contained minimal neuronal damage confined to a small area 
immediately adjacent to the needle tract in the caudate nucleus and cortex. Malonate 
caused an increased area of neuronal perikaryal damage in the caudate nucleus, and 
the lesion extended into the globus pallidus in two animals following injection of 
malonate (0.34pmol), and in all animals following injection of the higher doses 
(0.68, 1.35pmol). Intracerebral injection of malonate did not cause increased 
neuronal perikaryal damage in the overlying cortex compared with controls (Fig. 
4.12E), except for a small area overlying the external capsule in one animal 
following injection of the highest dose (1.35|xmol). Neuronal damage in distant 
areas such as thalamic nuclei and the hippocampus was not observed following 
intrastriatal injection of malonate. Quantification of the volume of tissue containing 
neuronal damage revealed that malonate caused a dose dependent increase when 
compared with controls (Fig. 4.12F).
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Figure 4.13 APP Immunostaining in the caudate and cortex following 
intracerebral injection of malonate (1.35|imol)
In the caudate nucleus contralateral to the injection site (A, C), APP 
imm unoreactivity was present at a diffuse, low level. In the core o f the m alonate- 
induced lesion, there were less APP im m unoreactive axons (B) com pared to the 
boundary o f the lesion (C). APP im m unoreactive axons were rarely observed in the 
overlying cortex (F) following malonate injection.
Scale Bar = 25pm.
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Figure 4.14 APP Immunostaining following intracerebral injection of 
malonate (1.35|imol)
In the globus pallidus (A), internal capsule (C) and thalam us (E) contralateral to the 
injection site, APP imm unoreactivity was present at a diffuse, low level. APP 
im m unoreactive axons were present in the globus pallidus (B) and internal capsule 
(D) following intracerebral injection o f malonate (1.35pm ol), but were rarely 
observed in the thalam us (F).
Scale bar = 25 jiim
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4.3.7 14C-2-deoxyglucose autoradiography
Mean plasma 14C and glucose concentrations did not differ significantly following 
intrastriatal injection of AMPA, malonate or vehicle (Fig. 4.15). The levels of 14C in 
the hypothalamus did not differ significantly between the three groups (Fig. 4.16A). 
In individual animals, the relationship between hypothalamic 14C levels and terminal 
plasma 14C/ glucose ratios was similar, irrespective of treatment (Fig. 4.16B). These 
data suggest that intrastriatal injection of AMPA and malonate did not alter the level 
of glucose utilisation in the hypothalamus, therefore this region was selected as the 
reference region.
The ratio of tissue 14C in the 17 structures relative to hypothalamic 14C for all three 
groups is presented in table 4.3. Local cerebral glucose utilisation (LCGU) did not 
differ significantly between structures in the hemisphere ipsilateral and contralateral 
to the injection site following intrastriatal injection of vehicle; with the exception of 
the piriform cortex and cerebellar cortex, where LCGU was increased; and the 
mediodorsal and ventrolateral thalamic nuclei, where LCGU was significantly lower 
than the contralateral side.
Following intrastriatal injection of AMPA (6nmol), LCGU was significantly 
increased in 11 of the 17 structures compared with the contralateral hemisphere. 
LCGU was increased by the greatest magnitude in the caudate nucleus (Fig. 4.17), 
and the increase seemed to be homogeneous throughout all affected areas of the 
caudate (Fig. 4.21). Other areas included thalamic nuclei (Fig. 4.18); the globus 
pallidus, entopeduncular nucleus and substantia nigra (Fig. 4.19); and white matter 
areas such as the external capsule, corpus callosum and internal capsule (Fig. 4.20). 
No significant changes were observed in the remaining structures, and no decreases 
in LCGU were observed.
Following intrastriatal injection of malonate (1.35pmol), LCGU was significantly 
reduced in the caudate nucleus (Fig. 4.17). The decrease in LGCU in the caudate 
nucleus was surrounded by a zone where LGCU appeared to be increased (not 
quantified, see Fig. 4.21). In contrast, LGCU was significantly increased in the 
entopeduncular nucleus, and 4 white matter areas; the corpus callosum, external 
capsule, anterior commissure and the internal capsule (Fig. 4.19, 4.20) following
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intrastriatal injection of malonate. There were no significant changes in LCGU 
the remaining 11 areas.
A Plasma Glucose
15 n
Vehicle AMPA Malonate
B Plasma 14C
>  300 "
Vehicle AMPA Malonate
Figure 4.15 Terminal plasma glucose and 14C levels
Plasm a glucose (A) and 14C levels (B) at the end o f the 45 minute 
deoxyglucose experimental period in animals that had received 
injection o f AM PA (6nmol), m alonate (1.34pm ol) or vehicle (PBS). 
Data are presented mean ± SEM. There was no significant difference 
between the plasma glucose (A) and l4C levels (B) in the three groups. 
(P>0.05, one way ANOVA) n=5 per group.
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Figure 4.16 Hypothalamic 14C concentration, and its relationship with 
the terminal plasma 14C : glucose ratio
(A) There was no significant difference between the 14C concentration in the 
hypothalamus ipsilateral and contralateral to the injected hemisphere following 
injection of AMPA (6nmol), malonate (1.34pmol) and vehicle into the caudate 
nucleus (P>0.05, Student’s paired t  test). No significant differences were detected in 
glucose utilisation values in the contralateral hypothalamus between animals in 
different treatment groups (P>0.05, one way ANOVA).
(B) The relationship was similar between hypothalamic 14C concentration and 
plasma 14C : glucose between groups, irrespective of injectate.
n=5 per group.
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Figure 4.17 LCGU in the caudate nucleus following injection of 
vehicle, AMPA (6nmol) or malonate (1.34//mol)
Data are presented mean ± SEM. ** P<0.01,*** P<0.001 for comparison 
between ipsilateral and contralateral hemisphere (Student’s paired t  test). 
n=5 per group.
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Figure 4.18 LCGU in the cortex and thalamus following
intrastriatal injection of vehicle, AMPA (6nmol) or 
malonate (1.34//mol)
A. Sensory Motor Cortex B. Mediodorsal Thalamic Nuclei 
C. Ventrolateral Thalamic Nuclei
Data are presented mean ± SEM. *P<0.05 for comparison between ipsilateral 
and contralateral hemisphere (Student’s paired t  test), n = 5 per group.
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Figure 4.19 LCGU in extrastriatal areas following intrastriatal injection 
of vehicle, AMPA (6nmol) or malonate (1.34//mol)
A. Globus Pallidus B. Entopeduncular Nuclei
C. Substantia Nigra, pars reticulata
Data are presented mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 for comparison 
between ipsilateral and contralateral hemisphere (Student’s paired t  test). 
n= 5 per group.
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Figure 4.20 LCGU in white matter areas following intrastriatal 
injection of vehicle, AMPA (6nmol) or malonate 
(1.34/ymol)
A. External Capsule B. Corpus Callosum 
C. Internal Capsule
Data are presented mean ± SEM. *P<0.05, **P<0.01,*** P<0.001 for 
comparison between ipsilateral and contralateral hemisphere (Student’s paired
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4.4 Discussion
To summarise, the data presented in this chapter demonstrate that intrastriatal 
injection of AMPA in the mouse caused a dose dependent increase in neuronal 
damage, and axonal damage quantified from NF 200 immunostained sections. 
However, AMPA did not induce an increase in axonal damage assessed with APP 
immunostaining. This contrasts with intrastriatal injection of malonate, which 
caused increased axonal damage assessed with both markers. The contrasting pattern 
of glucose utilisation in the acute period following injection of either toxin suggests 
that AMPA and malonate act by divergent mechanisms.
Differences in AMPA-induced pathology in NF 200 and APP immunostained 
sections
The reasons for the discrepancy between the extent of axonal pathology in NF 200 
and APP immunostained sections is unclear. Numerous studies have utilised 
neurofilament or APP immunohistochemistry to examine axonal pathology 
following brain injury (described in section 1.3.2), however these markers are rarely 
used together or compared. A recent study used dual label immunofluorescence to 
compare the distribution of neurofilament compaction/disruption with the 
accumulation of APP in damaged axons following experimental traumatic brain 
injury (Stone et a l , 2001). Compaction of neurofilament side arms was initially 
hypothesised to cause the impairment of axoplasmic transport that results in APP 
accumulation (Povlishock et al., 1997). However, dual labelling revealed that 
neurofilament compaction and APP accumulation were generally localised to distinct 
populations of axons, and were less commonly double labelled (Stone et al., 2001), 
and ultrastructural analysis confirmed this finding. Axons immunopositive for 
neurofilament compaction appeared thin, elongated, contained swollen mitochondria 
and were often vacuolated and segmented. In contrast, APP immunopositive axons 
contained accumulated organelles, which became progressively larger over time. 
Double labelling with APP and an antibody raised against calpain-mediated 
breakdown products (Ab38) in another study revealed that only 30-50% of the axons 
labelled with Ab38 were APP immunopositive (Buki et a l, 1999b). These findings, 
together with pilot data which revealed that APP immunopositvity and neurofilament 
disruption occurred in separate populations of axons in human head-injured patients, 
led the authors to conclude that APP immunohistochemistry may underestimate the
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full spectrum of axonal pathology following traumatic brain injury (Stone et al, 
2001). Discrepancies between the populations of damaged axons labelled with NF 
200 and APP are also described in the previous and subsequent chapter of this thesis.
The distinct populations of axons labelled by NF 200 and APP 
immunohistochemistry following brain injury may represent different mechanisms of 
injury. APP accumulation within an axon requires energy-demanding, kinesin- 
dependent axonal transport. Therefore it is conceivable that in situations where 
energy metabolism is impaired, or kinesin is not functioning, that APP will not 
accumulate. APP accumulation in damaged axons can occur very quickly, up to 15 
minutes following experimental traumatic brain injury (Stone et al., 2001). This 
suggests that the axonal cylinder is rapidly and directly damaged at an area that will 
go on to accumulate APP. The 2-deoxyglucose studies described in this chapter 
suggest that, when compared with malonate-induced damage where considerable 
APP accumulation does occur, AMPA-induced toxicity progresses more slowly. In 
addition, AMPA is unlikely to be directly toxic to axons, as there is no evidence that 
AMPA receptors are present on the axon cylinder. Instead, AMPA-induced axonal 
damage is likely to be secondary to excitotoxic events occurring at the 
oligodendrocytes, myelin sheath or neuronal perikarya. The neurofilament 
disruption and compaction that occurred following experimental traumatic brain 
injury was associated with disruption of the myelin sheath and infoldings of the 
axolemma (Stone et al., 2001). Normal cytoskeletal composition in axons is 
dependent upon intact myelin (Brady et al., 1999), therefore disruption of myelin 
following brain insults may lead to derangement of the neurofilament network; this 
may account for the cytoskeletal abnormalities following injection of AMPA.
‘Distant’ pathology following intrastriatal injection o f AMPA 
In addition to causing axonal and neuronal pathology in the caudate nucleus, axonal 
and/or neuronal damage was also evident in anatomical areas distant from the 
injection site, such as the thalamus, substantia nigra and hippocampus. Neuronal 
pathology has previously been reported in similar ‘distant’ anatomical areas 
following intrastriatal injection of kainate (Wuerthele et al., 1978; Wooten and 
Collins, 1980; Ciani et al., 1994). Because these brain areas are remote from the 
injection site, it is unlikely that diffusion of the toxin accounts for the pathology in
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these distant areas. In support o f  this, intrastriatal injection o f [3H]-kainate resulted 
in hippocampal damage that was not accompanied by diffusion o f the isotope to this 
area (Scherer-Singler and McGreer, 1979). Instead, the ‘distant’ pathology resulting 
from intrastriatal injection o f AMPA is likely to result from the excessive excitation 
o f brain areas that have excitatory polysynaptic connections with the striatum.
Striatal neurons project to the cortex via the globus pallidus, substantia nigra and 
thalamus (see Fig. 4.23). Furthermore, all regions o f the striatum receive a cortical 
input. Activation o f these pathways, excessive release o f endogenous glutamate in 
these structures and the resultant excessive neuronal activity are likely to result in the 
pathology observed in distant areas following intrastriatal injection o f AMPA. In 
support o f this, increases in glucose utilisation were demonstrated in the cortex, 
globus pallidus, thalamus and substantia nigra, 1 hour following intrastriatal injection 
o f AMPA. The excessive activation o f striatonigral pathways may also be enhanced 
by a loss o f inhibitory GABAergic inputs from the striatum, as infusion o f the GABA 
agonist muscimol reduces pathology observed in the substantia nigra following 
intrastriatal injection o f ibotenic acid (Saji and Reis, 1987).
AMPA
EP
S N R
Cortex
T h a la m u s
Striatum
LIMBIC
S T R U C T U R E S
Piriform C ortex  
A m ygdala  
H ip p o c a m p u s
Figure 4.23 Anatomical areas that may be involved in the pathology 
induced by AMPA
EP =  Entopeduncular Nucleus; SNR= Substantia Nigra, pars reticulata
The cortex is thought to play an integral role in intrastriatal kainate-induced 
pathology, as decortication protects against toxicity, whereas lesioning the substantia 
nigra or thalamus does not protect against kainate toxicity (McGeer et al., 1978;
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Biziere and Coyle, 1979). Extensive cortical damage is present when AMPA is co­
injected with the cytokine interleukin-1 (IL-1), which is not present when AMPA is 
injected alone (Lawrence et al, 1998). However, this cortical damage can be 
attenuated with intracortical infusion of the NMD A receptor antagonist D-AP5, 
suggesting the activation of endogenous glutamatergic pathways between the 
striatum and cortex (Allan and Rothwell, 2000). The cortical damage induced by co­
injection of AMPA and IL-1 in the rat is thought to be mediated, in part, by 
polysynaptic striatal outputs to the cortex via the hypothalamus (Allan et a l, 2000, 
see figure 4.23).
Other anatomical structures where neuronal pathology was observed following 
intrastriatal injection of AMPA are the piriform cortex, amygdala and hippocampus, 
which form part of the limbic system. Damage in the limbic system is also observed 
following intrastriatal injection of kainate (Wuerthele et al, 1978; Ciani et al, 1994). 
The pattern of pathology observed in the limbic system following intrastriatal 
injection of AMPA is similar to that observed following administration of 
convulsants, and suggests seizure like excessive activation of the limbic circuits. 
Dramatic increases in glucose utilisation correlate with seizure propagation following 
intrastriatal injection of kainate (Lothman and Collins, 1981). The administration of 
anti-convulsants such as diazepam reduces neuronal death in limbic brain distant 
from the site of administration following administration of kainate or AMPA and IL- 
1P (Zaczek et a l, 1978; Ben-Ari et al, 1980; Patel et a l, 2002). It is unclear how 
intrastriatal injection of AMPA induces damage in the limbic system when there are 
no major anatomical connections between the striatum and these limbic system areas. 
The pathologic response of these areas may arise indirectly, as a result of 
connections between the limbic system and the cortex/thalamus (Fig. 4.23).
Enhanced levels o f glucose utilisation following intrastriatal injection o f AMPA
Glucose utilisation was markedly increased in the caudate nucleus 1 hour following 
intrastriatal injection of AMPA. Similar increases in glucose utilisation have been 
reported 15 minutes and 1 hour following intracerebral injection of AMPA or kainate 
(Wooten and Collins, 1980; Browne et a l, 1998). A number of energy demanding 
processes could account for the increased glucose utilisation (enzyme synthesis, 
transmitter synthesis and reuptake, etc). However, dynamic alterations in glucose 
utilisation are thought to predominantly reflect the energy demanding process of ion
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transport at nerve terminals (Schwartz et al, 1979). The increase in glucose 
utilisation induced by AMPA in the caudate nucleus is likely to be caused by energy 
demanding ion pumps responding to excessive activation of AMPA/kainate 
receptors. Greatly increased neuronal activity assessed using electrophysiological 
methods follows intracerebral injection of kainate (Ben-Ari et al, 1980; Sawamura et 
al, 2001).
As mentioned earlier, increased glucose utilisation was also observed in the globus 
pallidus, entopeduncular nucleus, thalamus, substantia nigra and cortex following 
intrastriatal injection of AMPA. This supports the notion that the pathology 
observed in these areas results from the excessive release of endogenous excitatory 
amino acids and sustained neuronal activation in these polysynaptic pathways 
connected to the striatum.
Glucose utilisation was also elevated in several white matter areas. This applied not 
only to white matter areas in close proximity to the injection site, such as the corpus 
callosum and external capsule, but also to the internal capsule. Whilst the majority 
of glucose utilisation in grey matter is thought to predominately reflect activity at 
neuronal synaptic terminals, this cannot account for the increased glucose utilisation 
in white matter. It may be possible that AMPA has diffused or tracked up the needle 
tract to the external capsule and corpus callosum, activated AMPA receptors present 
on oligodendrocytes and astrocytes within the white matter, resulting in increased 
activity at ion pumps. However, this is unlikely to account for the increased glucose 
utilisation observed in the internal capsule.
Excessive activation of the internal capsule is likely to result in massive voltage 
dependent Na + and Ca2+ influx into the axons, therefore enhanced rates of glucose 
utilisation are presumably a reflection of enhanced activity at axonal ion pumps 
(Aiello and Bach-y-Rita, 2000). Stimulation of the hindlimb cortical area of the rat 
cortex results in frequency dependent increases in glucose utilisation in the corpus 
callosum and contralateral cortex, suggesting that changes in white matter energy 
metabolism reflect changes in electrical activity (Weber et a l, 2002). Ultrastructural 
analysis of brain tissue from rodents exposed to consultant agents revealed that 
axonal pathology preceeded changes in neuronal perikarya and dendrites (Auer et al,
1986). Furthermore, swollen mitochondria with damaged cristae were evident within
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swollen axons. Again, these changes were associated with hypermetabolism (Ingvar 
et al., 1987), and were presumed to be related to influx of Na+ into the excessively 
activated axon cylinder. It would appear likely therefore, that the swollen axons 
evident in the ‘distant’ brain areas 24 hours following intrastriatal injection of 
AMPA is caused by hypermetabolism of the polysynaptic circuits associated with 
striatum, influx of Na+ and Ca2+, loss of ionic membrane potentials and possible 
swelling of mitochondria. Increased Ca2+ and mitochondrial dysfunction has also 
been implicated in the production of reactive oxygen species, which can cause 
oxidative damage to cells (Kristian and Siesjo, 1998). The anticonvulsant agent 
carbamzepine, which acts by blocking sodium channels, reduces seizure activity and 
hyperactivity following intracerebral injection of kainate (Zaczek et al., 1978). It 
would be interesting to determine if sodium channel blocking agents could reduce 
hypermetabolism and axonal pathology observed following intrastriatal injection of 
AMPA.
Glucose utilisation was not significantly altered in any of the limbic structures 1 hour 
following intrastriatal injection of AMPA, however by 24 hours neuronal pathology 
was observed in these areas. Furthermore, despite the presence of damaged neurons 
in limbic structures at 24 hours, axons were minimally disrupted, and were rarely 
swollen to the same extent as axons in structures such as the thalamus, cortex, globus 
pallidus and substantia nigra, in which glucose utilisation was elevated by 1 hour. 
These observations suggest that the pathology in the limbic system may occur at a 
later timepoint, and is secondary to the changes in the striato-thalamo-cortical 
pathways. All mice in the 2-deoxyglucose studies received steady levels of the 
anaesthetic agent halothane for 38 minutes prior to administration of the 2- 
deoxyglucose. The depressant effects of the anaesthesia may have inhibited 
activation of the limbic system in the acute period following intrastriatal injection of 
AMPA.
Caution should always be applied when interpreting the results of 14C- 2- 
deoxyglucose experiments in pathological situations such as AMPA-receptor 
mediated excitotoxicity. Under physiologically normal circumstances, levels of 
deoxyglucose accumulation are the basis for the estimation of local glucose 
phosphorylation, which in turn is intimately related to energy consumption. In 
pathological situations such as seizure induction, dynamic alterations can occur in
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the value of rate constants and the ‘lumped constant’ (Ingvar and Siesjo, 1983; 
Greenberg et al., 1992). This in turn may alter the normal relationship between 
deoxyglucose uptake and glucose phosphorylation. The methodology employed in 
the current study is still valid to determine which anatomical structures have altered 
levels of glucose utilisation in the acute period following intrastriatal AMPA 
injection. However, the increased levels of glucose utilisation may not bear the 
direct relationship with energy production as it would under normal circumstances. 
Anaerobic metabolism, which yields considerably lower net energy gains per 
molecule of glucose, may increase in pathological circumstances. This occurs during 
experimental seizure induction, where levels of lactate are elevated (Ingvar et al,
1987). Therefore, it is possible that at least some of the elevation in glucose 
utilisation observed following AMPA administration may not reflect increased levels 
of energy utilisation per se, but instead may also reflect enhanced anaerobic 
glycolysis supplying the normal energy demands. Measuring levels of metabolites 
such as lactate, the product of anaerobic metabolism, would establish the 
contribution of anaerobic glycolysis or increased energy demand to the elevation of 
glucose utilisation observed following intrastriatal administration of AMPA. It is 
interesting to note that accumulation of lactate may also contribute to axonal 
pathology, as intracerebral injection of acidic lactate results in axonal swellings 
(Meller et al, 1993).
Comparison o f AMPA-induced pathology with malonate-induced pathology
The similarities and differences in the pattern of pathology observed following 
intrastriatal injection of AMPA or malonate are summarised in table 4.3.
Intrastriatal injection of malonate results in a significant increase in the amount of 
APP immunoreactive axons, whereas AMPA does not. This is likely to be a 
reflection of the ability of malonate to be directly toxic to axons, which contain 
numerous mitochondria. By inhibiting energy production in the axon cylinder, the 
ATP-dependent anterograde transport of APP will cease. This explains why APP 
immunoreactive axons are mainly located at the boundary of the malonate-induced 
lesion, as presumably intact cell bodies located out with the area affected by 
malonate transport APP along axons to the point of damage. In contrast, AMPA 
does not immediately cause energy inhibition, but instead acts through excitotoxic
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mechanisms that are not directly toxic to the axon cylinder. A diagrammatic 
comparison of the different effects of AMPA and malonate on axons is shown in 
figure 4.24.
AMPA Malonate
Neuronal pathology in caudate nucleus V V
Neuronal/axonal pathology in the cerebral cortex
V X
Axonal pathology (NF 200) in caudate nucleus V V
Axonal pathology (APP) in caudate nucleus
X V
‘Distant’ pathology V X
Effects on glucose utilisation in the caudate at 1 hr t 1
Table 4.4 Similarities and differences in AMPA or malonate-induced 
pathology
Whereas AMPA caused widespread damage in ‘distant’ brain areas, malonate mainly 
induced damage confined to the caudate nucleus and globus pallidus. As malonate 
does not primarily act by exciting glutamate receptors in the caudate, it does not 
result in the activation of the polysynaptic circuits shown in figure 4.23, therefore 
there is no ‘distant’ pathology, at least at the doses used in this experiment.
Intrastriatal injection of malonate resulted in a core area of suppressed glucose 
utilisation, surrounded by a rim of increased 2-deoxyglucose accumulation in the 
caudate nucleus. The pattern of altered glucose utilisation following malonate 
administration is similar to that observed following focal cerebral ischaemia 
(Ginsberg, 1990). The decreased glucose utilisation in the caudate nucleus indicates 
that a suppression of energy utilisation and neuronal function has occurred as soon as 
1 hour following malonate administration. In both focal cerebral ischaemia and 
malonate-induced damage, mitochondrial function is disturbed. This is due to O2 
deprivation in the former case, and as a result of succinate dehydrogenase inhibtion
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in the latter case. Either way, inhibition of mitochondrial function results in 
increased rates of anaerobic glycolysis and the production of lactate. Therefore, the 
enhanced levels of glucose utilisation in the boundary of the caudate are likely to 
reflect enhanced levels of anaerobic glycolysis. However, increased aerobic energy 
utilisation may also account for some of the 2-deoxyglucose accumulation in the 
caudate. Excitotoxic mechanisms, which result in elevated neuronal activity and 
hence energy consumption, are thought to contribute to the ensuing pathology caused 
by malonate (Greene et al., 1993). NMDA receptor antagonism attenuates malonate- 
induced damage (Greene et al., 1993), and recent data generated in our laboratory 
have shown that the AMPA receptor antagonist LY293558 can reduce neuronal 
pathology following intrastriatal injection of malonate (Cuthill, unpublished 
observations).
In addition to altering levels of glucose utilisation in the caudate nucleus, malonate 
also caused increases in glucose utilisation in the entopeduncular nucleus and 
internal capsule. It is unclear if activation of these areas arises due to their 
anatomical connectivity with the caudate nucleus, or if it results from diffusion of 
malonate or other pathogenic mediators of malonate-induced damage. Elevated 
glucose utilisation in these two brain areas following intrastriatal injection of AMPA 
correlated with activation of other areas such as the substantia nigra, thalamus and 
cortex; which was proposed to occur due to the activation of the polysynaptic circuits 
described earlier. However, the thalamus, cortex and substantia nigra have unaltered 
levels of glucose utilisation following intrastriatal injection of malonate. Therefore, 
it seems likely that diffusion of toxic substances may result in the elevated glucose 
utilisation and subsequent pathology in these areas. Examining the anatomical extent 
to which radioactively labelled malonate diffuses, or the pattern of glucose utilisation 
or pathology following intrastriatal injection of malonate with glutamate receptor 
antagonism would gain further insights into this phenomenon.
Four out of the 5 areas that contained markedly elevated levels of glucose utilisation 
following intrastriatal injection of malonate were white matter areas. These included 
the anterior commissure, external capsule and corpus callosum that were in close 
proximity to the injection site. Similar, marked elevations in glucose utilisation in 
white matter tracts have been reported following experimental hypoxemia in the rat, 
where 2-deoxyglucose accumulation was more pronounced in white matter than
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adjacent grey matter areas (Pulsinelli and Duffy, 1979). The authors proposed that 
the disproportionately greater change in glucose utilisation in white matter compared 
to grey matter was caused by enhanced anaerobic glycolysis, due to an increased 
vulnerability of white matter to hypoxia, perhaps related to a greater reduction in 
blood flow to white matter (Pulsinelli and Duffy, 1978). However, recent data has 
suggested that white matter is relatively resistant to anoxia, because it can utilise 
energy from anaerobic glycolysis (Ransom et al, 2002). Furthermore, mice optic 
nerves are reported to be more resistant to anoxia than rat optic nerves (Ransom et 
al, 2002). This may account for the fact that axonal pathology was consistently 
observed extending across the corpus callosum into the contralateral white matter 
following intrastriatal injection of malonate in the rat (Dewar et a l, 2001), but was 
rarely observed following the same treatment in the mouse, despite increased glucose 
utilisation in the same area. Evidently, further investigation of the metabolic 
responses of white matter compared to grey matter following brain injury is required. 
With the exception of the corpus callosum and anterior commissure of malonate- 
treated animals, all areas that had elevated glucose utilisation 1 hour following 
intrastriatal injection of malonate or AMPA had axonal pathology in these areas at 24 
hours. This suggests that alterations in the metabolic state of these anatomical areas 
occurs, and perhaps contributes to axonal pathology.
The pathological consequences of intrastriatal injection of AMPA in the mouse have 
now been characterised. The following chapter will determine if PLP and MBP 
deficient mice exhibit an altered sensitivity to intrastriatal injection of AMPA.
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Figure 4.24 Comparison of the mechanisms of AMPA or malonate 
mediated toxicity
A. M alonate acts directly by inhibiting energy production by com petitive 
inhibition o f  a mitochondrial enzym e, succinate dehydrogenase. Energy 
inhibition may lead to the production o f  reactive oxygen species (ROS), 
excitotoxicity, and the influx o f  N a and Ca2f, which in turn may have 
detrimental effects to the axon (orange arrows).
B. AM PA acts directly by over-activating AM PA receptors located on the 
neuronal perikarya, oligodendrocytes and myelin sheath (red arrow). 
Excitotoxic events at these cellular elements may lead to axonal dam age via 
the diffusion o f toxic factors such as reactive oxygen species, lack o f  trophic 
support from the oligodendrocytes or the influx o f Na" and C a2" (orange 
arrows).
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CHAPTER 5
AMPA-INDUCED AXONAL DAMAGE IS ATTENUATED 
IN PLP, BUT NOT MBP DEFICIENT (shiveret) MICE
5.1 Introduction
PLP deficient mice develop compacted myelin, and have a normal life span (Boison 
and Stoffel, 1994; Klugmann et al, 1997). However, 6-8 weeks following birth, 
swollen axons are detected in PLP deficient mice, using electron microscopy 
(Klugmann et a l, 1997). The axonal damage is more prominent in animals older 
than one year, and by 16 months, impairment of motor function is observed (Griffiths 
et al, 1998). Axonal swellings have also been reported in human patients lacking 
PLP (Garbem et al, 2002). PLP deficient oligodendrocytes transplanted into the 
spinal cord of shiverer mice induces axonal swellings (Edgar et a l, 2001). This 
suggests that the axonal swellings are due to the presence of PLP deficient 
oligodendrocytes, and not as a consequence of loss of PLP splice variants from the 
neuronal cell body. This suggests that interactions with myelin are important for 
normal functioning of the axon, and that PLP is involved in this process.
Due to a naturally arising mutation on the MBP gene, MBP cannot be synthesised in 
shiverer mice (Readhead et al, 1987). These mice lack compact myelin, develop a 
tremor, progressively increasing seizures, and die prematurely (50-100 days after 
birth). Unlike PLP deficient mice, there is no evidence that shiverer mice possess 
axonal swellings. However, abnormalities in axons of shiverer mice have been 
reported. Increased rates of slow axonal transport, altered amounts of neurofilaments 
and microtubules and altered levels of neurofilament phosphorylation have been 
reported in shiverer mice (Brady et al, 1999). These axonal abnormalities were also 
observed in transgenic mice containing two copies of a wild type MBP transgene, 
which results in an intermediate amount of compact myelin (Kirkpatrick et al,
2001). This suggests that it is not merely the lack of compact myelin that accounts 
for the axonal abnormalities, but MBP-mediated glial-axonal signals.
The abnormal axo-glial relationships that Pip knockout and shiverer mice possess 
may provide a useful model to examine the role of excitotoxic events at the myelin 
sheath and oligodendrocyte in mediating AMPA-induced axonal damage. In 
addition, it remains possible that the axonal abnormalities observed in PLP and MBP 
deficient mice may be mediated, in part, by secondary excitotoxic processes. 
Therefore the current study was undertaken to determine if PLP and MBP deficient 
mice exhibit altered sensitivity to AMPA-induced axonal damage.
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5.1.1 Aims of Study
The aim of the current study was to examine if Pip knockout and shiverer mice 
exhibited an altered sensitivity to AMPA-induced toxicity in vivo compared with 
their wild type counterparts. Axonal damage was assessed in neurofilament and APP 
immunostained sections. APP immunostaining of Pip knockout animals 
unexpectedly revealed axonal damage in widespread brain areas. To further examine 
this phenomenon, and to determine that is was not a consequence of the AMPA 
injection, APP and NF 200 immunostaining was performed on naive 2, 3, 4 month 
and 1 year old Pip knockout and wild type mice. In addition, the levels of the 
AMPA receptor subunits GluRl-4 were assessed in Pip knockout and wild type 
mice.
5.2 Methods
5.2.1 Generation of PLP knockout mice, s/?/Verer mice and PCR 
analysis
The Pip gene knockout mice were generated by Klugmann et al (1997) at the 
University of Heidelberg, Germany. A targeting vector, under the control of the 
herpes simplex virus (HSV) promoter, was designed to disrupt the Pip gene. This 
was introduced into R1 embryonic stem cells by electroporation, together with the 
thymidine kinase gene, also under the HSV promoter, to select against random vector 
insertion. Cells containing the Pip gene-null allele were microinjected into 
blastocyts from C57BL/6J mice. Pip +/- heterozygote females were crossed with 
wild type C57/BL/6J males to give wild type (+/y) and Pip knockout (-/y) male 
offspring. Shiverer mice, that lack MBP due to a naturally arising mutation, were 
maintained on the C3H/101 strain. These mice were donated by K-A Nave. All 
mice were maintained and bred at the Parasitology Unit, University of Glasgow 
Veterinary school. Pip knockout mice and shiverer mice were identified by 
Polymerase Chain Reaction (PCR) genotyping using DNA extracted from tail 
biopsies as described previously (Thomson et al, 1999). Dr Julia Edgar performed 
all PCR genotyping and tail biopsies.
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5.2.2 Examination of axonal damage in naive Pip knockout and wild- 
type animals from different age groups
Wild-type or Pip knockout mice were placed in a perspex chamber with increasing 
levels of CO2 for 5 minutes, then 0.9% saline followed by 4% paraformaldehyde was 
administered transcardially. Perfuse fixation of the naive mice was performed by Dr 
Julia Edgar, whilst subsequent tissue processing, sectioning, immunostaining and 
analysis was performed by myself. The different age groups examined were: 2 
month old (PLP knockout, n=2; wild-type, n=2), 3 month old (PLP knockout, n=3; 
wild type n=3), 4 month old (PLP knockout, n=l; wild-type, n=l) and 1 year old 
(PLP knockout, n=l; wild-type, n=l). Coronal sections were taken from eight levels 
throughout the brain, corresponding with the anatomical landmarks at the following 
levels (relative to Bregma in mm) from the stereotaxic atlas of Paxinos and Franklin, 
1997: 1.98, 1.1, 0.14, -0.58, -1.06, -1.7, -3.08, -3.88. Sections from each level were 
stained with H & E for histological assessment, and immunostained using antibodies 
raised against NF 200 and APP to examine axonal pathology. The extent and degree 
of axonal pathology in the three month old Pip knockout and wild type mice was 
characterised at each coronal level using a scoring system described in Figure 5.1 
and 5.2.
5.2.3 Stereotaxic injection of AMPA
Three month old male wild-type (n=7) or Pip knockout mice (n=6) (26-32g); and 
three month old male shiverer (n=5) or wild type mice (n=6) (23-33g) received 
stereotaxic injection of AMPA (1.5nmol) into the caudate nucleus as previously 
described (Section 2.3.1). Twenty-four hours later, animals were perfuse-fixed with 
saline (0.9%) then paraformaldehyde (4%); post-fixed, processed and paraffin 
embedded (section 2.3.2).
5.2.4 Histology, immunostaining and quantification of damage 
following stereotaxic injection of AMPA
Twenty coronal sections (6/xm) from every forty sections cut were retained on poly- 
L-lysine slides (2 sections per slide) for histology and immunostaining. One slide 
from each cycle was stained with H & E to examine neuronal perikaryal damage 
(section 2.6.1), and adjacent sections were immunostained using antibodies raised
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against phosphorylated NF 200 and APP to examine axonal pathology (2.5.5). 
Quantification of axonal and neuronal damage is outlined in section 2.5.9 and 2.6.4. 
The rostral and caudal limit for integration of the lesion induced by AMPA were 
2.8mm and -4.26mm respectively, from Bregma in the Pip knockout or wild type 
mice. The rostral and caudal limit for integration of the lesion induced by AMPA in 
the shiverer or wild type mice was 2.22mm and -3.16mm respectively, from 
Bregma. AMPA also induced neuronal and axonal damage in anatomical areas 
‘distant’ from lesion site in certain animals. This distant damage, which could be 
clearly differentiated from the focal lesion induced by AMPA was not included in the 
volumetric quantification of damage.
5.2.5 Quantification of AMPA receptor subunits GluR1-4 in Pip 
knockout and wild type mice
Whole mouse brains from postnatal day 20 Pip knockout (n=3) or wild-type mice 
(n=3) were homogenised, then a membrane-enriched fraction was prepared by Dr 
Mark McLaughlin as described in section 2.8.1. The protein content of the 
homogenates was determined using a BCA protein assay (section 2.8.2), then 
samples underwent SDS-PAGE electrophoresis (section 2.8.3). All samples were 
loaded onto the mini-gel apparatus together with colour markers of known molecular 
weights, to ensure that the protein bands detected were of the correct molecular 
weight. The separated proteins were then transferred onto a PVDF membrane using 
western blotting (section 2.8.4), and levels of GluRl, GluR2, GluR2/3, GluR4 and 
actin were detected using the appropriated antibodies, as outlined in table 2.3 
Antibody detection was performed using enhanced chemiluminescence, and the 
optical density of the bands was quantified using Scion Image for windows (Scion 
Corporation).
5.2.6 Statistics
All data were analysed for statistically significant differences using unpaired, two- 
tailed Student’s t test. Data are presented mean ± SEM.
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5.3 Results
5.3.1 NF 200 immunostaining of naive Pip knockout and wild-type mice
White matter tracts in NF 200 immunostained sections from wild type mice appeared 
to be smooth and uniformly stained. In contrast, in PLP knockout animals, white 
matter tracts appeared were less uniform, and more interspersed. Axonal swellings 
were present in several anatomical areas, however the magnitude of the swellings 
varied between regions. A scoring system was devised to describe these changes 
(Fig. 5.1, Table 5.1). The anatomical areas that contained the greatest amount of 
swollen axons were the reticular and dorsolateral thalamic nuclei. No differences 
were observed in the anatomical incidence and amount of axonal swellings in Pip 
knockout mice aged 2, 3 or 4 months. There appeared to be a greater number of 
axonal swellings, which also appeared to be larger, in the 12-month-old PLP 
knockout mouse, particularly in all parts of the cerebral cortex and in the superior 
colliculus. In contrast, axonal swellings were rarely observed in the wild type mice of 
any age.
5.3.2 APP immunostaining of naive Pip knockout and wild-type mice
APP immunostained sections from wild type mice exhibited a diffuse, low level of 
staining. In contrast, APP immunopositive axons, which were swollen and bulbous 
like, were evident in several anatomical areas in the brains of naive PLP knockout 
mice. The magnitude of the axonal swellings varied in different anatomical areas.
The anatomical incidence and magnitude of the axonal swellings evident in APP 
immunostained sections is shown in table 5.1 using the scoring system described in 
figure 5.2. The anatomical areas that contained the greatest amount of axonal 
swellings were: the anterior commissure, internal capsule (dorsal section), fimbria, 
stria terminalis, and the reticular and dorsolateral thalamic nuclei. No difference was 
observed in the anatomical incidence or magnitude of damaged axons between mice 
aged 2, 3 or 4 months. Whilst the anatomical areas that contained APP 
immunopositive axons did not differ in the Pip knockout mouse aged 12 months, the 
amount of damaged axons within each area increased, and furthermore, some axons 
appeared to have larger swellings when compared with the younger mice. Axonal 
swellings were only rarely observed in wild type mice of any age.
163
A B
. •-
Score +
L/ rk k .
< . . Jf. a\ 'V-*'- '4. * *>'.y
U i  ■ y V ' 4  ■ - v / v , / t. , ,
". * 
■ •'
Score +++
T * j X ' '  .VC i v .  •• ’■ f
< vx c i i  v v- r
• ; '•}
t»'- . .r '&>, . J S m l
Score ++ 
D
V ' p  k  ' v‘#- 
‘ t&.**>■
V - t  ,  V  O ’ " 1 *■ %- K v ■> P  f  \  ■
%*>
Score ++++
C f c V #  ‘n * •• ‘ • •• • • iztf-’ifr " . \  v t ■ v t ' T V i l . V *
Figure 5.1 NF 200 immunoreactivity in the brains of naive Pip 
knockout mice: method of scoring
Anatom ical areas were assigned a score depending on the am ount o f 
dam aged axons observed. The score ranged from  +, where only occasional 
axonal swellings were observed, to ++++, where axonal swellings were 
abundant. Scale bar = 50pm.
(A) Caudate nucleus (+)
(B) Sensory M otor Cortex (++)
(C) Superior Colliculus (+++)
(D) Dorsolateral Tham almic Nuclei (++++)
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Table 5.1
Anatomical Area NF200 APP
Cortex Sensory Motor ++ +
Parietal ++ +
Cingulate: Anterior + +
: Posterior ++ +
Caudate Nucleus Caudal + +
Rostral ++ ++
Corpus Callosum ++ +++
External Capsule + + +++
Anterior Commissure + + ++++
Globus Pallidus ++ ++
Internal Capsule ++ ++++
Optic Tract ++ ++
Thalamic Nuclei Anteroventral +++ ++
Dorsomedial + +
Dorsolateral ++++ ++++
Reticular ++++ ++++
Ventrolateral + +
Stria Terminalis ++ ++++
Fimbria +++ ++++
Hippocampus ++ ++
Lateral Habenula ++ ++
Substantia Nigra +++ +
Superior Colliculus: Deep Gray layer +++ +
Superior Colliculus: Other layers ++ +
The anatomical presence and extent of axonal swellings 
observed in Pip knockout mice aged three months
The scoring system, explained in figures 5.1 and 5.2, describes the magnitude of 
axonal swellings in the anatomical areas listed above in both NF 200 and APP 
immunostained sections.
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Score ++
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APP immunoreactivity in the brains of naive Pip 
knockout mice: method of scoring
Anatom ical areas were assigned a score depending on the am ount o f 
dam aged axons observed. The score ranged from +, where only occasional 
axonal swellings were observed, to ++++, where axonal swellings were 
abundant. Scale bar =  50pm.
(A) Caudate nucleus (+)
(B) Globus Pallidus (++)
(C) Corpus Callosum  (+++)
(D) Internal Capsule (++++)
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5.3.3 Histological staining of naive Pip knockout and wild-type mice
The white matter tracts in all wild type animals appeared uniform, and all 
oligodendrocyte like cells had a regular spherical appearance, and ran in organised 
profiles (Fig 5.3A, C, E). In Pip knockout animals of all ages, all white matter tracts 
appeared to be disrupted and less uniform (Fig. 5.3B, D, E). There appeared to be an 
increase in the number of glial cells within certain white matter tracts in animals 
aged 4 and 12 months, such as the fimbria, corpus callosum and internal capsule, 
when compared to the wild type mice. Neurons in Pip knockout and wild type 
animals of all ages appeared to be morphologically normal.
Wild type Pip  knockout
External Capsule
Figure 5.3 Histological staining of naive Pip knockout and wild 
type mice
Representative images from  the caudate nucleus (A), external capsule (C) 
and fimbira (E) o f  3 month old wild type mice and P i p  knockout mice (B, D 
and F respectively). The arrows in (A) and (B) point to the white matter 
tracts o f the caudate nucleus. Note the perforated apperance o f the white 
m atter tracts in P i p  knockout mice.
Scale bar = 50pm.
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5.3.4 Axonal damage a ssessed  in NF 200 immunostained sections
following intracerebral injection of AMPA in Pip knockout or wild 
type mice
In the contralateral hemisphere of Pip knockout animals, the white matter tracts in 
NF 200 immunostained sections appeared to be more perforated than white matter 
tracts in the contralateral hemisphere of wild type mice (Fig 5.4A and 5.4C). 
Intracerebral injection of AMPA resulted in a disrupted pattern of NF 200 
immunostaining, and the presence of axonal swellings in the caudate nucleus in Pip 
knockout and wild type mice. These swellings appeared to be larger near the needle 
tract, and smaller near the boundary of the lesion. Axonal swellings were also 
evident in the cortex and external capsule overlying the injection site (Fig. 5.5A).
The area of tissue containing damaged axons extended to the globus pallidus, internal 
capsule and substantia nigra of certain animals (see Table 5.2). As reported in 
section 5.3.1, axonal swellings are also evident in widespread anatomical areas in NF 
200 immunostained sections from naive Pip knockout mice. The anatomical areas 
that are normally damaged by intrastriatal injection of AMPA (1.5nmol; see chapter 
4) generally contained low/intermediate levels of axonal swellings in the naive PLP 
knockout brains. This enabled the distinction of axonal damage induced by AMPA 
from the naturally occurring axonal damage, with continual reference to the 
contralateral hemisphere. Quantification of the amount of AMPA-induced axonal 
damage in the NF 200 immunostained sections revealed that Pip knockout animals 
contained significantly less axonal damage compared to wild type animals (Fig. 5.5).
Anatomical Area Wild Type P i p  knockout
Globus Pallidus (ipsilateral) 5 of 7 2 of 6
Internal Capsule (ipsilateral) 5 of 7 1 of 6
Thalamus (ipsilateral) 2 of 7 Oof 6
Thalamus (contralateral) 1 of 7 Oof 6
Substantia Nigra 5 of 7 1 of 6
Table 5.2 Incidence of axonal damage in NF 200 immunostained 
sections following intrastriatal injection of AMPA in Pip 
knockout or wild type animals
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Wild Type
C D
Pip knockout
Figure 5.4 NF 200 immunostaining of the caudate nucleus of Pip 
knockout and wild type animals
The white m atter tracts o f  the contralateral caudate nucleus appeared
smooth and uniform ly stained in wild type animals (A). In contrast, in the 
contralateral caudate nucleus o f  P i p  knockout animals, the axons appeared 
to be less uniform, and more perforated (C). Axons in the boundary o f  the 
lesion in the caudate nucleus o f  w ild type animals appeared disrupted (B). 
In contrast, an equivalent area o f  the caudate nucleus o f P i p  knockout did 
not contain AM PA-induced axonal damage (D).
Scale bar = 25pm.
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Figure 5.5 Axonal damage quantified from NF 200 
immunostained sections in wild type and Pip 
knockout animals following intrastriatal injection of 
AMPA (1.5nmo!)
A. Digitised NF 200 stained sections demonstrating the anatomical 
extent of axonal disruption and swellings (contained within the 
dashed line) in a wild type and Pip knockout animal.
B. Quantification of the volume of tissue containing axonal damage. 
*P<0.05 Student’s unpaired t test.
Bar represents mean of each group.
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5.3.5 Axonal damage assessed in APP immunostained sections 
following intracerebral injection of AMPA in Pip knockout or wild 
type mice
APP immunopositive axons were evident in the caudate nucleus and subcortical 
white matter following intracerebral injection of AMPA. However, in both Pip 
knockout and wild type mice, this was generally confined to area adjacent to the 
needle tract (Fig. 5.6A and B). The occurrence of widespread axonal swellings in 
APP immunostained sections from the brains of Pip knockout mice was described in 
section 5.3.2. However, the injection site (rostral caudate nucleus) rarely contained 
damaged axons in naive PLP knockout brains, thus enabling the AMPA-induced 
lesion to be quantified. There was no significant difference in the amount of AMPA- 
induced axonal damage quantified from APP immunostained sections in PLP 
knockout compared with wild type mice (Fig. 5.6B).
5.3.6 Neuronal damage assessed in H & E sections following 
intracerebral injection of AMPA in Pip knockout or wild type mice
Intracerebral injection of AMPA induced the presence of shrunken, eosinophilic 
neurons in the caudate nucleus and overlying cortex. The lesion extended into the 
globus pallidus of certain animals (listed in table 5.3). Quantification of the volume 
of tissue containing neuronal damage showed that there was a reduction in the 
amount of neuronal damage in PLP knockout animals; however, this did not reach 
accepted levels of significance (P=0.06, Fig 5.7B). In addition to the focal lesion 
induced by AMPA, selective, widespread neuronal damage was observed in 
anatomical areas such as the endopiriform cortex and thalamic nuclei (Table 5.3). 
However, this was only observed in PLP wild type animals.
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Figure 5.6 Axonal damage quantified from APP immunostained 
sections in Pip knockout and wild type animals 
following intrastriatal injection of AMPA (1.5nmol)
A. Digitised APP immunostained sections demonstrating the 
anatomical extent of APP immunopositive swellings (contained 
within the dashed lines) in a wild type and Pip knockout mouse.
B. Quantification of the volume of tissue containing APP 
immunopositive swellings
P>0.05, Student’s t test.
Bar represents mean of each group.
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Figure 5.7 Neuronal damage in wild type and Pip knockout 
animals following intrastriatal injection of AMPA 
(1.5nmol)
A. Digitised H & E stained sections dem onstrating the anatomical 
extent o f histological dam age in a wild type and P i p  knockout 
animal.
B. Neuronal dam age is reduced in P i p  knockout anim als com pared to 
wild type animals, however this did not reach accepted levels o f 
significance
P=0.06, Student’s t  test.
Bar represents mean o f each group.
174
Anatomical Area Wild Type
P i p
Knockout
Globus Pallidus (ipsilateral) 5 of 7 2 of 7
Thalamus (ipsilateral) 2 of 7 Oof 7
Thalamus (contralateral) 1 of 7 Oof 7
Hippocampus (ipsilateral) Oof 7 Oof 7
Hippocampus (contralateral) Oof 7 Oof 7
Amydala (ipsilateral) Oof 7 Oof 7
Amydala (contralateral) Oof 7 Oof 7
Endopiriform cortex (ipsi) 3 of 7 Oof 7
Endopiriform cortex (contra) Oof 7 Oof 7
Piriform cortex (ipsilateral) 1 of 7 Oof 7
Substantia Nigra 4 of 7 2  o i l
Table 5.3 The incidence of selective neuronal damage in widespread 
brain areas following intrastriatal injection of AMPA in Pip 
knockout or wild type animals.
5.3.7 Levels of GluR1-4 a ssessed  by western blotting in P20 whole 
brain hom ogenates from Pip knockout or wild type mice
There was no significant difference in the levels of GluRl, GluR2, GluR2/3 or 
GluR4 in the membrane enriched samples prepared from 20 day old Pip knockout or 
wild type mice (Fig. 5.8 and 5.9). There was no significant difference in the levels of 
actin detected from the same samples; thus confirming equal loading of the samples 
(Fig. 5.8, and 5.9).
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Figure 5.8 Levels of glutamate receptor subunits in wild-type or 
Pip knockout brain hom ogenates (Post natal day 20)
G luR l (A), GluR2 (B), G luR2/3 (C), G luR4 (D) and actin (E) 
im m unoreactivity on western blots following gel electrophoresis o f P i p  
knockout (ko) or wild-type (wt) mouse brain hom ogenates. The m olecular 
w eights o f colour markers included with the samples are indicated on the left 
hand side.
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Figure 5.9 Quantification of AMPA receptor subunit levels in 
Pip knockout brains
Quantification of the levels of GluRl-4 in P i p  knockout mice brains, 
expressed as a percentage of wild type counterparts. Levels of actin were 
also detected from the same samples to test for equal loading. There was 
no significant difference between the levels of GluRl, GluR2, GluR2/3, 
GluR4 or actin in the brains of the P i p  knockout or wild type counterpart 
mice. (P>0.05, Students unpaired t  test, n=3 per group).
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5.3.8 Axonal damage a ssessed  in NF 200 immunostained sections
following intracerebral injection of AMPA in shiverer or wild type 
mice
In wild type mice, the contralateral hemisphere exhibited a similar pattern of NF 200 
immunostaining as previously described for C57 mice (section 4.3.1). In contrast, in 
the contralateral hemisphere of shiverer mice, a rougher, clumped, disrupted pattern 
of immunostaining was evident. This was most striking in basal forebrain areas such 
as the substantia innomita and the median forebrain bundle. Other areas such as the 
internal capsule and substantia nigra contained an irregular, clumped pattern of 
immunostaining when compared with wild type mice. The contralateral caudate 
nucleus exhibited very subtle alterations in NF 200 immunoreactivty when compared 
with wild type mice, appearing slightly rougher (Fig. 5.10A, C). Following 
intracerebral injection of AMPA, quantification of the volume of axonal damage in 
NF 200 immunostained sections revealed that there was a slight increase in shiverer 
mice compared to wild type, however this did not reach accepted levels of 
significance (Fig. 5.11). There was also an increase in the amount of axonal damage 
in ‘distant’ brain areas (table 5.4).
Anatomical Area Wild Type s h i v e r e r
Globus Pallidus (ipsilateral) 2 of 6 3 of 5
Internal Capsule (ipsilateral) 2 of 6 3 of 5
Thalamus (ipsilateral) 1 of 6 2 of 5
Thalamus (contralateral) Oof 6 Oof 5
Substantia Nigra 2 of 6 3of 5
Table 5.4 Incidence of axonal damage in NF 200 immunostained
section s following intrastriatal injection of AMPA in wild type or 
shiverer animals
5.3.9 Axonal damage a ssessed  in APP immunostained sections
following intracerebral injection of AMPA in shiverer or wild type 
mice
Intracerebral injection of AMPA induced the appearance of APP immunopositive 
axons in the caudate nucleus and overlying external capsule. However, in both 
shiverer and wild type mice, this was generally confined to area adjacent to the 
needle tract (Fig. 5.11 A). There was no significant difference in the amount of 
AMPA-induced axonal damage quantified from APP immunostained sections in Pip 
knockout compared with wild type mice (Fig. 5.1 IB).
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Figure 5.10 NF 200 immunostaining in the caudate nucleus of 
wild type and shiverer mice
W hite matter tracts in the hem isphere contralateral to the injection site 
appeared smooth and uniform  in wild type mice (A), but slightly more 
disrupted and clumped in s h i v e r e r  mice (C). In the boundary o f  the 
AM PA-induced lesion, swellings and a disrupted pattern o f  NF 200 
imm unostaining were evident in both wild type and s h i v e r e r  mice.
Scale bar = 25pm.
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Figure 5.11 Axonal damage quantified from NF 200
immunostained sections in wild type and shiverer 
mice following intrastriatal injection of AMPA 
(1.5nmol)
A. Digitised NF 200 immunostained sections demonstrating the 
anatomical extent of axonal swellings (contained within the dashed 
line).
B. Quantification of the volume of tissue containing axonal damage. 
P>0.05, Student’s unpaired t  test.
Bar represents mean of groups.
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Figure 5.12 Axonal damage quantified from APP immunostained 
sections in wild type and shiverer mice following 
intrastriatal injection of AMPA (1.5nmol)
A. Digitised APP immunostained sections demonstrating the 
anatomical extent of axonal damage in wild type and s h i v e r e r  mice. 
Tissue containing APP immunopositive swellings is contained 
within the dashed line.
B. Quantification of the extent of axonal damage in the APP 
immunostained sections. P>0.05, Sudent’s unpaired t  test.
Bar indicates mean of each group.
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5.3.10 Neuronal damage a ssessed  in H & E stained sections following 
intracerebral injection of AMPA in shiverer or wild type mice
Quantification of neuronal damage revealed that there was no significant difference 
between shiverer and wild type mice following intracerebral injection of AMPA. 
Similarly, analysis of selective neuronal damage in widespread brain areas induced 
by AMPA revealed that there were no striking differences between shiverer and wild 
type mice.
Anatomical Area Wild Type s h i v e r e r
Globus Pallidus (ipsilateral) 2 of 6 3 of 5
Thalamus (ipsilateral) 2 of 6 2 of 5
Thalamus (contralateral) Oof 6 1 of 5
Hippocampus (ipsilateral) Oof 6 Oof 5
Hippocampus (contralateral) Oof 6 Oof 5
Amydala (ipsilateral) Oof 6 2 of 5
Amydala (contralateral) Oof 6 Oof 5
Endopiriform cortex (ipsi) 2 of 6 2 of 5
Endopiriform cortex (contra) Oof 6 Oof 5
Piriform cortex (ipsilateral) 1 of 6 1 of 5
Substantia Nigra 2 of 6 3 of 5
Table 5.5 The incidence of selective neuronal damage in widespread 
brain areas following intrastriatal injection of AMPA in 
shiverer or wild type animals.
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Figure 5.13 Neuronal damage in wild type and shiverer animals 
following intrastriatal injection of AMPA (1.5nmol)
A. Digitised H & E sections dem onstrating the anatomical extent
o f histological dam age in a wild type and s h i v e r e r  animal.
The extent o f histological dam age is contained within the 
dashed line.
B. Quantification o f neuronal dam age in wild type and s h i v e r e r
mice. P>0.05, S tudent’s unpaired t  test.
Bar indicates mean of each eroup.
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5.4 Discussion
To summarise, the immunocytochemical studies deployed here revealed axonal 
damage in widespread anatomical areas in the brains of naive Pip knockout mice; 
furthermore, there was a differential distribution of axonal swellings labelled with 
either APP or NF 200 immunostaining. AMPA-induced axonal damage was 
attenuated in Pip knockout mice compared to wild type mice. This was not 
associated with a change in the levels of AMPA receptor subunit in naive Pip 
knockout mice at postnatal day 20. Finally, there was no significant difference in the 
level of AMPA-induced axonal or neuronal damage in the brains of shiverer 
compared to wild type mice.
Axonal damage in naive PLP deficient mice
The immunocytochemical methods used to detect axonal damage following 
intracerebral injection of AMPA revealed the presence of APP and neurofilamentous 
swellings in widespread brain areas in Pip knockout mice. To further examine this 
phenomenon, and to determine that it was not a consequence of the AMPA injection, 
the presence of axonal swellings in APP and NF 200 immunostained sections was 
confirmed in certain anatomical areas of naive Pip knockout mice. The reason for 
selective vulnerability of axons in particular anatomical areas is unknown. EM 
studies have revealed that axonal swellings are preferentially localised to small 
diameter axons, particularly at distal juxtaparanodes (area between node of ranvier 
and intemode) (Griffiths et al., 1998). The distal location of the axonal swellings, 
and accumulation of mitochondria and dense bodies within the swellings suggested 
that a deficit in retrograde axonal transport occurs (Griffiths et al, 1998; Garbem et 
al., 2002); and a series of elegant experiments support this hypothesis. Increased 
levels of dynein, the motor protein responsible for retrograde transport, are present in 
2 month old Pip knockout mice (Edgar et al., 2001). Decreased levels of a 
fluorescent tracer are found in the retina of Pip deficient mice following stereotaxic 
injection into the superior colliculus, when compared with wild type mice (Julia 
Edgar, personal communication.), suggesting aberrant retrograde transport. The 
selective vulnerability of the distal juxtaparanode may arise because of the 
organisation of the cytoskeleton in this region. Microtubules density is increased in 
small diameter compared to large diameter axons At paranodal regions, the 
diameter of axons is further reduced, the packing density of NFs is increased, and
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phosphorylation of NFs is reduced (Kirkpatrick and Brady, 1999). Thus, the 
cytoskeletal organisation at certain axonal regions may somehow predispose them to 
swelling and degeneration in the absence of PLP.
By analogy with the conditions that predispose selective axons to degenerate in ALS,
a role for Ca2+ binding proteins may account for the selective vulnerability of certain
2+axons in Pip knockout mice. Thus, motor neurons that lack expression of the Ca 
binding proteins calbindin and parvalbumin are more vulnerable to degeneration than 
motor neurons that express these proteins (Alexianu et al, 1994). 
Immunocytochemical studies would determine if these proteins were associated with 
degenerating axons in Pip knockout mice.
Immunostaining with NF 200 revealed axonal swellings in the brains of Pip 
knockout mice, which is consistent with the presence of neurofilamentous swellings 
in EM analysis of Pip knockout mice (Griffiths et al., 1998). NFs are transported by 
slow anterograde axonal transport. The presence of APP immunopositive swellings 
in naive PLP deficient brains is a novel finding. As APP is predominately associated 
with fast anterograde transport (Koo et al., 1990), this suggests a defect in fast 
anterograde transport may also occur in Pip knockout mice. Therefore, the 
neurofilamentous and APP-immunopositive swellings may label axons where slow 
and fast axonal transport is compromised, respectively. However, levels of kinesin, 
the motor protein responsible for anterograde transport, are normal at the ages in 
which APP immunopositive swellings are reported here (Edgar et a l, 2001). In 
addition, there was no difference in the amount of labelled anterograde tracer in the 
superior colliculus following injection into the retina in Pip mice aged four months 
(Julia Edgar, personal communication). Recent reports have suggested that up to 
20% of APP may be transported by retrograde axonal transport (Stamer et al., 2003). 
Taken collectively, this suggests that accumulation of APP within axons may also be 
caused by aberrant retrograde axonal transport. Further investigation is required to 
clarify this phenomenon. For example, it would be interesting to perform double 
labelling of APP with retrograde or anterograde radioactive tracers. A method that 
has been described for the ultrastructural visualisation of APP antibodies (Stone et 
al, 1999) would determine which calibre of axons that APP immunopositive 
swellings are located in, and whether they were predominately present at the distal 
juxtaparanode.
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Following acute brain injury, axonal swellings are thought to either resolve 
themselves, or undergo secondary axotomy within hours or days of the injury 
(Maxwell et al., 1997). Between 1 and 2 weeks following focal cerebral ischaemia, 
there is a reduction in the amount of APP-immunopositive axonal swellings (Irving 
et al, 2001). However, the presence of large amounts of APP immunopositive 
axonal swellings in naive Pip knockout animals, at all ages examined, suggests that 
these axons probably do not undergo immediate degeneration/axotomy. Instead, the 
axon may ‘suffer the swelling’. Increased expression of APP following traumatic 
brain injury has been associated with deposits of amyloid-p petitide (A0), the 
hallmark lesion of Alzheimer’s disease (Graham et al., 1996; Smith et al., 1999; 
Stone et al., 2002). However, the absence of plaque formation in Pip knockout mice 
in spite of the presence of large quantities of APP in swollen axons (Julia Edgar, 
personal communication) suggests that another factor initiated following traumatic 
brain injury, such as caspase-3 activation (Stone et al., 2002) is required for the 
formation of AP-containing plaques.
AMPA-induced axonal damage is attenuated in Pip knockout mice 
The reduction in AMPA-induced axonal damage in Pip knockout mice suggests that 
PLP-mediated interactions between the oligodendrocyte/myelin sheath and the axon 
may be important for mediating AMPA-induced axonal damage. PLP may act as an 
ion channel, allowing the flow of ions from glia to axon. In addition, the direct 
transfer of molecules from glia to axons has been demonstrated in invertebrates, and 
PLP may play a role in mediating these interactions (de Cozar et al., 1987; Kitagawa 
et a l, 1993; Sheller et al., 1995). Thus, it remains possible that toxic factors or ionic 
imbalances induced by AMPA at the myelin sheath could be transferred from glia to 
the axon by PLP-mediated interactions, or via a PLP channel pore. These 
interactions may not have occurred in the Pip knockout mice. However, direct 
conclusions about the role of glia in mediating AMPA-induced axonal damage 
cannot be drawn from the current study. Firstly, it remains possible that attenuation 
of damage evident in Pip knockout mice may not be caused directly by Pip 
deficiency, but may arise from another factor. For example, the histological and 
ultrastructural appearance of PLP deficient white matter is not normal, and lacks the 
normal apposition of extracellular myelin surfaces that occurs in wild type mice. It 
may be possible that AMPA injected into the brains of Pip knockout mice cannot 
diffuse in this abnormal white matter as it does in wild type mice. Secondly, a
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concomitant reduction in neuronal perikaryal damage also occurs in Pip knockout 
mice following AMPA administration. This suggests that axonal damage evident 
following AMPA administration may be secondary to changes in the neuronal 
perikarya. Analysis of the relative contribution of neurons and oligodendrocytes to 
AMPA-induced axonal damage is extremely complex in vivo. It is feasible that 
neither cellular element is exclusively responsible for mediating AMPA-induced 
axonal damage, but that they may both contribute to the pathology. Further in vitro 
experiments with Pip deficient tissue may clarify this issue. For example, the 
differential vulnerability of neuronal, oligodendoglial and astrocytes cultures to 
AMPA toxicity could be determined. It would also be interesting to compare these 
results with the vulnerability of mixed cultures of neurons and glia to AMPA 
toxicity. The campenot chamber, which allows the separation of neuronal perikarya 
from axons and oligodendrocytes, could also be utilised to understand more about 
axo-glial relationships mediating excitotoxicity in Pip knockout mice.
As PLP is predominantly expressed in oligodendrocytes and myelin, it was 
hypothesised that AMPA-induced axonal damage may have been altered without a 
concomitant effect on neurons. However, there are a number of means by which 
PLP could influence neurons. PLP RNA is expressed in a population of 
oligodendrocyte progenitor cells (OPCs; Mallon et al., 2002). Recent data has 
shown that GluR2 and the glutamate receptor interaction protein (GRIP) are co­
localised in NG2 expressing OPCs (Stegmuller et al, 2003). Furthermore, OPCs 
form functional synapses with neurons (Bergles et al., 2000), which are thought to be 
important for glial-neuronal signalling. Splice variants of PLP have also been 
localised to the neuronal perikarya of certain neurons, where they have been 
implicated with modulating neuronal viability (Bongarazone et al., 1999; Boucher et 
al, 2002). In shiverer mice, altered patterns of gene expression occur in the 
neuronal perikarya, which suggests that there must be a retrograde signalling 
pathway from glia to neurons (Brady et al., 1999). A similar pathway may allow 
PLP to influence neuronal perikarya.
As with many chronic neurodegenerative disorders, regardless of the underlying 
cause of the pathology, it is possible PLP deficiency may initiate a cascade of 
pathogenic mediators that could contribute to the ensuing damage. If Pip knockout 
mice had exhibited an increased sensitivity to AMPA-induced axonal damage, then it
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could be presumed that excitotoxic mechanisms contribute to axonal pathology in 
these mice. As the opposite was demonstrated in the current study, this argues 
against a pathogenic role for ‘slow’ excitotoxicity in Pip knockout mice. The 
reduction in AMPA-induced pathology in Pip knockout mice may be related to 
perturbations in glutamate homeostasis. For instance, there may be a reduction in the 
amount of AMPA receptors, an increase in the amount of glutamate transporters, or 
reduced levels of endogenous glutamate release at glutamatergic synapses in Pip 
knockout mice. An extensive down regulation of NMDA receptors occurs in the 
brainstem of the myelin-deficient rat, a spontaneously occurring Pip mutant (Miller 
et al., 2003). Whilst there was no significant difference in the levels of AMPA 
receptor subunits in P20 Pip knockout mice, the AMPA toxicity studies performed 
here utilised three-month-old mice. A decrease in the levels of AMPA receptor 
subunit may occur in three-month-old mice, and therefore further western blotting 
studies are required to determine this. These should be complimented by 
immunocytochemical or in situ hybridisation investigations, as western blotting 
experiments with whole brain homogenates may not be sensitive enough to 
discriminate subtle alterations in the cellular distribution of glutamate receptors in 
Pip knockout or wild type mice. There may be a switch in the Ca2+ permeability of 
AMPA receptors in Pip knockout mice, due to differential editing of AMPA 
receptors, or a switch in AMPA receptor subunit conformation. Electrophysiological 
studies could be performed to determine if there is a difference in the functional 
properties of AMPA receptors in Pip knockout and wild type mice.
In additions to altered glutamate homeostasis, there are other mechanisms that may 
account for the reduction in pathology observed in Pip knockout mice. Cultured PLP 
deficient oligodendrocytes survive for a longer time period than PLP expressing 
oligodendrocyte cultures (Yang and Skoff, 1997), suggesting that lack of PLP may 
have beneficial effects. The PLP deficient brains may have developed compensatory 
mechanisms that account for its ability to remain functional despite the great number 
of axonal swellings present. For example, it is possible that the axonal pathology in 
Pip knockout mice may induce increased levels of reactive oxygen species, and 
consequently, the mice may have upregulated endogenous anti-oxidant capacities, 
such as the anti-oxidant superoxide dimutase (SOD) enzymes. As ROS are 
implicated in the pathogenesis of excitotoxicity, increased levels of endogenous anti­
oxidant enzymes would be protective. The immunocytochemical studies in the
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naive Pip knockout mice revealed that axons in the injection site, the caudate 
nucleus, are less vulnerable to axonal swelling than axons in other brain areas, This 
may be related to increased levels of Ca2+ buffering enzymes, such as calbindin. 
These enzymes may play a role in protection against excitotoxicity, based on the 
importance of Ca2+-mediated processes in excitotoxicity.
AMPA-induced pathology in shiverer mice
There was no evidence to suggest that shiverer mice were more vulnerable to 
AMPA-induced neuronal damage. However the data does suggest that axons may be 
more vulnerable to AMPA-induced damage, although this did not reach accepted 
levels of significance. This may be related to an increased vulnerability of MBP 
deficient oligodendrocytes/myelin to AMPA-induced toxicity. It would be 
interesting to compare the volume of oligodendrocyte/myelin damage, assessed with 
Tau-1 or MBP immunohistochemistry, with the volume of neuronal/axonal damage 
in the brains of shiverer and wild type mice. Again, the vulnerability of mixed or 
isolated cultures of shiverer or wild type neurons, astrocytes and oligodendrocytes 
and campenot preparations to AMPA-induced toxicity would provide further 
information about the relative contribution of these cell types to AMPA-induced 
axonal damage. Axons may be more vulnerable to AMPA-induced toxicity based on 
their altered architecture in the absence of compact myelin. For example, there is an 
upregulation of K+ channels in shiverer mice, which suggests that other ion channels 
may also be upregulated (Wang et al, 1995). This may render the axon more 
vulnerable to ionic imbalances. There may also be an increased expression of 
AMPA receptors in white matter, and immunocytochemical studies could be 
deployed to examine this.
It was originally hypothesised, based on the pro-convulsant properties of AMPA, that 
it may exacerbate the seizures that are associated with the shiverer phenotype. On 
the contrary however, seizures were not observed in any of the shiverer animals 
injected with AMPA, although a systematic analysis was not performed. This may 
have been related to the anti-convulsant actions of the anaesthetics used for the 
surgical procedures. However, seizures were not present at 24 hours, a timepoint 
when anaesthetic would have been cleared from the CNS. It may be possible that the 
AMPA-induced neuronal pathology present by this time point had interrupted the 
anatomical circuitry required for seizure generation. Again, further investigation,
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perhaps with vehicle treated animals or sham animals would gain a greater insight 
into this phenomenon.
In conclusion, the current study suggests that PLP-mediated interactions between the 
oligodendrocyte/myelin and axons may be important for mediating AMPA-induced 
excitotoxicity. The focus of the thesis will now move from the toxic potential of 
glutamate and excitotoxicity, to examining AMPA receptor potentiators, which may 
have beneficial effects by enhancing glutamatergic transmission.
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CHAPTER 6
MAPPING THE FUNCTIONAL EFFECTS OF THE AMPA 
RECEPTOR POTENTIATOR LY404187 WITH 
14C-2-DEOXGLUCOSE AUTORADIOGRAPHY
6.1 Introduction
Activation of AMPA receptors contributes to the induction of long-term potentiation 
(LTP), which is suggested to be a major neural substrate for the formation and 
development of learning and memory (Lynch and Baudry, 1984; Morris et al., 1990; 
Bliss and Collinridge, 1993). Deficits in glutamatergic neurotransmission and AMPA 
receptor antagonism often result in cognitive deficits (Filliat et a l, 1998; Tamminga, 
1998; Carlsson et al., 1999; Riedel et al., 1999; Segovia et al., 2001). In contrast 
enhancing glutamatergic neurotransmission or AMPA receptor-mediated 
transmission appears to enhance cognition and may therefore be therapeutically 
beneficial where cognitive function is impaired. As predicted from their ability to 
enhance LTP in vivo (Staubli et al., 1994b), many of these compounds have 
demonstrated cognitive enhancing effects in rodent models of cognition (Granger et 
al., 1993,1996; Staubli et al., 1994a, Thompson et al., 1995; Zivkovic et al., 1995; 
Hampson et al., 1998).
A novel series of biarylpropylsulfonamide AMPA receptor potentiators have recently 
been developed (Omstein et al., 2000), which are highly potent, selective and 
centrally active (Baumbarger et al., 2001a,b; Gates et al., 2001; Linden et al., 2001; 
Miu et al., 2001; Vanergriff et al, 2001). LY404187 is a representative compound 
of this series and these molecules have efficacy in rodent models of depression and 
cognition (Quirk and Nisenbaum, 2002). These compounds also appear to increase 
BDNF expression in the hippocampus (Mackowiak et al, 2002). However a detailed 
analysis of the anatomical basis of AMPA receptor potentiators is not known. In 
vivo 2-deoxyglucose autoradiography is an effective tool for evaluating the 
functional consequences of central neurotransmitter system manipulation (section 
2.7.1).
6.1.1 Aims of Study
The aim of the current study was to determine the effects of the AMPA receptor 
potentiator LY404187 on cerebral glucose utilisation using 14C-2-deoxyglucose 
autoradiography, to gain an insight into the specific anatomical sites of action of 
AMPA receptor potentiators. In addition, to determine if the functional effects of 
LY404187 occurred through AMPA receptor-mediated mechanisms, the AMPA
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receptor antagonist, LY293558, was administered prior to administration of 
LY404187 (0.5mg/kg) in another group of animals.
6.2 Methods
6.2.1 Surgical Preparation of animals for 14C- 2-deoxyglucose 
autoradiography
Male Sprague Dawley rats (345-405g, n=38) were anaesthetised, cannulated, and 
restrained by Professor J. McCulloch according to protocol outlined in section 2.7.2.
6.2.2 Drug Administration and 14C- 2-deoxglucose technique
The AMPA receptor potentiator LY404187 (0.05, 0.5, 5mg/kg) or vehicle (30% 
ethanol, 35 % hydroxy-propyl-P-cyclodextrin) were administered subcutaneously 15 
minutes prior to administration of the 14C-2-deoxyglucose (n=28). Ten animals 
received intravenous administration of the AMPA receptor antagonist, LY293558 
(25mg/kg), dissolved in NaOH and 5.5% glucose solution (final pH 8.5, isotonic 
solution), 5 minutes prior to subcutaneous administration of the AMPA receptor 
potentiator, LY404187 (0.5mg/kg) or vehicle. Fifty p,Ci [14C]-2-deoxyglucose 
dissolved in 0.5ml of saline (specific activity 51 mCi/mol, Sigma) was administered 
into the venous catheter at a constant rate for 30 seconds. The subsequent 
experimental protocol is outlined in section 2.7.3. Local cerebral glucose utilisation 
was calculated in 52 anatomical brain areas based on the operational equation 
outlined in section 2.7.1 using an MCID-M4 image analysis system, as described in 
section 2.7.4.
6.2.3 Statistical Analysis
All 2-deoxglucose data for each anatomical region were analysed for statistical 
significance by one-way analysis of variance, then post-hoc Student’s f-test. A 
Bonferroni correction factor of 6 was applied to the probability values, to take into 
consideration the multiple comparisons between drug treated and control groups.
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6.3 Results
6.3.1 Effect of AMPA receptor potentiator LY404187 on physiological 
parameters
Prior to drug administration, rats were generally inquisitive, with periods of 
movement and grooming. LY404187 produced no overt changes in this behavioural 
pattern. In contrast, administration of the AMPA receptor antagonist LY293558 
produced sedative affects, reduced motor activity, with a loss of responsiveness to 
auditory stimuli. This sedative effect continued following the administration of the 
AMPA receptor potentiator, LY404187. LY404187 produced no significant changes 
in rectal temperature, blood glucose levels or arterial blood pressure (Table 6.1). 
There was a transient rise in blood pressure following administration of the AMPA 
receptor antagonist, LY293558, however this returned to control levels 
approximately 20 minutes later.
6.3.2 LY404187 and cerebral glucose utilisation
The effects of the AMPA receptor potentiator LY404187 (0.05, 0.5, 5mg/kg) 
compared with administration of the vehicle are presented in tables 6.2 -  6.6. 
LY404187 (0.5mg/kg) produced significant increases in glucose utilisation in 28 of 
the 52 anatomical areas examined. In contrast, LY404187 (0.05 or 5mg/kg) did not 
produce any significant increases in glucose utilisation, with the exception of the 
cerebellar cortex, where a significant increase in glucose utilisation was detected 
following administration of the high dose of LY404187 (5mg/kg). Administration of 
LY404187 (0.05, 0.5 or 5 mg/kg) did not result in significant decreases in glucose 
utilisation in any of the anatomical areas studied. The areas in which LY404187 
(0.5mg/kg) caused elevations in glucose utilisation included the hippocampus 
(molecular layer), several of the cortical areas examined (Fig.6.1, 6.5, 6.6, 6.7); the 
locus coeruleus, median raphe nucleus and the lateral habenula (Fig.6.2. 6.5, 6.8); 
and the lateral geniculate nucleus, visual cortex and superior colliculus (Fig 6.3). 
Other brain areas such as the hypothalamus and pons (Fig. 6.4) were relatively 
unaffected by LY404187 (0.5mg/kg). A hierarchy of responsiveness to LY404187 
(0.5mg/kg) in grey matter areas is presented in table 6.7.
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A Anterior Cingulate Cortex
Figure 6.1
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B Ventral Parietal Cortex (Layer IV)
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The effects of the AMPA potentiator LY404187 on cerebral 
glucose utilisation in cortical areas and hippocampus
A. Anterior Cingulate Cortex B. Ventral Parietal Cortex (Layer IV)
C. Superior Colliculus
D ata are presented as mean ± SEM (n=3-10 per group). *P<0.05, ***P<0.001 for 
statistical com parison between vehicle and drug treated groups (ANOVA followed 
by post-hoc Students unpaired Mest with Bonferroni correction factor o f 6).
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A Locus Coeruleus
Figure 6.2
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B Lateral Habenula
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The effects of LY404187 on cerebral glucose utilisation 
in components of the monoaminergic system
A. Locus Coeruleus B. Lateral Habenula C. Dorsal Raphe Nucleus 
Data are presented as mean ± SEM  (n=3-10 per group). *P<0.05, **P<0.01, 
***P<0.001 for statistical com parison between vehicle and drug treated 
groups (ANOVA followed by post-hoc Students unpaired M est with 
Bonferroni correction factor o f 6).
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A Visual Cortex
150 1
Vehicle 0.05
LY404187 (mg/kg)
B Lateral Geniculate Body
-
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LY404187 (mg/kg)
C Superior Colliculus
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Figure 6.3 The effects of the AMPA potentiator LY404187 on cerebral 
glucose utilisation in the visual system
A. Visual cortex (layer IV); B. Lateral Geniculate Body;
C. Superior Colliculus
Data are presented as mean ± SEM  (n = 3 -l0  per group). *P<0.05, **P<0.01, for 
statistical com parison between vehicle and drug treated groups (ANOVA followed 
by post-hoc Students unpaired /-test with Bonferroni correction factor of 6).
202
A Hypothalamus
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Figure 6.4 The effects of the AMPA potentiator LY404187 on cerebral 
glucose utilisation in the hypothalamus and pons
A. Hypothalamus B. Pons
Data are presented as mean ± SEM (n=3-10 per group). P>0.05 for statistical 
com parison between vehicle and drug treated groups (ANOVA followed by post- 
hoc Students unpaired /-test with Bonferroni correction factor o f 6).
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6.3.3 Effects of the AMPA receptor antagonist LY293558 prior to 
treatment with the AMPA receptor potentiator LY404187
Pre-treatment with the AMPA receptor antagonist LY293558 (25mg/kg) 
significantly reduced glucose utilisation in 42 out of the 52 anatomical areas 
examined, compared with administration of the vehicle (Tables 6.2 -  6.6; Fig. 6.9, 
6.10). There were no significant differences in glucose utilisation in any of the 
anatomical areas in the animals treated with LY293558 (25mg/kg) and vehicle 
compared with administration of LY293558 (25mg/kg) and the AMPA receptor 
potentiator LY404187 (0.5mg/kg).
A Anterior Cingulate Cortex
Figure 6.9
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Effects of the AMPA receptor antagonist LY293558 on cerebral 
glucose utilisation in cortical areas and the hippocampus 
following LY404187 administration
A. Anterior Cingulate Cortex B. Ventral Parietal Cortex (Layer IV)
C. Hippocam pus
Data are presented mean ± SEM . *P<0.05, ***P<0.001 for com parison between vehicle 
and the AM PA receptor potentiator LY404187 (0.5m g/kg). P>0.05 for comparison 
between AM PA receptor anatgonist LY 293558 (25m g/kg) and vehicle adm inistration with 
LY 293558 (25mg/kg) and LY 404I87 adm inistration (0.5m g/kg)
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Figure 6.10 Effects of the AMPA receptor antagonist LY293558 on 
cerebral glucose utilisation in monoaminergic areas 
following LY404187 administration
A. Locus coeruleus B. Lateral Habenula C. Dorsal Raphe Nucleus 
Data are presented mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 for com parison 
between vehicle and the AMPA receptor potentiator LY 404187 (0.5mg/kg). 
P>0.05 for comparison between AM PA receptor antagonist LY293558 (25mg/kg) 
and vehicle adm inistration with LY293558 (25m g/kg) and LY 404187 (0.5mg/kg)
211
6.4 Discussion
These results demonstrate that the AMPA receptor potentiator, LY404187 
(0.5mg/kg) significantly increased glucose utilisation in 28 anatomically discrete 
areas of the brain such as the hippocampus, layer IV of the cerebral cortex, the raphe 
nucleus and the locus coeruleus; anatomical areas that are associated with learning 
and memory or depression. These increases were attenuated by pre-treatment with 
the AMPA receptor antagonist LY293558, suggesting that LY404187 acts through 
AMPA receptor mediated mechanisms. These data provide an anatomical basis for 
the behavioural effects of this compound in animal models of learning and memory 
and depression.
LY404187 enhances AMPA receptor-mediated transmission 
LY404187 significantly increased glucose utilisation in 28 brain areas; no decreases 
in glucose utilisation were observed in any region. Under physiological normal 
conditions, glucose utilisation is closely related to energy consumption, which is 
thought to be predominately utilised for the maintenance of ionic gradients (Schwartz 
et al., 1979). Therefore, the increase in glucose utilisation observed following 
LY404187 administration is probably due to its ability to enhance action potential 
discharge rate at AMPA receptors in response to endogenous glutamate. LY404187 
has previously been shown to enhance ion influx in recombinant GLUai-4 and to 
selectively enhance AMPA-mediated responses in native hippocampal neurons in 
vitro and in vivo (Gates et al, 2001; Vandergriff et al., 2001). In the present study, 
the AMPA receptor antagonist LY293558 attenuated the effects of the LY404187, 
confirming that the effects of the AMPA receptor poteniator are mediated via AMPA 
receptors. The anatomical distribution of altered glucose utilisation following 
administration of the AMPA receptor potentiator LY404187 is distinct from that 
observed with agents acting on other aspects of glutamatergic transmission, such as 
metabotropic glutamate agonists or NMDA receptor antagonists (Kurumaji et al., 
1989; Lam et al., 1999). Even at the highest concentrations of LY404187, there was 
no evidence of the intense elevations in glucose utilisation observed with AMPA or 
kainate receptor agonists (Wooten & Collins, 1980; data in chapter 4).
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Regional localisation o f increased glucose utilisation in the rat brain 
AMPA receptor antagonists produce widespread depression in glucose utilisation; for 
example NBQX (lOOmg/kg) and LY293558 (lOOmg/kg) produced significant 
reductions in glucose utilisation in 43 and 48 brain areas respectively (Browne and 
McCulloch, 1994). In contrast, the AMPA receptor potentiator LY404187 produced 
discrete increases in glucose utilisation in 28 out of the 52 brain areas analysed, even 
though AMPA receptors are widely distributed throughout the brain. NBQX and 
LY293558 are mixed AMPA/kainate antagonists, whereas recent developments in 
the molecular biology of glutamate receptors enabled the development LY404187, 
which selectively potentiates only AMPA receptors. Even so, there are some 
discrepancies when comparing the anatomical distribution of AMPA receptors 
revealed by [3H]-AMPA binding studies with the areas that were activated by 
LY404187 (0.5mg/kg). Anatomical areas such as the superficial layers of the cortex 
and stratum lacunosum-moleculare of the hippocampus which contain the highest 
levels of AMPA receptors (Monaghan et al., 1984; Rainbow et al., 1984) did have 
significant elevations in glucose utilisation following LY404187 administration. In 
contrast, LY404187 had no significant influence on glucose utilisation in other areas 
with high levels of AMPA receptors, such as the caudate nucleus, nucleus 
accumbens and the amydala. In addition, LY404187 was found to activate areas 
such as the lateral habenula, and the lateral geniculate nucleus which were reported 
to contain lower levels of [3H]AMPA binding sites (Monaghan et al, 1984). In 
neuropharmacological investigations, the anatomical distribution of altered glucose 
utilisation after drug administration does not reflect the distribution of receptors at 
which the drug is targeted, but rather the polysynaptic circuits in which activity can 
be modulated by the drug. For instance, LY404187 may activate areas such as the 
superior colliculus, which contain lower levels of AMPA receptor subunits, as a 
consequence of activation of regions functionally associated with AMPA receptor- 
mediated activity.
This discrepancy may be further explained by the heterogeneity of AMPA receptor 
subunit composition in the brain. LY404187 and related biarylpropylsulfonamides 
have different profiles (potency and efficacy) at potentiating recombinant GLUam
213
(Miu et al., 2001) and this effect is also observed on rat native neurons from various 
brain regions (M. J O’Neill, personal communication). The distribution of the 
individual AMPA receptor subunits, GLUai-4 in the rat brain, also varies from the 
distribution pattern of [3H]AMPA binding (Petralia and Wenthold, 1992). For 
example, high levels of the glutamate receptor subunits GluR2/3 have been reported 
in the lateral habenula and lateral geniculate nucleus (Petralia and Wenthold, 1992). 
LY404187 is most potent at recombinant receptors composed of the GLUa2 subunit 
(GLUa2>GLUa4>GLUa3>GLUai; Miu et al., 2001).
LY404187 caused increased c-fos protein expression
Using the same dosing regime as that deployed in the current chapter, the effects of 
the AMPA receptor potentiator LY404187 on Fos protein expression were also 
examined in a limited number of brain regions in a separate set of experiments 
carried out an Eli Lilly (M.J. O’Neill, personal communication, presented in Fowler 
et al., 2003). Neurons transiently express the immediate early gene c-fos when 
stimulated (Sagar et al, 1988). The protein expressed by the c-fos gene, Fos, can be 
detected using immunocytochemical techniques, enabling the detection of neuronal 
activation (Sharp et al., 1993). The AMPA receptor potentiator, LY404187 
(0.5mg/kg) caused increases in Fos expression 6 hours following administration, in 
the dorsal raphe nuclues, parietal cortex and locus coeruleus; whilst other brain 
regions such as the hypothalamus and substantia nigra were unaffected (Fig 6.12). A 
bell-shaped dose response curve for Fos expression was also evident following 
LY404187 administration (Fig. 6.12), which parallels the dose responses observed in 
the glucose utilisation studies. The changes in Fos expression occurred in areas that 
were most sensitive to the effects of LY404187 in the glucose utilisation studies, thus 
confirming that LY404187 causes neuronal activation in these anatomically discrete 
areas.
Effects ofLY404187 on glucose utilisation in brain areas related to cognition 
There are several theories on the anatomical basis of memory formation. Evidence 
suggests that there are many distinct classes of memory, such as declarative/episodic 
memory, which involves representations of facts and events that are subject to 
conscious recollection; and non-declarative/implicit memory, a heterogeneous
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collection of nonconscious learning capacities (Milner et a l, 1998). These distinct 
entities are likely to depend on different anatomical areas, and this is supported by 
evidence from amnesic patients, lesioning studies and a combination of physiological 
and functional MRI measures (Brewer et al, 1998; Milner et a l, 1998; Wagner et 
al, 1998; Deweer et al, 2001). However, whilst multiple brain areas may contribute 
to the anatomical basis of memory, there is a general consensus that the cortex and 
hippocampus play a pivotal role in the formation, storage or retrieval of memories 
(Markowitsch, 1995; Fletcher et al, 1997; Milner et a l, 1998; Bontempi et al, 1999; 
Buckner et al, 1999; Deweer et al, 2001; Manns et al, 2003). Molecular studies 
have indicated that LTP involves rapid increases in intracellular calcium and this 
then recruits a second slower LTP that involves secondary messengers and protein 
synthesis-dependant changes in synapses (Kandel, 2001). The effects can be 
observed using metabolic mapping of hippocampal and cortical activation with 14C- 
2-deoxglucose autoradiography during a variety of cognitive tasks, aimed to test 
different memory entities in the non-human primate (Bontempi et al, 1999; Sybirska 
et al, 2000; Davachi and Goldman-Ravic, 2001). Intrahippocampal injection of 
AMPA receptor antagonists markedly and selectively reduce glucose use in this 
region and disrupt encoding, retrieval and storage of spatial memory (Riedel et 
al, 1999). Here, it has been demonstrated that the AMPA receptor potentiator 
LY404187, causes activation of the hippocampus and the frontal, anterior cingulate, 
sensory motor and parietal cortex in the rodent, suggesting that this compound 
activates brain areas that are associated with memory formation. It is not clear if 
these studies reflect increased glucose utilisation caused by the initial calcium influx, 
such as that observed with LTP produced by tetanic stimulation; or a secondary 
event. LY404187 also causes increases in BDNF expression in the hippocampus 
(Mackowiak et a l, 2002). BDNF and its receptor TrkB are highly localised in the 
hippocampus. BDNF secretion increases in an activity dependent manner and there 
is a substantial literature linking BDNF to learning and memory (Lu and Gottschalk, 
2000; Poo, 2001).
Cognitive enhancing effects ofLY404187
The cognitive enhancing effect of AMPA receptor potentiators has been 
demonstrated in a number of animal models of cognition. Cognitive enhancing 
effects of aniracetam and piracetam in delayed non-matching to sample and maze
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exploration tasks (Pontecorvo et al., 1985; Verloes, 1988) were demonstrated before 
the AMPA receptor mediated action of theses pyrrolidinones were discovered. 
Benzoylpiperidine compounds have since demonstrated positive effects in rodents in 
the radial arm maze, delayed-nonmatch-to-sample tests and the Morris water maze 
(Granger et al., 1993, 1996; Staubli et al., 1994a, b; Davis et al., 1997; Hampson et 
al., 1998). IDRA-21 also improves rodent performance in the water maze (Zivkovic 
et al., 1995), and ablates pharamacologically induced cognitive impairments in non­
human primates (Thompson et al, 1995). In parallel studies, it has been 
demonstrated that the active isomer of LY404187, LY451646, enhances rodent 
performance in the radial arm maze, at equivalent doses that caused activation of the 
hippocampus and cortex in the 2-deoxglucose studies (Fowler et al., 2003). Previous 
studies have indicated that LY404187 and related biarylpropylsulfonamide also 
improve performance in the water maze (Quirk and Nisenbaum, 2002) and passive 
avoidance tasks. The glucose utilisation studies described here therefore demonstrate 
that activation of the hippocampus and cerebral cortex may contribute to the 
anatomical circuitry involved in memory processes engaged during these tasks.
Effects ofLY404187 on glucose utilisation in brain areas related to anti-depressant 
activity
The results described here demonstrate that administration of LY404187 produced 
activation of the locus coeruleus, the dorsal raphe nucleus and the lateral habenula, a 
key relay nucleus from the forebrain to the midbrain raphe. The locus coeruleus and 
raphe nucleus are the origin of noradrenergic and serotenergic projections, which 
may have a modulatory influence over memory processes (Meneses, 1999; Buhot et 
al., 2000; Kobayashi And Yasoshima, 2001). Activation of the raphe nucleus and 
locus coeruleus with LY404187 may also contribute to the antidepressant effects of 
the drug. In recent years several new drug targets and animal models for 
development of antidepessants are emerging (Nestler et al., 2002). As stated earlier, 
LY404187 has been reported to increase levels of BDNF (Legutko et al., 2001, 
Mackowiak et a l, 2002). BDNF is up-regulated by both electroconvulsive shock 
treatment and by many conventional anti-depressants, and may exert a range of 
trophic and protective effects on monoaminergic neurons (Altar, 1999; Skolnick et 
al., 2001). It has also been demonstrated that direct infusion of BDNF into the 
hippocampus produces effects in animal models of depression (Shirayama et al,
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2002). LY404187, related biarylpropylsulfonamides and other AMPA receptor 
potentiators are efficacious in the same rodent models (forced swim and tail 
suspension) of depression (Li et al, 2001; Knapp et al, 2002; Quirk and Nisenbaum, 
2002). The present findings suggest that in addition to modulating BDNF, 
LY404187 also has actions on the biogenic amine neurotransmitter systems. Taken 
together, these data may provide a neurochemical basis for the antidepressant-like 
action of LY404187 and suggest that AMPA receptor potentiators may be effective 
in treating depression.
Based on the ability of AMPA receptor potentiators to enhance BDNF levels, the 
potential of the AMPA receptor potentiator, LY404187, to enhance regeneration 
following brain injury was examined next.
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CHAPTER 7
THE EFFECTS OF THE AMPA RECEPTOR 
POTENTIATOR LY404187 ON REGENERATION IN THE 
DENTATE GYRUS FOLLOWING ENTORHINAL 
CORTEX LESION
7.1 Introduction
BDNF can enhance regeneration following brain injury (Mamounas et al., 2000; 
Coumans et al., 2001; Klocker et al., 2001; Takano et al., 2002). Based on the 
ability of AMPA receptor potentiators to enhance BDNF levels in vitro and in vivo 
(Lauterbom et al., 2000; Legutko et al., 2001; Mackowiak et al., 2002), it can be 
hypothesised that they may enhance regenerative processes following brain injury. 
Trophic factors are thought to be involved in the regeneration and reorganisation in 
the dentate gyrus following entorhinal cortex lesioning (Deller and Frotscher, 1997). 
Adenovirus-mediated BDNF gene administration to rodents with entorhinal cortex 
lesions enhances LTP and performance in certain cognitive tests, suggesting that 
BDNF may enhance plasticity in this model (Ando et al., 2002).
Increased rates of neurogenesis occur following brain injury such as entorhinal 
cortex lesion (Gould and Tanapat, 1997). BDNF has been shown to promote 
endogenous stem cell proliferation, survival and differentiation in vivo (Pencea et al., 
2001). The AMPA receptor potentiator LY451646 (the active isomer of LY404187) 
increases the rate of endogenous stem cell proliferation in the adult rat hippocampus 
(Bai et al., 2003), however the fate of these cells is unknown.
7.1.1 Aim of Study
The aim of the current study was to determine if the AMPA receptor potentiator 
LY404187 could increase fibre sprouting and synaptogenesis in the molecular layer 
of the dentate gyrus 14 or 21 days following entorhinal cortex lesion with the 
excitotoxin, ibotenic acid. Drug or vehicle treatment commenced 7 days following 
the entorhinal cortex lesion, and GAP-43 and synaptophysin immunohistochemistry 
were deployed to examine degeneration and regeneration. In addition, the fate of 
proliferating stem cells in the dentate gyrus, labelled with BrdU one day before drug 
treatment commenced was compared for drug or vehicle treated animals.
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7.2 Methods
7.2.1 Entorhinal Cortex Lesion
Thirty-three adult male Sprague Dawley rats (weight, Harlan Olac, Bicester, UK) 
received intracerebral injection of 0.5/xl of ibotenic acid (lOmg/ml) as outlined in 
section 2.4.1. Animals were housed individually post-operatively and returned to the 
animal unit the following day. After the appropriate survival time (see below), 
animals were re-anaesthetised, transcardially perfuse-fixed with saline (0.9%) then 
paraformaldehyde (4%); post-fixed, processed and paraffin embedded (section 
2.4.3).
7.2.2 Drug Treatment
The experimental design is illustrated below. Animals were randomly assigned into 
either vehicle or drug treated groups. Six days following entorhinal cortex lesion, all 
animals were given an intraperitoneal injection of BrdU (lOOmg/kg in 0.007N 
NaOH/O.9% saline). Drug treatment commenced on day 7. Animals in group A 
received subcutaneous injections of either LY404187 (0.5mg/kg; n=10) or vehicle 
(10% ethanol, 3.75% hydroxypropyl-6-cyclodextrin; n=9) for a further 7 days. 
Animals in group B received either LY404187 (n=7) or vehicle (n=7) treatment for 
14 days.
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7.2.3 Histology and Immunocytochemistry
Sections (6/tm) were taken from the entorhinal cortex area (2 sections were retained 
from every 20 cut) to confirm lesion placement, then sections (2 per slide) were 
retained from the hippocampus, at the level of the lateral habenula, for 
immunostaining. Sections from the anterior and posterior portion of the lateral 
habenula of each animal were processed for GAP-43 and synaptophysin 
immunostaining as described in section 2.5.5, however microwave pre-treatment was 
not undertaken for these antibodies. All GAP-43 or synaptophysin immunostaining 
was done simultaneously with reagents from the same batch, and DAB solution was 
applied to 6 sections at a time for precisely 3 minutes per section. Two sections from 
the anterior and posterior portion of the lateral habenula were also processed for 
BrdU immunostaining. These sections were pre-treated with pepsin (0.4% in 0.01 
HC1) for 15 minutes, and washed for 15 minutes prior to microwave pre-treatment.
To quantify the GAP-43 and synaptophysin immunoreactivity, Tiff images were 
captured in grey scale from the molecular layer of the dentate gyrus at xlO 
magnification, using a Leica microscope and Image ProPlus software, as described in 
section 2.5.10. Images were also captured from a reference area, the optic tract and 
corpus callosum for GAP 43 and synaptophysin immunostaining, respectively. 
Relative optical densities of the inner, middle and outer molecular layer of the 
dentate gyrus ipsilateral and contralateral to the ECL, as well as the appropriate 
reference region from each section were measured using an MCID image analyser, as 
described in section 2.5.10. The optical density values from the inner, middle and 
outer molecular layer of the dentate gyrus of each animal were averaged and 
expressed as a percentage of the contralateral dentate gyrus.
Less than ten BrdU immunopositive cells were detected in the ipsilateral or granule 
cell layer of the dentate gyrus per section, therefore the total number of 
immunopositive cells in the ipsilateral and contralateral molecular layer was counted 
per section. Four sections were examined per animal, two from the anterior portion 
of the lateral habenula, and two from the posterior portion of the lateral habenula.
The cell counts from the ipsilateral and contralateral molecular layer from these 
sections were then averaged for each animal.
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7.2.4 Statistical Analysis
To determine if there was any significant difference in the synaptophysin or GAP-43 
immunoreactivity (% change in optical density compared to the contralateral dentate 
gyrus) of vehicle or drug treated groups, two-tailed, unpaired Student’s t test was 
used. To determine if there was any significant difference between the number of 
BrdU immunopositive cells in vehicle or drug treated groups, two-tailed, unpaired 
Student’s t test was used.
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7.3 Results
7.3.1 Assessment of lesion placement
All animals included in the study contained a lesion in the entorhinal cortex area, a 
representative example o f the extent o f the lesion in shown in figure 7.1. The lesions 
were confined to the entorhinal cortex and did not involve other cortical areas. The 
lesion spread approximately 1 -2mm in a rostro-caudal extent but did not directly 
involve the hippocampus.
A
Figure 7.1 Entorhinal cortex lesion induced by stereotaxic injection of 
ibotenic acid
A. Digitised H & E stained section illustrating the extent o f  the lesion (within 
dashed black line)
B. Higher power image from the lesion site, illustrating the pallor and glial 
cell reaction.
Scale bar =  50/rm.
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7.3.2 GAP 43 immunostaining
In the dentate gyrus contralateral to the lesioned entorhinal cortex, the granule cell 
layer showed little staining, whilst the molecular layer displayed a granular pattern of 
immunostaining (Fig. 7.2A). The inner molecular layer was most intensely 
immunostained, whereas the outer two layers exhibited a lighter level of 
immunostaining. Quantification of GAP 43 immunoreactivity in the contralateral 
dentate gyrus revealed that there was no significant difference in the optical density 
values in the molecular layers of vehicle and LY404187 (0.5mg/kg) treated animals, 
thus validating this area as a control region (Fig 7.3A, B). In addition, there was no 
significant difference in the levels of immunostaining in the optic tract of vehicle or 
LY404187 (0.5mg/kg) treated animals (Fig 7.2B;7.3C, D).
In the dentate gyrus ipsilateral to the lesioned entorhinal cortex, changes in the 
intensity of immunostaining in the molecular layer were rarely observed when 
compared to the contralateral molecular layer, however a decrease in 
immunostaining in the outer molecular layer was observed in some animals (Fig.
7.4). Quantification of the immunoreactivity in the molecular layers of group A (14 
days following entorhinal cortex lesion, 7 days of drug treatment) revealed that there 
were minimal changes in the levels of GAP-43 immunoreactivity in the MML and 
OML of vehicle treated animals compared to the contralateral dentate gyrus, and that 
there was no significant difference between vehicle and LY404187 treated animals 
(Figure 7.5A). There was a modest increase in the intensity of GAP 43 
immunostaining in the IML compared to the contralateral IML of vehicle treated 
animals from Group A, however treatment with LY404187 (0.5mg/kg) significantly 
reduced the levels of GAP 43 immunostaining in the IML compared to the vehicle 
treated group (Figure 7.5A). In group B (21 days following entorhinal cortex lesion, 
14 days of drug treatment), there were minimal changes in the levels of 
immunostaining in the 3 molecular layers of vehicle treated animals compared to the 
contralateral dentate gyrus; and no significant changes between vehicle and 
LY404187 treated animals was detected (Fig. 7.5B).
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Figure 7.2 GAP 43 immunostaining in control regions
A. GAP 43 im m unostaining in the dentate gyrus contralateral to the lesioned 
entorhinal cortex. In the m olecular layer (m.l.) the inner molecular layer 
(IM L) is most densely stained, whereas the middle (M M L) and outer 
m olecular layers (OM L) are more lightly stained. The granule cell layer 
(g.c.l.) is relatively unstained.
B. The optic tract contains the lowest level o f  imm unostaining at this coronal 
level in the brain.
Scale bar = 400/rm.
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Figure 7.4 GAP 43 immunostaining in the dentate gyrus
A. GAP 43 immunostaining in the dentate gyrus contralateral to the lesioned 
entorhinal cortex. Imm unostaining is evident in the outer (OM L), middle 
(MML) and inner (IM L) m olecular layer o f  the dentate gyrus, however the 
granule cell layer is relatively unstained.
B. -E . GAP 43 imm unostaining in the dentate gyrus ipsilateral to the entorhinal
cortex lesion in representative animals that survived for 14 (B, C) or 28 
days (D, E) following the lesion, that were treated with either vehicle (B, 
D), or LY404187 (0.5mg/kg; C, E ) .
Scale bar =  100/tm.
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Figure 7.5 Quantification of GAP-43 immunoreactivity in the inner 
(IML), middle (MML) and outer molecular layers (OML) of 
the dentate gyrus
A. GAP 43 immunoreactivity was significantly reduced in the IML following 
treatment with the AMPA receptor poteniator LY404187 (0.5mg/kg) compared to 
vehicle treatment, but unchanged in the MML and OML, 14 days following 
entorhinal cortex lesion (Student’s t  test *P<0.05).
B. GAP 43 immunoreactivity was not significantly different in the IML, MML or 
OML after drug or vehicle treatment 21 days following entorhinal cortex lesion 
(Student’s t  test). Bar indicates means of groups.
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7.3.3 Synaptophysin immunostaining
In the dentate gyrus contralateral to the lesioned entorhinal cortex, there was a 
granular, trilaminar synaptophysin immunostaining pattern in the molecular layer, 
whilst the granule cell layer was relatively unstained (Fig. 7.6A). The OML 
contained the densest level of synaptophysin immunostaining, whilst the IML and 
MML were more lightly immunostained. Comparison of the optical densities of the 
molecular layers in the contralateral dentate gyrus of vehicle or LY404187 
(0.5mg/kg) treated animals revealed that there was no significant difference in the 
intensity of immunostaining; thus validating this anatomical area as the control 
region (Fig. 7.7A, B). There was minimal immunostaining of the corpus callosum, 
and this did not significantly differ between vehicle and drug treated animals (Fig. 
7.6B; 7.7C, D).
In the dentate gyrus ipsilateral to the lesioned entorhinal cortex, there were minimal 
changes in the pattern of immunoreactivity in the IML and MML of vehicle treated 
animals compared to the contralateral molecular layer (Fig. 7.8). There was no 
significant difference in the density of synaptophysin immunostaining in 
vehicle or LY404187 (0.5mg/kg) treated groups in the IML or MML (Figure X.x) in 
either group A (14 days post ECL, 7 days of drug treatment) or group B (21 days 
post ECL, 14 days of drug treatment) (Fig. 7.9). In both group A and group B, there 
were modest reductions in the levels of immunostaining in the OML compared to the 
contralateral dentate gyrus (Fig7.8). However, there was no significant difference 
between the intensity of synaptophysin immunostaining in the OML of vehicle or 
LY404187 (0.5mg/kg) treated animals (Fig. 7.9).
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Figure 7.6 Synaptophysin immunostaining in control regions
A. Synaptophysin imm unostaining in the dentate gyrus contralateral to the 
lesioned entorhinal cortex. In the m olecular layer (m.l.) the outer 
molecular layer (OM L) is most densely stained, whereas the middle 
(MML) and inner m olecular layers (IM L) are more lightly stained. The 
granule cell layer (g.c.l.) is relatively unstained.
B. The corpus callosum (c.c) contains the low levels o f  imm unostaining. 
Scale bar = 400/rm.
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Figure 7.8 Synaptophysin immunostaining in the dentate gyrus
A. Synaptophysin imm unostaining in the dentate gyrus contralateral to 
the lesioned entorhinal cortex. A trilam inar pattern o f 
im m unostaining is evident in the outer (OM L), middle (MML) and 
inner (IM L) m olecular layer o f the dentate gyrus, however the 
granule cell layer is relatively unstained.
B. -E . Synaptophysin im m unostaining in the dentate gyrus ipsilateral to
the entorhinal cortex lesion in representative animals that survived 
for 14 (B, C) or 28 days(D, E) following the lesion, that were 
treated with either vehicle (B, D), or LY404187 (0.5mg/kg; C, E ) . 
Scale bar = 100/zm.
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Figure 7.9 Quantification of synaptophysin immunoreactivity in the 
inner (IML), middle (MML) and outer molecular layers 
(OML) of the dentate gyrus
A. Synaptophysin immunoreactivity was not significantly altered in the IML, MML 
or OML after treatment with the AMPA receptor poteniator LY404187 
(0.5mg/kg) compared to vehicle treatment, 14 days following entorhinal cortex 
lesion (Student’s t  test).
B. Synaptophysin immunoreactivity was not significantly different in the IML, 
MML or OML following LY404187 (0.5mg/kg) compared to vehicle treatment, 
21 days after entorhinal cortex lesion (Student’s t  test).
Bars indicate means of groups. 233
7.3.4 Quantification of BrdU immunopositive cells
BrdU was administered on day 6 following ECL for all animals. Therefore, the 
number of 8 day old (Group A) and 15 day old (Group B) cells were compared 
following LY404187 or vehicle administration. BrdU immunopositive cells were 
present in the granule cell layer and hilus of the dentate gyrus, and in other areas of 
the hippocampus. Within the granule cell layer, cells were mainly present in the 
lower part of the cell layer, where the subgranular zone exists. BrdU 
immunostaining was present in the nuclei of BrdU immunopositive cells. In some 
cells, there was uniform, dark staining of the nuclei (Fig. 7.10A), whereas other cells 
were more lightly stained (Fig. 7.10B). Occasionally a punctate, spotted pattern of 
immunostaining was observed. No attempt was made to differentiate between these 
different patterns of immunostaining in the quantification. Quantification of the 
number of BrdU immunopositive cells in the granule cell layer revealed that there 
was no significant difference between the number of BrdU immunopositive cells in 
vehicle or LY404187 (0.5mg/kg) treated animals in group A (Fig. 7.11 A). In group 
B, there was an increase in the mean number of BrdU cells in animals that had 
received 14 days of LY404187 (0.5mg/kg) treatment compared with vehicle treated 
animals, however, this increase did not reach accepted levels of statistical 
significance (Fig. 7.1 IB).
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AFigure 7.10 BrdU immunostaining in the dentate gyrus
A. A BrdU imm unopositive cell in the granule cell layer o f  the dentate gyrus 
(arrow). The nucleus o f  this cell is uniform ly, darkly stained. Nuclei o f 
other cells have been stained with haem atoxylin in these sections
B. Two BrdU im m unopositive cells which are more lightly im m unostained 
that the cell in A (arrow).
Scale bar = 25/rm.
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Figure 7.11 Quantification of BrdU immuoreactive cells in the granule 
cell layer of the dentate gyrus
A. There was no significant difference in the number of BrdU immunopositive cells in 
the dentate gyrus following 7 days of LY404187 (0.5mg/kg) compared to vehicle 
treatment, in animals which survived for 14 days following entorhinal cortex 
lesioning (Student’s t  test). BrdU was injected on day 6  following entorhinal cortex 
lesioning, 1 day before vehicle or LY404187 treatment commenced.
B. There was no significant difference in the number of BrdU immunopositive cells in
the dentate gyrus following 14 days of LY404187 (0.5mg/kg) or vehicle treatment, 
in animals which survived for 21 days following entorhinal cortex lesioning 
(Student’s t  test). BrdU was injected on day 6  following entorhinal cortex lesioning, 
24 hours prior to commencement of vehicle or LY404187 treatment. 2 3 5
7.4 Discussion
To summarise, the data presented in this chapter illustrates that lesioning the 
entorhinal cortex of adult rats resulted in very modest alterations in the pattern of 
GAP 43 and synaptophysin immunoreactivity in the dentate gyrus 14 and 21 days 
post lesion. Seven or 14 days of treatment with the AMPA receptor potentiator 
LY404187 did not enhance sprouting or synaptogenesis assessed with these markers. 
Treatment with the AMPA receptor potentiator LY404187 did not alter the number 
of BrdU cells in the granule cell layer 14 days following entorhinal cortex.
However, by 21 days post ECL, there were increased numbers of BrdU cells in the 
LY404187 treated animals, although these did not reach significance levels.
Use o f ibotenic acid to lesion the entorhinal cortex
A variety of techniques have been used to lesion the entorhinal cortex in studies that 
characterised the temporal evolution of degeneration and regeneration in the dentate 
gyrus. However, the most commonly used techniques are electrolytic and 
aspirational lesions and knife cuts of the perforant pathway. For instance, the 
laboratory of Dellar, Nitsch and Frotscher, who have extensively characterised the 
response of the hippocampus to ECL, deploy electrolytic lesions of the entorhinal 
cortex. This technique severs the area between entorhinal cortex and the 
hippocampus, resulting in the complete destruction of the entorhinal afferent input 
into dentate gyrus (eg Forster et al., 1997). These electrolytic lesions result in an 80- 
90% loss of afferent synapses in the OML of the dentate gyrus (Matthews et al., 
1976). Masliah et al (1991) characterised degeneration and regeneration in the 
dentate gyrus of the rat using GAP 43 and synaptophysin following an aspirative 
lesion that removed the subiculum and parasubiculum, which is likely to have 
removed the majority of the afferent entorhinal input into the dentate gyrus. This 
resulted in a 50% loss of synapses in the OML at 7 days (Masliah et al., 1991). The 
entorhinal cortex lesions induced by ibotenic acid in the current study resulted in 
small, discrete lesions confined to the caudal entorhinal cortex that generally did not 
involve the subiculum, parasubiculum or hippocampus. The entorhinal cortex is a 
large structure, extending approximately 4.5mm in a rostro-caudal direction in the 
brain. A large area of entorhinal cortex was undamaged in the current study, which 
presumably accounts for the minimal degeneration detected.
A similar protocol used in the current study with ibotenic acid has been used to 
lesion the caudal entorhinal cortex of the mouse, which resulted in a 40% loss of
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synapses in the MML 28 days following lesion (White et a l, 2001). However, 
injecting a similar dose of ibotenic into the relatively smaller mouse brain will 
presumably result in a larger area of damaged entorhinal cortex, and more chance of 
involvement of the subiculum, parasubiculum and hippocampus. Inherent species 
differences may also exist in the degenerative and regenerative processes that occur 
following ibotenic acid ECL in rats and mice (Kadish and Van Groen, 2003). Few 
studies have examined the effects of ibotenic acid lesioning of the rat entorhinal 
cortex on plasticity in the hippocampus. Kurumaji and McCulloch (1990) injected 
the same concentration of ibotenic acid into the entorhinal cortex at similar 
stereotaxic co-ordinates to that deployed in the current study, and reported that there 
were no alterations in glucose utilisation in the dentate gyrus 14 days following the 
lesion. As alterations in glucose utilisation are thought to predominately reflect 
activity at synaptic terminals, this suggests there was a minimal loss of synapses in 
the dentate gyrus using this method (Kurumaji and McCulloch, 1991). However, 
removing the entire entorhinal cortex together with the pre- and parasubiculum 
resulted in significant reductions in glucose utilisation in the dentate gyrus, indicative 
of significant synapse loss (Jorgensen and Wright, 1988). Ibotenic acid lesions of the 
entorhinal cortex have also been shown to induce cognitive deficits in rats, assessed 
in the Morris water maze (Eijkenboom et al, 2000). However, the rats in this study 
received 3 injections of ibotenic acid (0.5/xl, lOmg/ml) over a 0.5mm area of each 
caudal entorhinal cortex, resulting in an extensive lesion that included the subiculum 
and a substantial portion of hippocampus. Collectively, these studies indicate that 
extensive damage to the entorhinal cortex and adjacent subiculum is required to 
induce substantial deafferation and degeneration in the dentate gyrus. The subtle 
levels of degeneration reported in the current study may reflect small, discrete lesions 
of the entorhinal cortex that contrast with the more extensive lesioning techniques 
used by other groups.
Alternatively, incorrect time points may have been chosen to examine degeneration 
in the current study. Sprouting of neighbouring afferent fibre systems has been 
reported to occur between 7-30 days following electrolytic entorhinal cortex 
lesioning (Matthews et al, 1976; Lee et al, 1977; Steward and Vinsant, 1983; 
Benowitz et al, 1990; Masliah et al, 1991). Fibre loss and sprouting may already 
have occurred prior to the time point chosen in the current study. The replacement of 
synapses is reported to occur over a slower time course than sprouting. For example
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following electrolytic ECL, only 80% of synapses are recovered at 30 days, and 
synaptogenesis continues for months (Matthews et al, 1976; Masliah et al., 1991). 
However, the temporal evolution of synaptogenesis has not been characterised 
following ibotenic acid-induced ECL. Therefore it remains possible that a 
significant loss of synapses did occur in the current model, and that reactive 
synaptogenesis progressed over a quicker time course in the current paradigm. In 
addition to altering the density of GAP 43 and synaptophysin immunoreactivity 
following ECL, the width of the EML can expand, and outer molecular layer can 
shrink during the period of degeneration (Masliah et al., 1991). The width of the 
molecular layers was not examined in the present study. However alterations in the 
width of these layers may have led to alterations in the optical density readings, 
which may not truly reflect the extent of sprouting or synaptogenesis.
Effect o f the AMPA receptor potentiator LY404187 on regeneration in the dentate 
gyrus
Although there were only subtle alterations in GAP 43 and synaptophysin 
immunostaining in the current study, there were no indications that the AMPA 
receptor potentiator enhanced sprouting or synatogenesis. The adequacy of the 
dosing regime must firstly be addressed when discussing the observed 
ineffectiveness of LY404187 in this experimental paradigm. The ability of 
LY404187 to cross the blood brain barrier has been demonstrated in a number of 
studies where intravenous or subcutaneous administration of the compound has 
produced effects in the CNS (Vandergriff et al., 2001; Mackowiak et a l, 2002; Bai 
et al., 2003; results presented in chapter 6). In the current study, animals received 
twice-daily injections of LY404187 (0.5mg/kg) for seven or fourteen days. 
Administration of LY404187 (0.5mg/kg) was sufficient to induce significant 
increases in glucose utilisation, however these effects were not present following 
administration of the higher dose of LY404187 (5mg/kg; results in chapter 6). Bell 
shaped dose response curves have also been reported following administration of 
LY404187 or its active isomer LY451646, in the forced swim test and when 
examining stem cell proliferation in the dentate gyrus (Li et al, 2001; Quirk and 
Nisenbaum, 2002; Bai et a l, 2003). Similarly, bell shaped dose response curves 
have been reported when examining axonal regeneration following administration of 
exogenous BDNF (Mamounas et al., 2000); raising the possibility that higher doses 
of neurotrophins or AMPA receptor potentiators may be ineffective. It is therefore
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possible that the cumulative effects of twice-daily injections of LY404187 
(0.5mg/kg) have exceeded the dose range at which LY404187 is efficacious. 
However, twice daily injections of LY404187 (0.5mg/kg) for 28 days have been 
shown to enhance levels of GAP 43 and protect against 6-hydroxydopamine (6- 
OHDA) lesioning of the striatum (O’Neill et al, 2003).
In the current study, animals were allowed to recover for 7 days following the 
entorhinal cortex lesion until drug treatment commenced. Studies have suggested 
that degenerative processes are at their peak 2 - 8  days following entorhinal cortex 
lesioning (Savaskan and Nitsch, 2001). As the lesion was caused by an excitotoxin 
and involves degeneration of glutamatergic fibres, it was decided not to administer 
the AMPA receptor potentiator LY404187 during the degenerative period so that 
excitotoxic mechanisms were not enhanced. However, the first week following the 
ECL may be a crucial time point when BDNF could enhance sprouting. In addition, 
recent studies have suggested, perhaps paradoxically, that AMPA receptor 
potentiators may be neuroprotective. For example, the AMPA receptor potentiator 
LY4503430 can reduce the loss of tyrosine hydroxylase immunopositive neurons 
following 6-OHDA administration in the substantia nigra or caudate nucleus (Murray 
et al, 2003). Pre- or post-treatment with CX-516 can attenuate AMPA-induced 
pathology in hippocampal slice cultures, and co-injection of AMPA (50nmol) with 
CX-516 produces a dose-dependent reduction in lesion volume; conferring more than 
a 50% reduction at the highest dose (Bahr et al, 2002). These studies suggest that 
AMPA receptor potentiators may protect rather than exacerbate excitotoxicity, and 
suggest that immediate treatment with LY04187 may have been efficacious in the 
current study.
Further experiments with different dosing protocols of LY404187 may reveal 
whether or not this AMPA receptor potentiator has the potential to enhance sprouting 
following an entorhinal cortex lesion. However, another possibility is that in this 
experimental paradigm, AMPA receptor potentiators may simply be ineffective in 
enhancing regeneration. A variety of neurotrophic factors, such as NGF, BDNF, 
CNTF, IL-1, FGF-2, TGF-61 and have been implicated in the regenerative 
reorganisation of the dentate gyrus following ECL based on reports of up regulation 
following entorhinal cortex lesion (reviewed in Deller and Frotcher, 1997).
However, the temporal evolution, and relative importance of each of these growth
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factors has not been examined or compared. BDNF mRNA is markedly upregulated 
following entorhinal cortex lesioning, however this generally occurs within 4 hours; 
between 24 hours and 10 days there is no evidence for further increases in BDNF 
(Lapchak et al., 1993; Gwag et al., 1994; Forster et al., 1997). Furthermore, the 
initial large increase in BDNF mRNA can be mimicked with high frequency 
stimulation of the perforant pathway (Springer et a l, 1994), and can be blocked with 
the NMDA receptor antagonist MK-801; however this blockade did not attenuate the 
sprouting of cholinergic fibres 14 days post ECL (Forster et al., 1997). These data 
suggest that the initial increase in BDNF mRNA following ECL may be related to 
glutamate release from the entorhinal terminals, and subsequent to this, there may be 
no role for BDNF in the mechanisms of sprouting. The ability of the structurally 
related AMPA receptor potentiator, LY503430, to enhance regeneration, assessed 
with GAP 43 immunohistochemistry, following 6-OHDA lesioning suggests that 
these group of compounds may be more effective in the striato-nigral system 
(Murray et al, 2003). Whilst the lack of a concomitant increase in BDNF levels 
reported 6-OHDA study (Murray et al., 2003) may simply reflect that BDNF was 
upregulated at an earlier timepoint, they also suggest that these compounds may act 
through a different mechanism to enhance plasticity. Finally, it is possible that 
LY404187 may have enhanced plasticity in the dentate gyrus without having an 
effect on fibre sprouting or synapse density. Phosporylation of AMPA receptor is a 
means of enhancing ion flux through the receptor (Wenthold and Roche, 1998), 
thereby enhancing glutamatergic transmission. Thus, it remains possible that the 
AMPA receptor potentiator LY404187 may have acted by this mechanism to 
enhance glutamatergic transmission. Electrophysiological studies could be used to 
examine this phenomenon.
Effect o f the AMPA receptor potentiator LY404187 on the number o f BrdU cells in 
the dentate gyrus
Several thousand new cells are generated in the dentate gyrus of mammals every day 
from proliferating neuronal and glial progenitor cells, yet between 1 -2  weeks later; 
many of these cells die (Cameron et al., 1993; Gould et al., 1999). However, 
learning hippocampal dependent cognitive tasks can enhance the survival of these 
cells, the majority of which express neuronal markers (Gould et al., 1999). This
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study suggests that newly generated neurons that survive in the dentate gyrus may be 
involved in memory formation (Gould et al, 1999; Shors et al, 2001). In the current 
study, there was a reduction in the number of BrdU immunopositive cells between 1 
and 2 weeks following BrdU administration. However, compared with vehicle 
treated animals, there were increased numbers of BrdU cells in the dentate gyrus 
ipsilateral to the ECL of animals treated with the AMPA receptor potentiator 
LY404187 (0.5mg/kg), although these were not statistically significant. At present, 
it is unclear if this signifies enhanced proliferation of the BrdU cells, or if these pilot 
studies suggest that LY404187 has the capacity to influence the survival of newly 
generated cells. Further experiments with different dosing regimes of LY404187, at 
later time points would determine if LY404187 could enhance the number of 
surviving, functional neurons in the dentate gyrus.
Clinical interventions that could enhance the proliferation of endogenous stem cells 
and the genesis and survival of new neurons would be beneficial in a number of 
clinical disorders. Arvidsson and colleagues (2002) recently demonstrated that focal 
cerebral ischaemia markedly increased the proliferation of endogenous stem cells in 
the subventricular zone of rats, which migrate into the core of the ischaemic lesion, 
where they develop the phenotype of striatal medium spiny neurons. However, 
between 2 and 8 weeks following ischaemia, approximately 80% of the new neurons 
died, presumably due to an unfavourable environment and lack of trophic support 
(Arvidsson et a l, 2002). The production of new dentate gyrus granule cells also 
decreases markedly in old age (Cameron and McKay, 1999); based on their proposed 
role in memory formation, this decline in neurogenesis may contribute to age-related 
memory deficits. Decreased serotenergic transmission, which is commonly 
associated with depression, attenuates the rate of neurogenesis (Brezun and Daszuta, 
1999; 2000). These examples illustrate that altered levels of neurogenesis are 
associated with clinical disorders; however, whilst the brain has the capacity for self­
repair, interventions which could augment this process would be highly desirable.
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CHAPTER 8 
GENERAL DISCUSSION
8.1 General Discussion
8.1.1 Role of AMPA-receptor mediated excitotoxicity in white matter 
damage
Considerable in vitro evidence has suggested a role for AMPA receptors in 
mediating white matter pathology; the data presented in this thesis has extended 
these observations in vivo. Thus, AMPA can induce white matter damage in vivo, in 
both the rat and the mouse, and AMPA receptor antagonism can attenuate white 
matter pathology following focal cerebral ischaemia in vivo. AMPA receptors 
therefore represent a pathogenic mediator of both grey and white matter damage, and 
may be an attractive focus for neuroprotective strategies. AMPA receptor 
antagonism also reduces axonal and oligodendrocyte damage following in vivo spinal 
cord ischaemia and trauma (Wrathall et al., 1997; Kanellopoulous et al., 2000; Li et 
al., 1999; Rosenberg et al., 1999b). Furthermore, the protection of axons and 
oligodendrocytes with AMPA antagonists has been shown to correlate with 
improved functional recovery, following spinal cord ischaemia (Kanellopoulos et al, 
2000; Wrathall et al., 1994, 1997) and experimental autoimmune encephalomyelitis 
(Pitt et al., 2000). However, more studies are required to establish if AMPA receptor 
antagonism has the potential to protect the cellular components of white and grey 
matter in the clinic.
A number of studies have demonstrated the presence of AMPA receptors in certain 
white matter tracts of rats and mice (see section 1.3.3). Yet relatively little 
information is known about the expression of AMPA receptors in the many other 
white matter tracts and glial cells in the rodent brain. As with grey matter AMPA 
receptors, a number of transcriptional and post-translational modifications of the 
AMPA receptor may give rise to vastly heterogeneous receptors with differing 
physiological properties. However little is known about such diversity in white 
matter AMPA receptors. A more anatomically widespread, systematic analysis of 
glutamate receptor subunit distribution in white matter would be valuable. A method 
that combines whole-cell patch clamp recording with RT-PCR (Lambolez et al,
1992; Dixon et a l, 2000) would also be useful to correlate information about AMPA 
receptor subunit expression with the functional properties of AMPA receptors in 
white matter.
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In comparison to the rodent brain, even less is known about the expression of 
AMPA/kainate receptors in white matter tracts of the human brain. Only a few 
studies have examined the expression of certain receptor subunits in limited human 
brain areas. For example, GluR4 has been localised to oligodendrocyte-precursor- 
like cells in the cerebral cortex, however, GluRl is absent from cortical white matter 
(He et al., 1996; Ong and Garey, 1996). Of interest however, it has been reported 
recently with PCR analysis of post mortem tissue that 7% of GluR2 in the prefrontal 
cortex (PFC) white matter of humans is unedited, which contrasts with <0.1% 
unedited GluR2 in human pre-frontal cortical grey matter (Akbarian et al., 1995). As 
the unedited form of GluR2 is permeable to Ca2+, this suggests that a higher 
proportion of glial cells in the PFC are Ca2+ permeable, which has implications for 
disease states (Pellegrini-Giampietro et al., 1997; Weiss and Sensi, 2000). More 
studies like these, with post mortem brain tissue, are required to further elucidate the 
prevalence of white matter AMPA receptor expression in human brains, both in 
normal and diseased states. More sophisticated imaging techniques could also 
contribute to an increased understanding of AMPA receptor expression in human 
white matter. For instance, isotopically labelled MK 801 has been used to examine 
NMDA receptor activation during an ischaemic episode in living human patients 
with single photon emission tomography (SPET; Owens et al., 1997). The 
development of isotopically labelled AMPA receptor ligands or subunit specific 
ligands for use with imaging techniques would contribute greatly to knowledge about 
AMPA receptor distribution in normal human brains, and possible 
pathophysiological processes occurring at these receptors in humans.
The concept of ‘secondary’ excitotoxicity as a pathogenic mediator of neuronal loss 
in chronic neurodegenerative diseases is frequently suggested by a number of groups. 
However, the experimental evidence for this is less compelling than for the role of 
excitotoxicity in acute neurological diseases. Thus, the role of ‘secondary’ 
excitotoxicity as a pathogenic mediator of axonal pathology in chronic neurological 
disorders remains purely hypothetical. However, there is evidence that excitotoxicity 
may contribute to the pathogenesis of ALS and multiple sclerosis, two disorders that 
are characterised by axonal swellings and degeneration (Ferguson et al., 1997; Trapp 
et al., 1998). Chronic treatment with the AMPA receptor antagonist NBQX reduced
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axonal damage in EAE mice, a demyelinating model of multiple sclerosis (Pitt et al, 
2000; Werner et a l, 2001). In post mortem MS tissue, increased levels of 
glutaminase, the enzyme that synthesises glutamate, and decreased levels of the 
glutamate transporter GLT-1 and the glutamate-metabolising enzymes glutamate 
dehydrogenase and glutamate synthetase were associated with oligodendrocyte loss 
and axonal damage (Werner et al, 2001). This suggests that excitotoxicity may be 
induced by perturbations in normal glutamate homeostasis. Similar alterations have 
been reported in ALS. The glutamate transporter EAAT2 is decreased in the brain 
and spinal cord of ALS patients; furthermore, a decrease in the transport velocity of 
glutamate transporters has been localised to areas of the brain and spinal cord 
associated with ALS (Rothstein et al, 1992; Rothstein et a l, 1995). It remains 
unclear if these perturbations in glutamate homeostasis are associated with, or are 
causative of axonal damage in ALS or MS. AMPA receptor activation may 
represent a common mechanism of neuronal, axonal, myelin and oligodendrocyte 
damage. AMPA receptor antagonists may have therapeutic potential in the treatment 
of a number of neurological conditions, where they offer superiority over drugs that 
protect only neuronal perikarya.
8.1.2. Other mechanisms of white matter damage
A number of other pathogenic mediators of cellular damage can affect white matter. 
Mitochondria contained within white matter to produce energy can also produce 
increased levels of oxygen radicals, such as superoxide, hydrogen peroxide and 
hydroxyl radicals in pathological situations. These have the potential to induce 
peroxidation injury of lipid membranes and proteins. Inhibiting mitochondria with 
3-nitropropionic acid or malonate causes axonal damage (Dewar et a l, 2001; 
McCracken et a l, 2001; results in chapter 6) that is associated with increased 
oxidative stress (McCracken et al, 2001). Intracerebral injection of 4- 
hydroxynoneal, a by-product of lipid peroxidation, induces axonal damage in vivo 
(McCracken et a l, 2000). The anti-oxidant compound ebselen and the spin trap 
agent PBN can protect axons (Imai et al, 2001) and oligodendrocytes from focal 
cerebral ischaemia, (Irving et a l, 1997; Imai et a l, 2001). Nitric oxide, in 
submicromolar concentrations, can kill axons and oligodendroglia in white matter
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(Smith et a l, 2001; Garthwaite et al, 2002). Nitric oxide can react with free radicals 
to produce the highly toxic molecule, peroxynitrite, which can induce axonal damage 
(Touil et al, 2001).
Studies from the laboratory of Stys and Waxman amongst others have highlighted 
the role of altered ionic homeostasis in causing axonal damage (reviewed in Waxman 
et a l, 1991; Stys, 1998). Thus, energy depletion and other pathogenic circumstances 
can induce influxes of Na+ and Ca2+ into the axolemma, which can damage the axon. 
Intra-axonal Ca2+ influx can activate various Ca2+ enzymes, including proteases or 
caspases such as calpain, which can devastate the intra-axonal cytoskeleton and 
organelles ( McCracken et al, 1999; Buki et al, 1999b, 2000; Jiang and Stys, 2000). 
Inhibitors of Na+ influx can protect white matter from anoxic, traumatic or ischaemic 
insults (Teng and Wrathall, 1997; Garthwaite et a l, 1999; Rosenberg et a l, 1999a).
Inflammatory cells may invade white matter and produce cytotoxic factors that can 
cause axonal damage. For example, invading microglia and macrophages in post 
mortem MS lesions and EAE tissue containing damaged axons also contained high 
levels of the glutamate-producing enzyme, glutaminase, suggesting that these cells 
produce excitotoxic levels of glutamate. Treatment of EAE mice with NBQX did 
not alter lesion size or the amount of glutaminase producing cells, but it did attenuate 
axonal damage, further supporting this theory (Werner et a l, 2001). Inflammatory 
cells may also produce nitric oxide and oxygen radicals, which are implicated in 
axonal damage (see above). Inflammation can also result in uncontrolled expression 
of extracellular proteases known as matrix metalloproteinases (MMPs). Myelin 
basic protein is one of the substrates of MMP-9 (Chandler et a l, 1995). Intracerebral 
injection of MMP-9 and other MMPs induces axonal damage, whilst ischaemically- 
induced myelin damage is attenuated in MMP-9 gene knockout mice (Asahi et al, 
2001; Newman et al, 2001).
The various pathogenic mediators of white matter damage described above are 
unlikely to act alone, but rather act in concert with each other to cause deleterious 
effects. As an examples of this, excitotoxic mechanisms can induce oxygen radicals 
(Underhill et al, 2002b); nitric oxide mediated damage causes Na+ and Ca2+ influx 
(Kapoor et a l, 2003); and inflammatory cells can produce glutamate (Werner et al, 
2001). Each of these mechanisms has been implicated in neuronal perikaryal
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damage as well, thus representing appropriate targets for interventions which will 
protect components of grey and white matter.
The importance of white matter brain protection in addition to grey matter protection 
is becoming increasingly recognised (Stys, 1998; Bjartmar et al, 1999; Dewar et al., 
1999; Petty and Wettstein, 1999; Coleman and Perry, 2002; Gladstone et a l, 2002; 
Medana and Esiri, 2003). The widespread use of sensitive immunocytochemical 
methods such as APP and NF immunohistochemistry has undoubtedly aided the 
increasing recognition of white matter damage. However, the discrepancies reported 
in the distribution of damaged axons in APP and NF immunostained sections in 
chapter 3-5 of this thesis, and in another study (Stone et a l, 2001) have highlighted 
the need for multiple markers for the evaluation of white matter damage. The use of 
sensitive imaging techniques in humans, such as MRS/MRI imaging of N- 
acetylaspartate (axonal marker) levels will also contribute to the understanding of 
white matter pathology and progression in human neurological conditions.
8.1.3 Clinical potential of AMPA receptor potentiators
The study described in chapter 6 suggests that the AMPA receptor potentiator 
LY404187 and related molecules may have therapeutic utility in the treatment of 
cognitive deficits arising in certain neurological conditions where glutamatergic 
hypofunction occurs. Administration of an AMPA receptor potentiator to healthy 
humans was well tolerated, and positive effects in certain memory tests were 
demonstrated. (Ingvar et al, 1997). Deficits in glutamatergic transmission may 
contribute to cognitive decline in the elderly (Segovia et a l, 2001). CX-516 
administration in elderly humans (65-76 years) improves delayed recall of nonsense 
syllables (Lynch et a l, 1997). Disruption in glutamatergic transmission may also 
contribute to the cognitive deficits observed in Alzheimer’s disease and 
schizophrenia (Carlsson et al, 1999; Tamminga et al, 1999). Positive effects have 
been demonstrated in patients with Alzheimer’s disease or schizophrenia following 
administration of AMPA receptor potentiator compounds (Lee and Benfield, 1994; 
Goff et a l, 2001). In this thesis, for the first time, an anatomical basis for the pre- 
clinical effects of LY404187 in models of depression and cognition has been 
determined. LY404187 is systemically active and far more potent that previous
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AMPA potentiators. It has recently been shown that a related 
biarylpropylsulfonamide, LY451395 can be safely administered to humans; 
suggesting that these AMPA receptor potentiators may be useful in situations of 
cognitive decline. In addition to enhancing glutamatergic transmission, AMPA 
receptor potentiators may have neuroprotective and neurotrophic properties which 
augments their clinical potential. Whilst there was no evidence in this thesis that 
AMPA receptor potentiators can enhance regeneration following ECL, other studies 
have demonstrated the neurotrophic and neuroprotective potential of these 
compounds (Bahr et al, 2002; Murray et al, 2003).
8.1.4 Potential side effects of AMPA receptor antagonists and AMPA 
receptor potentiators?
Because excitotoxicity is mediated by over-activation of glutamate receptors, this 
raises the concern that enhancing glutamatergic transmission with AMPA receptor 
potentiators may have toxic effects. Conversely, the role of AMPA receptor 
potentiators in LTP and cognitive enhancement suggests that AMPA receptor 
antagonists may induce cognitive deficits. The latter has been demonstrated in a 
number of studies (Zivkovic et al, 1995; Filliat et al, 1998; Riedel et a l, 1999), 
although other studies have reported no effects (Miztal and Danysz, 1995). A 
temporary loss of cognitive function might be acceptable and justified to prevent 
permanent disability in conditions such as ischaemia and trauma. However, use of 
AMPA receptor antagonists as treatment for epilepsy, neuropathic pain or chronic 
neurodegenerative disorders may cause cognitive defects. More studies are required 
to establish if AMPA receptor antagonists are efficacious without inducing cognitive 
deficits. The reported involvement of specific AMPA receptor subunits or splice 
variants in neurological disorders (reviewed in Lees et a l, 2000; Sattler and 
Tymianski, 2001) suggests that the development of subunit- or splice-variant-specific 
ligands may be therapeutically beneficial in these disorders. Similarly, improved 
knowledge about the downstream, signal-transduction pathways involved in 
excitotoxicity may consequently lead to the identification of molecular targets for 
future therapy (Sattler and Tymianski, 2001).
Cyclothiazide is an AMPA receptor potentiator known to have toxic effects, causing 
seizures, cell death and lethality when administered to the brain (Yamada et al,
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1998a). However, other AMPA receptor potentiators do not seem to possess the 
same toxic effects as cyclothiazide. 1-BCP and IDRA-21 potentiate neuronal 
damage caused by glutamate exposure in vitro and global ischaemia in vivo, 
respectively (Yamada et al, 1998a, b). However, the doses used in the latter studies 
are much higher than doses effective to enhance cognition (Staubli et a l, 1994; 
Zivkovic et a l, 1994). A number of other in vivo studies have reported no adverse 
side effects or toxicity. Indeed, administration of AMPA receptor potentiators is 
well tolerated in humans (Ingvar et al, 1997; Lynch et al, 1997). It has been 
hypothesised AMPA receptor potentiators are less likely to cause toxicity than 
AMPA receptor agonists, based on their mechanism of action. Thus, by enhancing 
only natural rates of glutamatergic transmission, rather than causing continued 
stimulation, they are less likely to induce toxicity. In addition, it is thought that 
drugs which affect only receptor deactivation have reduced toxic potential as 
desensitisation of receptors at high firing rates is not affected (Lees, 2000).
8.1.5 Concluding remarks
Based on their ubiquitous distribution in the CNS, and their involvement in both 
essential and damaging CNS functions, AMPA receptors are a therapeutic target in a 
number of CNS disorders. The data presented in the thesis have highlighted clinical 
usefulness of AMPA receptor ligands in a number of neurological disorders.
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Appendix 1: Rat and Mouse Tissue Processing
Whole rat and mouse brains were processed using a Tissue-Tek® automated processor 
(VIP).
Station Solution Temp
Time 
Rat Mouse
1 70% Alcohol 35°C 2 hours 2 hours
2 80% Alcohol 35°C 3 hours 2 hours
3 96% Alcohol 35°C 4 hours 2 hours
4 Absolute Alcohol 35°C 4 hours 2 hours
5 Absolute Alcohol 35°C 5 hours 2 hours
6 Absolute Alcohol 35°C 5 hours 2 hours
7 Absolute Alcohol 35°C 6 hours 2 hours
8 Xylene/Abs A1 35°C 4 hours 2 hours
9 Xylene 1 35°C 5 hours 2 hours
10 Xylene 2 35°C 5 hours 2 hours
11 Paraffin wax 1 60°C 5 hours 2 hours
12 Paraffin wax 2 60°C 5 hours 2 hours
13 Paraffin wax 3 60°C 6 hours 2 hours
A1
Appendix 2: Details of solutions used
Perfusion fixation, processing and immunohistochemistrv
• 50mM phosphate buffer
Solution A 31.2g/L of NaH2 P 0 4 (0.2M)
Solution B 28.4g/L of Na2HP04 (0.2M)
Take 95ml of stock solution A and 405mls of stock solution B; make up to 2L 
with distilled H20
• 4% Paraformaldehyde Fixative
40g/L of paraformaldehyde (Sigma) was dissolved into 50mM phosphate 
buffer heated to 65°C, which was then allowed to cool before being filtered.
• Phosphate buffered Saline (PBS, lOmM, pH 7.2)
Made from 1:20 dilution of following stock:-
NaCl 174g/L
KH2P 0 4 10.2g/L
Na2HP04 31.6g/L
• Poly-L-lysine slides
Slides were racked, then placed in a 1:10 dilution of Poly-L-lysine (0.1%, 
Sigma) solution for 5 minutes, then dried in an oven at 65°C for 1 hour
• Cryoprotectant
30% glycerol/30% ethylene glycol in 10 mM sodium phosphate buffer, store at 
-20°C
Western Blotting
• For preparation of membrane enriched brain homogenates
Solution A 0.85M sucrose, lOmM hepes pH 7.4, 2mM DTT, ImM TLCK
(Na-p-Tosyl-L-lysine chicromethyl ketone hydrochloride)
Solution B 0.25M sucrose, lOmMH hepes pH 7.4
A2
Acrylamide Gels
To make 2 gels for mini gel system:-
Resolving Stacking
Gel (10%) Gel (4%)
Acrylamide 6.6mls 880pl
1.5M Tris pH 8.8 5mls
0.5M Tris pH 6.8 1.64mls
10% SDS 200pl 30pl
10% APS 100pl 50pl
Distilled H20 8.1mls 4mls
Temed lOjal 8 pi
• IX T-TBS Tris buffered saline
Made from 1:10 dilution of stock
Tris 24.2g
NaCl 175.4g
Tween 20ml
H20  2L pH7.4
. 10X PAGE buffer
Made from 1:10 dilution of stock:- 
Glycine 144g/L
Tris 30.3g/L Dissolve glycine, then add Tris, add SDS last
SDS lOg/L J
• Anode I buffer
Tris 36g/L
Methanol 74ml/L
• Anode II buffer
Tris 3g/L
Methanol 74ml/L
• Cathode buffer
Tris 3g/L
Glycine 3g/L
Methanol 74ml/L
A3
Appendix 3: Reproducibility of MAP 5 scoring system
To quantify axonal damage following intracerebral injection of AMP A into the 
subcortical white matter of rats, a grid scoring system was used. Firstly, MAP 5 
immunostained sections were captured and digitised with a video camera connected 
to an MCID-M4 image analyser (Imaging Research, Canada). The image of each 
coronal section was printed, at a fixed magnification, onto A4 paper using a laser 
printer, and areas containing axonal damage were plotted onto the images with the 
aid of a light microscope. A 2mm spaced transparent grid was then placed over each 
digitised MAP 5 image, and the number of grid intersections that fell within the area 
containing damaged axons was counted. To determine the reproducibility of the grid 
scoring technique, it was repeated the following day for the animals described in 
section 3.2.1. The results, presented in the graph below, demonstrate that the grid 
system is a highly reproducible technique.
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Figure A.1 Reproducibility of 
the grid scoring 
method
Day 1
Next, the reproducibility of the entire technique (plotting axonal damage onto 
digitised sections and the grid scoring system) was tested by repeating the 
quantification two days after the original analysis, for the animals described in 
section 3.2.1. The results are presented in figure A.2. overleaf. As would be 
expected, there is slightly more variability in this trial. However, the strong 
correlation between the analyses done on the two days confirms the reproducibility 
of this technique.
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Figure A.2 Reproducibility of the MAP 5 scoring system  
for quantifying axonal damage
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Appendix 4: Quantification of axonal and neuronal 
damage following intrastriatal injection 
of AMPA or malonate -  Reproducibility 
of technique
I performed the quantification of all neuronal and axonal damage in the AMPA- 
induced lesions, whilst Mr Daniel Cuthill performed all quantification of the 
malonate-induced lesions. However, the ability of Mr Daniel Cuthill to quantify 
AMPA-induced lesions, and my ability to quantify malonate-induced lesions was 
also assessed in eight animals from each group (2 per dose), to determine inter-rater 
variability. The results are presented in figure A.3 and A.4. Slight discrepancies 
were detected from animal to animal (Fig A.3.A, C, E; Fig. A.4.A, C, E) when 
comparing the results of individual animals. However, correlation analysis revealed 
that our results were highly reproducible (Fig A.3.B, D, F -  Fig. A.4.B, D, F). The 
only exception was the quantification of APP immunostaining following 
intracerebral injection of AMPA (Fig A.4.E and A.4.F). However, this is because the 
actual volume of damaged axons assessed in APP immunostained sections is very 
low, therefore slight variations can appear exaggerated.
Fig A.3 (Overleaf) Quantification of malonate-induced neuronal 
and axonal damage -  reproducibility studies.
Comparison of my results (Clear bars) with Dan’s results (Black bars) for 
individual animals following intracerebral injection of vehicle or malonate 
(0.34-1.35/xmol) (A, C, F). Correlating these data (B, D, F) revealed that our 
results were highly reproducible.
Fig A.4 (On page A8) Quantification of AMPA-induced neuronal 
and axonal damage -  reproducibility studies.
Comparison of my results (Clear bars) with Dan’s results (Black bars) for 
individual animals following intracerebral injection of vehicle or AMPA (1.5- 
6nmol) (A, C, F). Correlating these data (B, D, F) revealed that our results were 
highly reproducible, with the exception of APP immunostaining (see above).
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